SB 40: Health care coverage: insulin.
- Session Year: 2025-2026
- House: Senate
- Latest Version Date: 2025-10-13
Current Status:
Passed
(2025-10-13: Chaptered by Secretary of State. Chapter 737, Statutes of 2025.)
Introduced
In Committee
Awaiting First Chamber Vote
Passed First Chamber
In Committee
Awaiting Second Chamber Vote
Passed Second Chamber
Enacted
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the acts requirements a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan contract or disability insurance policy issued, amended, delivered, or renewed on or after January 1, 2000, that covers prescription benefits to include coverage for insulin if it is determined to be medically necessary.
This bill would prohibit a large group health care service plan contract or health insurance policy issued, amended, delivered, or renewed on or after January 1, 2026, or an individual or small group health care service plan contract or health insurance policy on or after January 1, 2027, from imposing a copayment, coinsurance, deductible, or other cost sharing of more than $35 for a 30-day supply of an insulin prescription drug, except as specified. On and after January 1, 2026, the bill would prohibit a health care service plan or health insurer from imposing step therapy as a prerequisite to authorizing coverage of insulin, and, for a large group health care service plan contract or health insurance policy, would require at least one insulin for a given drug type in all forms and concentrations to be on the prescription drug formulary. The bill would limit the $35 cap for an individual or small group health care service plan contract or health insurance policy to only Tier 1 and Tier 2 insulin if the drug formulary is grouped into tiers, except as provided. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the acts requirements a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan contract or disability insurance policy issued, amended, delivered, or renewed on or after January 1, 2000, that covers prescription benefits to include coverage for insulin if it is determined to be medically necessary.
This bill would prohibit a large group health care service plan contract or health insurance policy issued, amended, delivered, or renewed on or after January 1, 2026, or an individual or small group health care service plan contract or health insurance policy on or after January 1, 2027, from imposing a copayment, coinsurance, deductible, or other cost sharing of more than $35 for a 30-day supply of an insulin prescription drug, except as specified. On and after January 1, 2026, the bill would prohibit a health care service plan or health insurer from imposing step therapy as a prerequisite to authorizing coverage of insulin, and, for a large group health care service plan contract or health insurance policy, would require at least one insulin for a given drug type in all forms and concentrations to be on the prescription drug formulary. The bill would limit the $35 cap for an individual or small group health care service plan contract or health insurance policy to only Tier 1 and Tier 2 insulin if the drug formulary is grouped into tiers, except as provided. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the acts requirements a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan contract or disability insurance policy issued, amended, delivered, or renewed on or after January 1, 2000, that covers prescription benefits to include coverage for insulin if it is determined to be medically necessary.
This bill would prohibit a large group health care service plan contract or health insurance policy issued, amended, delivered, or renewed on or after January 1, 2026, or an individual or small group health care service plan contract or health insurance policy on or after January 1, 2027, from imposing a copayment, coinsurance, deductible, or other cost sharing of more than $35 for a 30-day supply of an insulin prescription drug, except as specified. On and after January 1, 2026, the bill would prohibit a health care service plan or health insurer from imposing step therapy as a prerequisite to authorizing coverage of insulin, and, for a large group health care service plan contract or health insurance policy, would require at least one insulin for a given drug type in all forms and concentrations to be on the prescription drug formulary. The bill would limit the $35 cap for an individual or small group health care service plan contract or health insurance policy to only Tier 1 and Tier 2 insulin if the drug formulary is grouped into tiers, except as provided. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the acts requirements a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan contract or disability insurance policy issued, amended, delivered, or renewed on or after January 1, 2000, that covers prescription benefits to include coverage for insulin if it is determined to be medically necessary.
This bill would prohibit a large group health care service plan contract or health insurance policy issued, amended, delivered, or renewed on or after January 1, 2026, or an individual or small group health care service plan contract or health insurance policy on or after January 1, 2027, from imposing a copayment, coinsurance, deductible, or other cost sharing of more than $35 for a 30-day supply of an insulin prescription drug, except as specified. On and after January 1, 2026, the bill would prohibit a health care service plan or health insurer from imposing step therapy as a prerequisite to authorizing coverage of insulin, and, for a large group health care service plan contract or health insurance policy, would require at least one insulin for a given drug type in all forms and concentrations to be on the prescription drug formulary. The bill would limit the $35 cap for an individual or small group health care service plan contract or health insurance policy to only Tier 1 and Tier 2 insulin if the drug formulary is grouped into tiers, except as provided. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the acts requirements a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan contract or disability insurance policy issued, amended, delivered, or renewed on or after January 1, 2000, that covers prescription benefits to include coverage for insulin if it is determined to be medically necessary.
This bill would generally prohibit a large group health care service plan contract or health insurance policy issued, amended, delivered, or renewed on or after January 1, 2026, or a contract or policy offered in the individual or small group market an individual or small group health care service plan contract or health insurance policy on or after January 1, 2027, from imposing a copayment, coinsurance, deductible, or other cost sharing of more than $35 for a 30-day supply of an insulin prescription drug, except as specified. On and after January 1, 2026, the bill would prohibit a health care service plan or health insurer from imposing step therapy as a prerequisite to authorizing coverage of insulin, and, for a large group health care service plan contract or health insurance policy, would require at least one insulin for a given drug type in all forms and concentrations to be on the prescription drug formulary. The bill would limit the $35 cap for an individual or small group health care service plan contract or health insurance policy to only Tier 1 and Tier 2 insulin if the drug formulary is grouped into tiers, except as provided. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the acts requirements a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan contract or disability insurance policy issued, amended, delivered, or renewed on or after January 1, 2000, that covers prescription benefits to include coverage for insulin if it is determined to be medically necessary.
This bill would generally prohibit a health care service plan contract or health insurance policy issued, amended, delivered, or renewed on or after January 1, 2026, or a contract or policy offered in the individual or small group market on or after January 1, 2027, from imposing a copayment, coinsurance, deductible, or other cost sharing of more than $35 for a 30-day supply of an insulin prescription drug, except as specified. On and after January 1, 2026, the bill would prohibit a health care service plan or health insurer from imposing step therapy as a prerequisite to authorizing coverage of insulin, except as provided. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the acts requirements a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan contract or disability insurance policy issued, amended, delivered, or renewed on or after January 1, 2000, that covers prescription benefits to include coverage for insulin if it is determined to be medically necessary.
This bill would generally prohibit a health care service plan contract or health insurance policy issued, amended, delivered, or renewed on or after January 1, 2026, or a contract or policy offered in the individual or small group market on or after January 1, 2027, from imposing a copayment, coinsurance, deductible, or other cost sharing of more than $35 for a 30-day supply of an insulin prescription drug, except as specified. On and after January 1, 2026, the bill would prohibit a health care service plan or health insurer from imposing step therapy as a prerequisite to authorizing coverage of insulin. insulin, except as provided. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the acts requirements a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan contract or disability insurance policy issued, amended, delivered, or renewed on or after January 1, 2000, that covers prescription benefits to include coverage for insulin if it is determined to be medically necessary.
This bill would generally prohibit a health care service plan contract or disability health insurance policy issued, amended, delivered, or renewed on or after January 1, 2026, from imposing a copayment copayment, coinsurance, deductible, or other cost sharing of more than $35 for a 30-day supply of an insulin prescription drug or imposing a deductible, coinsurance, or any other cost sharing on an insulin prescription drug, drug, except as specified. On and after January 1, 2026, the bill would prohibit a health care service plan or disability health insurer from imposing step therapy protocols as a prerequisite to authorizing coverage of insulin. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the acts requirements a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan contract or disability insurance policy issued, amended, delivered, or renewed on or after January 1, 2000, that covers prescription benefits to include coverage for insulin if it is determined to be medically necessary.
This bill would generally prohibit a health care service plan contract or disability insurance policy issued, amended, delivered, or renewed on or after January 1, 2026, from imposing a copayment of more than $35 for a 30-day supply of an insulin prescription drug or imposing a deductible, coinsurance, or any other cost sharing on an insulin prescription drug, except as specified. On and after January 1, 2026, the bill would prohibit a health care service plan or disability insurer from imposing step therapy protocols as a prerequisite to authorizing coverage of insulin. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
(a)The Legislature finds and declares all of the following:
(1)Approximately 263,000 Californians are diagnosed with type 1 diabetes each year. Approximately 4,037,000 Californian adults have diabetes.
(2)Every Californian with type 1 diabetes, and many with type 2 diabetes, rely on daily doses of insulin to survive.
(3)Insulin prices have nearly tripled, creating financial hardships for people who rely on it to survive.
(4)One in four people using insulin have reported insulin underuse due to the high cost of insulin.
(5)Imposing a deductible on insulin, and requiring individuals to meet that deductible, creates a financial burden that presents a barrier to accessing insulin.
(6)Diabetes is the seventh leading cause of death, and it is a leading cause of disabling and life-threatening complications, including heart disease, stroke, kidney failure, amputation of the lower extremities, and new cases of blindness among adults.
(7)Studies have shown that managing diabetes can prevent complications and medical emergencies associated with diabetes that result in emergency room visits, hospitalizations, and costly treatments.
(b)Therefore, it is the intent of the Legislature to enact legislation on important policies to reduce the costs for Californians with diabetes to obtain lifesaving and life-sustaining insulin.
SEC. 2.Section 1367.51 of the Health and Safety Code is amended to read:1367.51.(a)A health care service plan contract, except a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after January 1, 2000, and that covers hospital, medical, or surgical expenses shall include coverage for the following equipment and supplies for the management and treatment of insulin-using diabetes, non-insulin-using diabetes, and gestational diabetes as medically necessary, even if the items are available without a prescription:
(1)Blood glucose monitors and blood glucose testing strips.
(2)Blood glucose monitors designed to assist the visually impaired.
(3)Insulin pumps and all related necessary supplies.
(4)Ketone urine testing strips.
(5)Lancets and lancet puncture devices.
(6)Pen delivery systems for the administration of insulin.
(7)Podiatric devices to prevent or treat diabetes-related complications.
(8)Insulin syringes.
(9)Visual aids, excluding eyewear, to assist the visually impaired with proper dosing of insulin.
(b)A health care service plan contract, except a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after January 1, 2000, that covers prescription benefits shall include coverage for the following prescription items if the items are determined to be medically necessary:
(1)Insulin.
(2)Prescriptive medications for the treatment of diabetes.
(3)Glucagon.
(c)The copayments and deductibles for the benefits specified in subdivisions (a) and (b) shall not exceed those established for similar benefits within the given plan.
(d)(1)Notwithstanding subdivision (c), a large group health care service plan contract that is issued, amended, or renewed on or after January 1, 2026, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply. At least one insulin for a given drug type in all forms and concentrations shall be on the prescription drug formulary.
(2)Notwithstanding subdivision (c), an individual or small group health care service plan contract that is issued, amended, or renewed on or after January 1, 2027, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply. If an individual or small group health care service plan contract maintains a drug formulary grouped into tiers, the cost-sharing cap pursuant to paragraph (1) shall apply only to insulin prescription drugs that are in Tier 1 and Tier 2. At least one insulin for a given drug type in all forms and concentrations shall be on Tier 1 or Tier 2. If there is no Tier 1 or Tier 2 insulin prescription drug that is clinically appropriate for an enrollee, the health care service plan shall limit the cost sharing for a higher tier drug to no more than thirty-five dollars ($35) for a 30-day supply for an individual enrollee.
(3)If a health care service plan contract is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose a deductible, coinsurance, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply, unless applying the thirty-five-dollar ($35) limitation for a 30-day supply of an insulin prescription drug would conflict with federal requirements for high deductible health plans.
(4)When the state has the capacity to label or produce an insulin prescription drug, the deductible and copayment limitations in paragraph (1) shall also apply to an insulin prescription drug, or any therapeutic equivalent insulin prescription drug, that is labeled or produced by the state.
(5)For purposes of this subdivision and subdivision (e):
(A)Drug type includes, but is not limited to, rapid acting, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed.
(B)Insulin prescription drug means a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.
(e)(1)Consistent with this section, on and after January 1, 2026, a health care service plan shall not impose step therapy protocols as a prerequisite to authorizing coverage of an insulin prescription drug described in subdivision (d), except as provided in paragraph (2). For purposes of this section, step therapy protocol means a process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed. For purposes of this section, step therapy is prohibited for both self-administered drugs and physician-administered drugs, except as provided in paragraph (2).
(2)Because the United States Food and Drug Administration has approved one or more types of insulin, this section does not require a health care service plan to cover all of the types of insulin without step therapy, if at least one insulin in each drug type is covered without step therapy.
(3)This subdivision does not apply to Medi-Cal managed care plans contracting with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14591) of Part 3 of Division 9 of the Welfare and Institutions Code.
(f)A health care service plan shall provide coverage for diabetes outpatient self-management training, education, and medical nutrition therapy necessary to enable an enrollee to properly use the equipment, supplies, and medications set forth in subdivisions (a) and (b), and additional diabetes outpatient self-management training, education, and medical nutrition therapy upon the direction or prescription of those services by the enrollees participating physician. If a plan delegates outpatient self-management training to contracting providers, the plan shall require contracting providers to ensure that diabetes outpatient self-management training, education, and medical nutrition therapy are provided by appropriately licensed or registered health care professionals.
(g)The diabetes outpatient self-management training, education, and medical nutrition therapy services identified in subdivision (f) shall be provided by appropriately licensed or registered health care professionals as prescribed by a participating health care professional legally authorized to prescribe the service. These benefits shall include, but not be limited to, instruction that will enable diabetic patients and their families to gain an understanding of the diabetic disease process, and the daily management of diabetic therapy, in order to thereby avoid frequent hospitalizations and complications.
(h)The copayments for the benefits specified in subdivision (f) shall not exceed those established for physician office visits by the plan.
(i)A health care service plan governed by this section shall disclose the benefits covered pursuant to this section in the plans evidence of coverage and disclosure forms.
(j)A health care service plan shall not reduce or eliminate coverage as a result of this section.
(k)This section does not deny or restrict in any way the departments authority to ensure plan compliance with this chapter if a plan provides coverage for prescription drugs.
(l)This section does not apply to Medi-Cal managed care plans contracting with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14591) of Part 3 of Division 9 of the Welfare and Institutions Code to the extent that the services described in this section are excluded from coverage under the contract between the Medi-Cal managed care plans and the State Department of Health Care Services.
SEC. 3.Section 10176.61 of the Insurance Code is amended to read:10176.61.(a)An insurer issuing, amending, delivering, or renewing a disability insurance policy on or after January 1, 2000, that covers hospital, medical, or surgical expenses shall include coverage for the following equipment and supplies for the management and treatment of insulin-using diabetes, non-insulin-using diabetes, and gestational diabetes as medically necessary, even if the items are available without a prescription:
(1)Blood glucose monitors and blood glucose testing strips.
(2)Blood glucose monitors designed to assist the visually impaired.
(3)Insulin pumps and all related necessary supplies.
(4)Ketone urine testing strips.
(5)Lancets and lancet puncture devices.
(6)Pen delivery systems for the administration of insulin.
(7)Podiatric devices to prevent or treat diabetes-related complications.
(8)Insulin syringes.
(9)Visual aids, excluding eyewear, to assist the visually impaired with proper dosing of insulin.
(b)An insurer issuing, amending, delivering, or renewing a disability insurance policy on or after January 1, 2000, that covers prescription benefits shall include coverage for the following prescription items if the items are determined to be medically necessary:
(1)Insulin.
(2)Prescriptive medications for the treatment of diabetes.
(3)Glucagon.
(c)The coinsurances and deductibles for the benefits specified in subdivisions (a) and (b) shall not exceed those established for similar benefits within the given policy.
(d)(1)Notwithstanding subdivision (c), a large group health insurance policy that is issued, amended, or renewed on or after January 1, 2026, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply. At least one insulin for a given drug type in all forms and concentrations shall be on the prescription drug formulary.
(2)Notwithstanding subdivision (c), an individual or small group health insurance policy that is issued, amended, or renewed on or after January 1, 2027, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply. If an individual or small group health insurance policy maintains a drug formulary grouped into tiers, the cost-sharing cap pursuant to paragraph (1) shall apply only to insulin prescription drugs that are in Tier 1 and Tier 2. At least one insulin for a given drug type in all forms and concentrations shall be on Tier 1 or Tier 2. If there is no Tier 1 or Tier 2 insulin prescription drug that is clinically appropriate for an insured, the health insurer shall limit the cost sharing for a higher tier drug to no more than thirty-five dollars ($35) for a 30-day supply for an individual insured.
(3)If a health insurance policy is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the policy shall not impose a deductible, coinsurance, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply, unless applying the thirty-five-dollar ($35) limitation for a 30-day supply of an insulin prescription drug would conflict with federal requirements for high deductible health plans.
(4)When the state has the capacity to label or produce an insulin prescription drug, the deductible and copayment limitations in paragraph (1) shall also apply to an insulin prescription drug, or any therapeutic equivalent insulin prescription drug, that is labeled or produced by the state.
(5)For purposes of this subdivision and subdivision (e):
(A)Drug type includes, but is not limited to, rapid acting, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed.
(B)Insulin prescription drug means a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.
(e)(1)Consistent with this section, on and after January 1, 2026, a health insurer shall not impose step therapy as a prerequisite to authorizing coverage of an insulin prescription drug described in subdivision (d), except as provided in paragraph (2). For purposes of this section, step therapy has the same meaning as defined in paragraph (2) of subdivision (i) of Section 10123.201. For purposes of this section, step therapy is prohibited for both self-administered drugs and physician-administered drugs, except as provided in paragraph (2).
(2)Because the United States Food and Drug Administration has approved one or more types of insulin, this section does not require a health care service plan to cover all of the types of insulin without step therapy, if at least one insulin in each drug type is covered without step therapy.
(f)An insurer shall provide coverage for diabetes outpatient self-management training, education, and medical nutrition therapy necessary to enable an insured to properly use the equipment, supplies, and medications set forth in subdivisions (a) and (b) and additional diabetes outpatient self-management training, education, and medical nutrition therapy upon the direction or prescription of those services by the insureds participating physician. If an insurer delegates outpatient self-management training to contracting providers, the insurer shall require contracting providers to ensure that diabetes outpatient self-management training, education, and medical nutrition therapy are provided by appropriately licensed or registered health care professionals.
(g)The diabetes outpatient self-management training, education, and medical nutrition therapy services identified in subdivision (f) shall be provided by appropriately licensed or registered health care professionals as prescribed by a health care professional legally authorized to prescribe the services.
(h)The coinsurances and deductibles for the benefits specified in subdivision (f) shall not exceed those established for physician office visits by the insurer.
(i)Every disability insurer governed by this section shall disclose the benefits covered pursuant to this section in the insurers evidence of coverage and disclosure forms.
(j)An insurer shall not reduce or eliminate coverage as a result of this section.
(k)This section does not apply to vision-only, dental-only, accident-only, specified disease, hospital indemnity, Medicare supplement, long-term care, or disability income insurance, except that for accident-only, specified disease, and hospital indemnity insurance coverage, benefits under this section only apply to the extent that the benefits are covered under the general terms and conditions that apply to all other benefits under the policy. This section does not impose a new benefit mandate on accident-only, specified disease, or hospital indemnity insurance.
SEC. 4.The provisions of this act are severable. If any provision of this act or its application is held invalid, that invalidity shall not affect other provisions or applications that can be given effect without the invalid provision or application.
SEC. 5.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)The Legislature finds and declares all of the following:
(1)Approximately 263,000 Californians are diagnosed with type 1 diabetes each year. Approximately 4,037,000 Californian adults have diabetes.
(2)Every Californian with type 1 diabetes, and many with type 2 diabetes, rely on daily doses of insulin to survive.
(3)Insulin prices have nearly tripled, creating financial hardships for people who rely on it to survive.
(4)One in four people using insulin have reported insulin underuse due to the high cost of insulin.
(5)Imposing a deductible on insulin, and requiring individuals to meet that deductible, creates a financial burden that presents a barrier to accessing insulin.
(6)Diabetes is the seventh leading cause of death, and it is a leading cause of disabling and life-threatening complications, including heart disease, stroke, kidney failure, amputation of the lower extremities, and new cases of blindness among adults.
(7)Studies have shown that managing diabetes can prevent complications and medical emergencies associated with diabetes that result in emergency room visits, hospitalizations, and costly treatments.
(b)Therefore, it is the intent of the Legislature to enact legislation on important policies to reduce the costs for Californians with diabetes to obtain lifesaving and life-sustaining insulin.
SEC. 2.Section 1367.51 of the Health and Safety Code is amended to read:1367.51.(a)A health care service plan contract, except a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after January 1, 2000, and that covers hospital, medical, or surgical expenses shall include coverage for the following equipment and supplies for the management and treatment of insulin-using diabetes, non-insulin-using diabetes, and gestational diabetes as medically necessary, even if the items are available without a prescription:
(1)Blood glucose monitors and blood glucose testing strips.
(2)Blood glucose monitors designed to assist the visually impaired.
(3)Insulin pumps and all related necessary supplies.
(4)Ketone urine testing strips.
(5)Lancets and lancet puncture devices.
(6)Pen delivery systems for the administration of insulin.
(7)Podiatric devices to prevent or treat diabetes-related complications.
(8)Insulin syringes.
(9)Visual aids, excluding eyewear, to assist the visually impaired with proper dosing of insulin.
(b)A health care service plan contract, except a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after January 1, 2000, that covers prescription benefits shall include coverage for the following prescription items if the items are determined to be medically necessary:
(1)Insulin.
(2)Prescriptive medications for the treatment of diabetes.
(3)Glucagon.
(c)The copayments and deductibles for the benefits specified in subdivisions (a) and (b) shall not exceed those established for similar benefits within the given plan.
(d)(1)Notwithstanding subdivision (c), a large group health care service plan contract that is issued, amended, or renewed on or after January 1, 2026, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply. At least one insulin for a given drug type in all forms and concentrations shall be on the prescription drug formulary.
(2)Notwithstanding subdivision (c), an individual or small group health care service plan contract that is issued, amended, or renewed on or after January 1, 2027, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply. If an individual or small group health care service plan contract maintains a drug formulary grouped into tiers, the cost-sharing cap pursuant to paragraph (1) shall apply only to insulin prescription drugs that are in Tier 1 and Tier 2. At least one insulin for a given drug type in all forms and concentrations shall be on Tier 1 or Tier 2. If there is no Tier 1 or Tier 2 insulin prescription drug that is clinically appropriate for an enrollee, the health care service plan shall limit the cost sharing for a higher tier drug to no more than thirty-five dollars ($35) for a 30-day supply for an individual enrollee.
(3)If a health care service plan contract is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose a deductible, coinsurance, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply, unless applying the thirty-five-dollar ($35) limitation for a 30-day supply of an insulin prescription drug would conflict with federal requirements for high deductible health plans.
(4)When the state has the capacity to label or produce an insulin prescription drug, the deductible and copayment limitations in paragraph (1) shall also apply to an insulin prescription drug, or any therapeutic equivalent insulin prescription drug, that is labeled or produced by the state.
(5)For purposes of this subdivision and subdivision (e):
(A)Drug type includes, but is not limited to, rapid acting, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed.
(B)Insulin prescription drug means a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.
(e)(1)Consistent with this section, on and after January 1, 2026, a health care service plan shall not impose step therapy protocols as a prerequisite to authorizing coverage of an insulin prescription drug described in subdivision (d), except as provided in paragraph (2). For purposes of this section, step therapy protocol means a process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed. For purposes of this section, step therapy is prohibited for both self-administered drugs and physician-administered drugs, except as provided in paragraph (2).
(2)Because the United States Food and Drug Administration has approved one or more types of insulin, this section does not require a health care service plan to cover all of the types of insulin without step therapy, if at least one insulin in each drug type is covered without step therapy.
(3)This subdivision does not apply to Medi-Cal managed care plans contracting with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14591) of Part 3 of Division 9 of the Welfare and Institutions Code.
(f)A health care service plan shall provide coverage for diabetes outpatient self-management training, education, and medical nutrition therapy necessary to enable an enrollee to properly use the equipment, supplies, and medications set forth in subdivisions (a) and (b), and additional diabetes outpatient self-management training, education, and medical nutrition therapy upon the direction or prescription of those services by the enrollees participating physician. If a plan delegates outpatient self-management training to contracting providers, the plan shall require contracting providers to ensure that diabetes outpatient self-management training, education, and medical nutrition therapy are provided by appropriately licensed or registered health care professionals.
(g)The diabetes outpatient self-management training, education, and medical nutrition therapy services identified in subdivision (f) shall be provided by appropriately licensed or registered health care professionals as prescribed by a participating health care professional legally authorized to prescribe the service. These benefits shall include, but not be limited to, instruction that will enable diabetic patients and their families to gain an understanding of the diabetic disease process, and the daily management of diabetic therapy, in order to thereby avoid frequent hospitalizations and complications.
(h)The copayments for the benefits specified in subdivision (f) shall not exceed those established for physician office visits by the plan.
(i)A health care service plan governed by this section shall disclose the benefits covered pursuant to this section in the plans evidence of coverage and disclosure forms.
(j)A health care service plan shall not reduce or eliminate coverage as a result of this section.
(k)This section does not deny or restrict in any way the departments authority to ensure plan compliance with this chapter if a plan provides coverage for prescription drugs.
(l)This section does not apply to Medi-Cal managed care plans contracting with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14591) of Part 3 of Division 9 of the Welfare and Institutions Code to the extent that the services described in this section are excluded from coverage under the contract between the Medi-Cal managed care plans and the State Department of Health Care Services.
SEC. 3.Section 10176.61 of the Insurance Code is amended to read:10176.61.(a)An insurer issuing, amending, delivering, or renewing a disability insurance policy on or after January 1, 2000, that covers hospital, medical, or surgical expenses shall include coverage for the following equipment and supplies for the management and treatment of insulin-using diabetes, non-insulin-using diabetes, and gestational diabetes as medically necessary, even if the items are available without a prescription:
(1)Blood glucose monitors and blood glucose testing strips.
(2)Blood glucose monitors designed to assist the visually impaired.
(3)Insulin pumps and all related necessary supplies.
(4)Ketone urine testing strips.
(5)Lancets and lancet puncture devices.
(6)Pen delivery systems for the administration of insulin.
(7)Podiatric devices to prevent or treat diabetes-related complications.
(8)Insulin syringes.
(9)Visual aids, excluding eyewear, to assist the visually impaired with proper dosing of insulin.
(b)An insurer issuing, amending, delivering, or renewing a disability insurance policy on or after January 1, 2000, that covers prescription benefits shall include coverage for the following prescription items if the items are determined to be medically necessary:
(1)Insulin.
(2)Prescriptive medications for the treatment of diabetes.
(3)Glucagon.
(c)The coinsurances and deductibles for the benefits specified in subdivisions (a) and (b) shall not exceed those established for similar benefits within the given policy.
(d)(1)Notwithstanding subdivision (c), a large group health insurance policy that is issued, amended, or renewed on or after January 1, 2026, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply. At least one insulin for a given drug type in all forms and concentrations shall be on the prescription drug formulary.
(2)Notwithstanding subdivision (c), an individual or small group health insurance policy that is issued, amended, or renewed on or after January 1, 2027, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply. If an individual or small group health insurance policy maintains a drug formulary grouped into tiers, the cost-sharing cap pursuant to paragraph (1) shall apply only to insulin prescription drugs that are in Tier 1 and Tier 2. At least one insulin for a given drug type in all forms and concentrations shall be on Tier 1 or Tier 2. If there is no Tier 1 or Tier 2 insulin prescription drug that is clinically appropriate for an insured, the health insurer shall limit the cost sharing for a higher tier drug to no more than thirty-five dollars ($35) for a 30-day supply for an individual insured.
(3)If a health insurance policy is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the policy shall not impose a deductible, coinsurance, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply, unless applying the thirty-five-dollar ($35) limitation for a 30-day supply of an insulin prescription drug would conflict with federal requirements for high deductible health plans.
(4)When the state has the capacity to label or produce an insulin prescription drug, the deductible and copayment limitations in paragraph (1) shall also apply to an insulin prescription drug, or any therapeutic equivalent insulin prescription drug, that is labeled or produced by the state.
(5)For purposes of this subdivision and subdivision (e):
(A)Drug type includes, but is not limited to, rapid acting, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed.
(B)Insulin prescription drug means a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.
(e)(1)Consistent with this section, on and after January 1, 2026, a health insurer shall not impose step therapy as a prerequisite to authorizing coverage of an insulin prescription drug described in subdivision (d), except as provided in paragraph (2). For purposes of this section, step therapy has the same meaning as defined in paragraph (2) of subdivision (i) of Section 10123.201. For purposes of this section, step therapy is prohibited for both self-administered drugs and physician-administered drugs, except as provided in paragraph (2).
(2)Because the United States Food and Drug Administration has approved one or more types of insulin, this section does not require a health care service plan to cover all of the types of insulin without step therapy, if at least one insulin in each drug type is covered without step therapy.
(f)An insurer shall provide coverage for diabetes outpatient self-management training, education, and medical nutrition therapy necessary to enable an insured to properly use the equipment, supplies, and medications set forth in subdivisions (a) and (b) and additional diabetes outpatient self-management training, education, and medical nutrition therapy upon the direction or prescription of those services by the insureds participating physician. If an insurer delegates outpatient self-management training to contracting providers, the insurer shall require contracting providers to ensure that diabetes outpatient self-management training, education, and medical nutrition therapy are provided by appropriately licensed or registered health care professionals.
(g)The diabetes outpatient self-management training, education, and medical nutrition therapy services identified in subdivision (f) shall be provided by appropriately licensed or registered health care professionals as prescribed by a health care professional legally authorized to prescribe the services.
(h)The coinsurances and deductibles for the benefits specified in subdivision (f) shall not exceed those established for physician office visits by the insurer.
(i)Every disability insurer governed by this section shall disclose the benefits covered pursuant to this section in the insurers evidence of coverage and disclosure forms.
(j)An insurer shall not reduce or eliminate coverage as a result of this section.
(k)This section does not apply to vision-only, dental-only, accident-only, specified disease, hospital indemnity, Medicare supplement, long-term care, or disability income insurance, except that for accident-only, specified disease, and hospital indemnity insurance coverage, benefits under this section only apply to the extent that the benefits are covered under the general terms and conditions that apply to all other benefits under the policy. This section does not impose a new benefit mandate on accident-only, specified disease, or hospital indemnity insurance.
SEC. 4.The provisions of this act are severable. If any provision of this act or its application is held invalid, that invalidity shall not affect other provisions or applications that can be given effect without the invalid provision or application.
SEC. 5.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)The Legislature finds and declares all of the following:
(1)Approximately 263,000 Californians are diagnosed with type 1 diabetes each year. Approximately 4,037,000 Californian adults have diabetes.
(2)Every Californian with type 1 diabetes, and many with type 2 diabetes, rely on daily doses of insulin to survive.
(3)Insulin prices have nearly tripled, creating financial hardships for people who rely on it to survive.
(4)One in four people using insulin have reported insulin underuse due to the high cost of insulin.
(5)Imposing a deductible on insulin, and requiring individuals to meet that deductible, creates a financial burden that presents a barrier to accessing insulin.
(6)Diabetes is the seventh leading cause of death, and it is a leading cause of disabling and life-threatening complications, including heart disease, stroke, kidney failure, amputation of the lower extremities, and new cases of blindness among adults.
(7)Studies have shown that managing diabetes can prevent complications and medical emergencies associated with diabetes that result in emergency room visits, hospitalizations, and costly treatments.
(b)Therefore, it is the intent of the Legislature to enact legislation on important policies to reduce the costs for Californians with diabetes to obtain lifesaving and life-sustaining insulin.
SEC. 2.Section 1367.51 of the Health and Safety Code is amended to read:1367.51.(a)A health care service plan contract, except a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after January 1, 2000, and that covers hospital, medical, or surgical expenses shall include coverage for the following equipment and supplies for the management and treatment of insulin-using diabetes, non-insulin-using diabetes, and gestational diabetes as medically necessary, even if the items are available without a prescription:
(1)Blood glucose monitors and blood glucose testing strips.
(2)Blood glucose monitors designed to assist the visually impaired.
(3)Insulin pumps and all related necessary supplies.
(4)Ketone urine testing strips.
(5)Lancets and lancet puncture devices.
(6)Pen delivery systems for the administration of insulin.
(7)Podiatric devices to prevent or treat diabetes-related complications.
(8)Insulin syringes.
(9)Visual aids, excluding eyewear, to assist the visually impaired with proper dosing of insulin.
(b)A health care service plan contract, except a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after January 1, 2000, that covers prescription benefits shall include coverage for the following prescription items if the items are determined to be medically necessary:
(1)Insulin.
(2)Prescriptive medications for the treatment of diabetes.
(3)Glucagon.
(c)The copayments and deductibles for the benefits specified in subdivisions (a) and (b) shall not exceed those established for similar benefits within the given plan.
(d)(1)Notwithstanding subdivision (c), a large group health care service plan contract that is issued, amended, or renewed on or after January 1, 2026, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply. At least one insulin for a given drug type in all forms and concentrations shall be on the prescription drug formulary.
(2)Notwithstanding subdivision (c), an individual or small group health care service plan contract that is issued, amended, or renewed on or after January 1, 2027, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply. If an individual or small group health care service plan contract maintains a drug formulary grouped into tiers, the cost-sharing cap pursuant to paragraph (1) shall apply only to insulin prescription drugs that are in Tier 1 and Tier 2. At least one insulin for a given drug type in all forms and concentrations shall be on Tier 1 or Tier 2. If there is no Tier 1 or Tier 2 insulin prescription drug that is clinically appropriate for an enrollee, the health care service plan shall limit the cost sharing for a higher tier drug to no more than thirty-five dollars ($35) for a 30-day supply for an individual enrollee.
(3)Notwithstanding paragraphs (1) and (2), if If a health care service plan contract is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose a deductible, coinsurance, or any other cost sharing on an insulin prescription drug, unless not applying the deductible, coinsurance, or other cost sharing to drug that exceeds thirty-five dollars ($35) for a 30-day supply, unless applying the thirty-five-dollar ($35) limitation for a 30-day supply of an insulin prescription drug would conflict with federal requirements for high deductible health plans.
(4)When the state has the capacity to label or produce an insulin prescription drug, the deductible and copayment limitations in paragraph (1) shall also apply to an insulin prescription drug, or any therapeutic equivalent insulin prescription drug, that is labeled or produced by the state.
(5)For purposes of this subdivision and subdivision (e):
(A)Drug type includes, but is not limited to, rapid acting, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed.
(B)Insulin prescription drug means a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.
(e)(1)Consistent with this section, on and after January 1, 2026, a health care service plan shall not impose step therapy protocols as a prerequisite to authorizing coverage of an insulin prescription drug described in subdivision (d), except as provided in paragraph (2). For purposes of this section, step therapy protocol means a process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed. For purposes of this section, step therapy is prohibited for both self-administered drugs and physician-administered drugs, except as provided in paragraph (2).
(2)Because the United States Food and Drug Administration has approved one or more types of insulin, this section does not require a health care service plan to cover all of the types of insulin without step therapy, if at least one insulin in each drug type is covered without step therapy.
(3)This subdivision does not apply to Medi-Cal managed care plans contracting with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14591) of Part 3 of Division 9 of the Welfare and Institutions Code.
(f)A health care service plan shall provide coverage for diabetes outpatient self-management training, education, and medical nutrition therapy necessary to enable an enrollee to properly use the equipment, supplies, and medications set forth in subdivisions (a) and (b), and additional diabetes outpatient self-management training, education, and medical nutrition therapy upon the direction or prescription of those services by the enrollees participating physician. If a plan delegates outpatient self-management training to contracting providers, the plan shall require contracting providers to ensure that diabetes outpatient self-management training, education, and medical nutrition therapy are provided by appropriately licensed or registered health care professionals.
(g)The diabetes outpatient self-management training, education, and medical nutrition therapy services identified in subdivision (f) shall be provided by appropriately licensed or registered health care professionals as prescribed by a participating health care professional legally authorized to prescribe the service. These benefits shall include, but not be limited to, instruction that will enable diabetic patients and their families to gain an understanding of the diabetic disease process, and the daily management of diabetic therapy, in order to thereby avoid frequent hospitalizations and complications.
(h)The copayments for the benefits specified in subdivision (f) shall not exceed those established for physician office visits by the plan.
(i)A health care service plan governed by this section shall disclose the benefits covered pursuant to this section in the plans evidence of coverage and disclosure forms.
(j)A health care service plan shall not reduce or eliminate coverage as a result of this section.
(k)This section does not deny or restrict in any way the departments authority to ensure plan compliance with this chapter if a plan provides coverage for prescription drugs.
(l)This section does not apply to Medi-Cal managed care plans contracting with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14591) of Part 3 of Division 9 of the Welfare and Institutions Code to the extent that the services described in this section are excluded from coverage under the contract between the Medi-Cal managed care plans and the State Department of Health Care Services.
SEC. 3.Section 10176.61 of the Insurance Code is amended to read:10176.61.(a)An insurer issuing, amending, delivering, or renewing a disability insurance policy on or after January 1, 2000, that covers hospital, medical, or surgical expenses shall include coverage for the following equipment and supplies for the management and treatment of insulin-using diabetes, non-insulin-using diabetes, and gestational diabetes as medically necessary, even if the items are available without a prescription:
(1)Blood glucose monitors and blood glucose testing strips.
(2)Blood glucose monitors designed to assist the visually impaired.
(3)Insulin pumps and all related necessary supplies.
(4)Ketone urine testing strips.
(5)Lancets and lancet puncture devices.
(6)Pen delivery systems for the administration of insulin.
(7)Podiatric devices to prevent or treat diabetes-related complications.
(8)Insulin syringes.
(9)Visual aids, excluding eyewear, to assist the visually impaired with proper dosing of insulin.
(b)An insurer issuing, amending, delivering, or renewing a disability insurance policy on or after January 1, 2000, that covers prescription benefits shall include coverage for the following prescription items if the items are determined to be medically necessary:
(1)Insulin.
(2)Prescriptive medications for the treatment of diabetes.
(3)Glucagon.
(c)The coinsurances and deductibles for the benefits specified in subdivisions (a) and (b) shall not exceed those established for similar benefits within the given policy.
(d)(1)Notwithstanding subdivision (c), a large group health insurance policy that is issued, amended, or renewed on or after January 1, 2026, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply. At least one insulin for a given drug type in all forms and concentrations shall be on the prescription drug formulary.
(2)Notwithstanding subdivision (c), an individual or small group health insurance policy that is issued, amended, or renewed on or after January 1, 2027, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply. If an individual or small group health insurance policy maintains a drug formulary grouped into tiers, the cost-sharing cap pursuant to paragraph (1) shall apply only to insulin prescription drugs that are in Tier 1 and Tier 2. At least one insulin for a given drug type in all forms and concentrations shall be on Tier 1 or Tier 2. If there is no Tier 1 or Tier 2 insulin prescription drug that is clinically appropriate for an insured, the health insurer shall limit the cost sharing for a higher tier drug to no more than thirty-five dollars ($35) for a 30-day supply for an individual insured.
(3)Notwithstanding paragraphs (1) and (2), if If a health insurance policy is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the policy shall not impose a deductible, coinsurance, or any other cost sharing on an insulin prescription drug, unless not applying the deductible, coinsurance, or other cost sharing to drug that exceeds thirty-five dollars ($35) for a 30-day supply, unless applying the thirty-five-dollar ($35) limitation for a 30-day supply of an insulin prescription drug would conflict with federal requirements for high deductible health plans.
(4)When the state has the capacity to label or produce an insulin prescription drug, the deductible and copayment limitations in paragraph (1) shall also apply to an insulin prescription drug, or any therapeutic equivalent insulin prescription drug, that is labeled or produced by the state.
(5)For purposes of this subdivision and subdivision (e):
(A)Drug type includes, but is not limited to, rapid acting, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed.
(B)Insulin prescription drug means a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.
(e)(1)Consistent with this section, on and after January 1, 2026, a health insurer shall not impose step therapy as a prerequisite to authorizing coverage of an insulin prescription drug described in subdivision (d), except as provided in paragraph (2). For purposes of this section, step therapy has the same meaning as defined in paragraph (2) of subdivision (i) of Section 10123.201. For purposes of this section, step therapy is prohibited for both self-administered drugs and physician-administered drugs, except as provided in paragraph (2).
(2)Because the United States Food and Drug Administration has approved one or more types of insulin, this section does not require a health care service plan to cover all of the types of insulin without step therapy, if at least one insulin in each drug type is covered without step therapy.
(f)An insurer shall provide coverage for diabetes outpatient self-management training, education, and medical nutrition therapy necessary to enable an insured to properly use the equipment, supplies, and medications set forth in subdivisions (a) and (b) and additional diabetes outpatient self-management training, education, and medical nutrition therapy upon the direction or prescription of those services by the insureds participating physician. If an insurer delegates outpatient self-management training to contracting providers, the insurer shall require contracting providers to ensure that diabetes outpatient self-management training, education, and medical nutrition therapy are provided by appropriately licensed or registered health care professionals.
(g)The diabetes outpatient self-management training, education, and medical nutrition therapy services identified in subdivision (f) shall be provided by appropriately licensed or registered health care professionals as prescribed by a health care professional legally authorized to prescribe the services.
(h)The coinsurances and deductibles for the benefits specified in subdivision (f) shall not exceed those established for physician office visits by the insurer.
(i)Every disability insurer governed by this section shall disclose the benefits covered pursuant to this section in the insurers evidence of coverage and disclosure forms.
(j)An insurer shall not reduce or eliminate coverage as a result of this section.
(k)This section does not apply to vision-only, dental-only, accident-only, specified disease, hospital indemnity, Medicare supplement, long-term care, or disability income insurance, except that for accident-only, specified disease, and hospital indemnity insurance coverage, benefits under this section only apply to the extent that the benefits are covered under the general terms and conditions that apply to all other benefits under the policy. This section does not impose a new benefit mandate on accident-only, specified disease, or hospital indemnity insurance.
SEC. 4.The provisions of this act are severable. If any provision of this act or its application is held invalid, that invalidity shall not affect other provisions or applications that can be given effect without the invalid provision or application.
SEC. 5.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)The Legislature finds and declares all of the following:
(1)Approximately 263,000 Californians are diagnosed with type 1 diabetes each year. Approximately 4,037,000 Californian adults have diabetes.
(2)Every Californian with type 1 diabetes, and many with type 2 diabetes, rely on daily doses of insulin to survive.
(3)Insulin prices have nearly tripled, creating financial hardships for people who rely on it to survive.
(4)One in four people using insulin have reported insulin underuse due to the high cost of insulin.
(5)Imposing a deductible on insulin, and requiring individuals to meet that deductible, creates a financial burden that presents a barrier to accessing insulin.
(6)Diabetes is the seventh leading cause of death, and it is a leading cause of disabling and life-threatening complications, including heart disease, stroke, kidney failure, amputation of the lower extremities, and new cases of blindness among adults.
(7)Studies have shown that managing diabetes can prevent complications and medical emergencies associated with diabetes that result in emergency room visits, hospitalizations, and costly treatments.
(b)Therefore, it is the intent of the Legislature to enact legislation on important policies to reduce the costs for Californians with diabetes to obtain lifesaving and life-sustaining insulin.
SEC. 2.Section 1367.51 of the Health and Safety Code is amended to read:1367.51.(a)A health care service plan contract, except a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after January 1, 2000, and that covers hospital, medical, or surgical expenses shall include coverage for the following equipment and supplies for the management and treatment of insulin-using diabetes, non-insulin-using diabetes, and gestational diabetes as medically necessary, even if the items are available without a prescription:
(1)Blood glucose monitors and blood glucose testing strips.
(2)Blood glucose monitors designed to assist the visually impaired.
(3)Insulin pumps and all related necessary supplies.
(4)Ketone urine testing strips.
(5)Lancets and lancet puncture devices.
(6)Pen delivery systems for the administration of insulin.
(7)Podiatric devices to prevent or treat diabetes-related complications.
(8)Insulin syringes.
(9)Visual aids, excluding eyewear, to assist the visually impaired with proper dosing of insulin.
(b)A health care service plan contract, except a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after January 1, 2000, that covers prescription benefits shall include coverage for the following prescription items if the items are determined to be medically necessary:
(1)Insulin.
(2)Prescriptive medications for the treatment of diabetes.
(3)Glucagon.
(c)The copayments and deductibles for the benefits specified in subdivisions (a) and (b) shall not exceed those established for similar benefits within the given plan.
(d)(1)Notwithstanding subdivision (c), a large group health care service plan contract that is issued, amended, or renewed on or after January 1, 2026, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply. At least one insulin for a given drug type in all forms and concentrations shall be on the prescription drug formulary.
(2)Notwithstanding subdivision (c), an individual or small group health care service plan contract that is issued, amended, or renewed on or after January 1, 2027, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply. If an individual or small group health care service plan contract maintains a drug formulary grouped into tiers, the cost-sharing cap pursuant to paragraph (1) shall apply only to insulin prescription drugs that are in Tier 1 and Tier 2. At least one insulin for a given drug type in all forms and concentrations shall be on Tier 1 or Tier 2. If there is no Tier 1 or Tier 2 insulin prescription drug that is clinically appropriate for an enrollee, the health care service plan shall limit the cost sharing for a higher tier drug to no more than thirty-five dollars ($35) for a 30-day supply for an individual enrollee.
(3)Notwithstanding paragraphs (1) and (2), if a health care service plan contract is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose a deductible, coinsurance, or any other cost sharing on an insulin prescription drug, unless not applying the deductible, coinsurance, or other cost sharing to an insulin prescription drug would conflict with federal requirements for high deductible health plans.
(4)When the state has the capacity to label or produce an insulin prescription drug, the deductible and copayment limitations in paragraph (1) shall also apply to an insulin prescription drug, or any therapeutic equivalent insulin prescription drug, that is labeled or produced by the state.
(5)For purposes of this subdivision: subdivision and subdivision (e):
(A)Drug type includes, but is not limited to, rapid acting, rapid acting inhaled, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed.
(B)Insulin prescription drug means a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.
(e)(1)Consistent with this section, on and after January 1, 2026, a health care service plan shall not impose step therapy protocols as a prerequisite to authorizing coverage of an insulin prescription drug described in subdivision (d), except as provided in paragraph (2). For purposes of this section, step therapy protocol means a process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed. For purposes of this section, step therapy is prohibited for both self-administered drugs and physician-administered drugs, except as provided in paragraph (2).
(2)Because the United States Food and Drug Administration has approved one or more types of insulin, this section does not require a health care service plan to cover all of the types of insulin without step therapy, if at least one insulin in each drug type is covered without step therapy. For purposes of this paragraph, drug type includes, but is not limited to, rapid acting, rapid acting inhaled, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed.
(f)A health care service plan shall provide coverage for diabetes outpatient self-management training, education, and medical nutrition therapy necessary to enable an enrollee to properly use the equipment, supplies, and medications set forth in subdivisions (a) and (b), and additional diabetes outpatient self-management training, education, and medical nutrition therapy upon the direction or prescription of those services by the enrollees participating physician. If a plan delegates outpatient self-management training to contracting providers, the plan shall require contracting providers to ensure that diabetes outpatient self-management training, education, and medical nutrition therapy are provided by appropriately licensed or registered health care professionals.
(g)The diabetes outpatient self-management training, education, and medical nutrition therapy services identified in subdivision (f) shall be provided by appropriately licensed or registered health care professionals as prescribed by a participating health care professional legally authorized to prescribe the service. These benefits shall include, but not be limited to, instruction that will enable diabetic patients and their families to gain an understanding of the diabetic disease process, and the daily management of diabetic therapy, in order to thereby avoid frequent hospitalizations and complications.
(h)The copayments for the benefits specified in subdivision (f) shall not exceed those established for physician office visits by the plan.
(i)A health care service plan governed by this section shall disclose the benefits covered pursuant to this section in the plans evidence of coverage and disclosure forms.
(j)A health care service plan shall not reduce or eliminate coverage as a result of this section.
(k)This section does not deny or restrict in any way the departments authority to ensure plan compliance with this chapter if a plan provides coverage for prescription drugs.
SEC. 3.Section 10176.61 of the Insurance Code is amended to read:10176.61.(a)An insurer issuing, amending, delivering, or renewing a disability insurance policy on or after January 1, 2000, that covers hospital, medical, or surgical expenses shall include coverage for the following equipment and supplies for the management and treatment of insulin-using diabetes, non-insulin-using diabetes, and gestational diabetes as medically necessary, even if the items are available without a prescription:
(1)Blood glucose monitors and blood glucose testing strips.
(2)Blood glucose monitors designed to assist the visually impaired.
(3)Insulin pumps and all related necessary supplies.
(4)Ketone urine testing strips.
(5)Lancets and lancet puncture devices.
(6)Pen delivery systems for the administration of insulin.
(7)Podiatric devices to prevent or treat diabetes-related complications.
(8)Insulin syringes.
(9)Visual aids, excluding eyewear, to assist the visually impaired with proper dosing of insulin.
(b)An insurer issuing, amending, delivering, or renewing a disability insurance policy on or after January 1, 2000, that covers prescription benefits shall include coverage for the following prescription items if the items are determined to be medically necessary:
(1)Insulin.
(2)Prescriptive medications for the treatment of diabetes.
(3)Glucagon.
(c)The coinsurances and deductibles for the benefits specified in subdivisions (a) and (b) shall not exceed those established for similar benefits within the given policy.
(d)(1)Notwithstanding subdivision (c), a large group health insurance policy that is issued, amended, or renewed on or after January 1, 2026, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply. At least one insulin for a given drug type in all forms and concentrations shall be on the prescription drug formulary.
(2)Notwithstanding subdivision (c), an individual or small group health insurance policy that is issued, amended, or renewed on or after January 1, 2027, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply. If an individual or small group health insurance policy maintains a drug formulary grouped into tiers, the cost-sharing cap pursuant to paragraph (1) shall apply only to insulin prescription drugs that are in Tier 1 and Tier 2. At least one insulin for a given drug type in all forms and concentrations shall be on Tier 1 or Tier 2. If there is no Tier 1 or Tier 2 insulin prescription drug that is clinically appropriate for an insured, the health insurer shall limit the cost sharing for a higher tier drug to no more than thirty-five dollars ($35) for a 30-day supply for an individual insured.
(3)Notwithstanding paragraphs (1) and (2), if a health insurance policy is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the policy shall not impose a deductible, coinsurance, or any other cost sharing on an insulin prescription drug, unless not applying the deductible, coinsurance, or other cost sharing to an insulin prescription drug would conflict with federal requirements for high deductible health plans.
(4)When the state has the capacity to label or produce an insulin prescription drug, the deductible and copayment limitations in paragraph (1) shall also apply to an insulin prescription drug, or any therapeutic equivalent insulin prescription drug, that is labeled or produced by the state.
(5)For purposes of this subdivision: subdivision and subdivision (e):
(A)Drug type includes, but is not limited to, rapid acting, rapid acting inhaled, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed.
(B)Insulin prescription drug means a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.
(e)(1)Consistent with this section, on and after January 1, 2026, a health insurer shall not impose step therapy as a prerequisite to authorizing coverage of an insulin prescription drug described in subdivision (d), except as provided in paragraph (2). For purposes of this section, step therapy has the same meaning as defined in paragraph (2) of subdivision (i) of Section 10123.201. For purposes of this section, step therapy is prohibited for both self-administered drugs and physician-administered drugs, except as provided in paragraph (2).
(2)Because the United States Food and Drug Administration has approved one or more types of insulin, this section does not require a health care service plan to cover all of the types of insulin without step therapy, if at least one insulin in each drug type is covered without step therapy. For purposes of this paragraph, drug type includes, but is not limited to, rapid acting, rapid acting inhaled, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed.
(f)An insurer shall provide coverage for diabetes outpatient self-management training, education, and medical nutrition therapy necessary to enable an insured to properly use the equipment, supplies, and medications set forth in subdivisions (a) and (b) and additional diabetes outpatient self-management training, education, and medical nutrition therapy upon the direction or prescription of those services by the insureds participating physician. If an insurer delegates outpatient self-management training to contracting providers, the insurer shall require contracting providers to ensure that diabetes outpatient self-management training, education, and medical nutrition therapy are provided by appropriately licensed or registered health care professionals.
(g)The diabetes outpatient self-management training, education, and medical nutrition therapy services identified in subdivision (f) shall be provided by appropriately licensed or registered health care professionals as prescribed by a health care professional legally authorized to prescribe the services.
(h)The coinsurances and deductibles for the benefits specified in subdivision (f) shall not exceed those established for physician office visits by the insurer.
(i)Every disability insurer governed by this section shall disclose the benefits covered pursuant to this section in the insurers evidence of coverage and disclosure forms.
(j)An insurer shall not reduce or eliminate coverage as a result of this section.
(k)This section does not apply to vision-only, dental-only, accident-only, specified disease, hospital indemnity, Medicare supplement, long-term care, or disability income insurance, except that for accident-only, specified disease, and hospital indemnity insurance coverage, benefits under this section only apply to the extent that the benefits are covered under the general terms and conditions that apply to all other benefits under the policy. This section does not impose a new benefit mandate on accident-only, specified disease, or hospital indemnity insurance.
SEC. 4.The provisions of this act are severable. If any provision of this act or its application is held invalid, that invalidity shall not affect other provisions or applications that can be given effect without the invalid provision or application.
SEC. 5.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)The Legislature finds and declares all of the following:
(1)Approximately 263,000 Californians are diagnosed with type 1 diabetes each year. Approximately 4,037,000 Californian adults have diabetes.
(2)Every Californian with type 1 diabetes, and many with type 2 diabetes, rely on daily doses of insulin to survive.
(3)Insulin prices have nearly tripled, creating financial hardships for people who rely on it to survive.
(4)One in four people using insulin have reported insulin underuse due to the high cost of insulin.
(5)Imposing a deductible on insulin, and requiring individuals to meet that deductible, creates a financial burden that presents a barrier to accessing insulin.
(6)Diabetes is the seventh leading cause of death, and it is a leading cause of disabling and life-threatening complications, including heart disease, stroke, kidney failure, amputation of the lower extremities, and new cases of blindness among adults.
(7)Studies have shown that managing diabetes can prevent complications and medical emergencies associated with diabetes that result in emergency room visits, hospitalizations, and costly treatments.
(b)Therefore, it is the intent of the Legislature to enact legislation on important policies to reduce the costs for Californians with diabetes to obtain lifesaving and life-sustaining insulin.
SEC. 2.Section 1367.51 of the Health and Safety Code is amended to read:1367.51.(a)A health care service plan contract, except a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after January 1, 2000, and that covers hospital, medical, or surgical expenses shall include coverage for the following equipment and supplies for the management and treatment of insulin-using diabetes, non-insulin-using diabetes, and gestational diabetes as medically necessary, even if the items are available without a prescription:
(1)Blood glucose monitors and blood glucose testing strips.
(2)Blood glucose monitors designed to assist the visually impaired.
(3)Insulin pumps and all related necessary supplies.
(4)Ketone urine testing strips.
(5)Lancets and lancet puncture devices.
(6)Pen delivery systems for the administration of insulin.
(7)Podiatric devices to prevent or treat diabetes-related complications.
(8)Insulin syringes.
(9)Visual aids, excluding eyewear, to assist the visually impaired with proper dosing of insulin.
(b)A health care service plan contract, except a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after January 1, 2000, that covers prescription benefits shall include coverage for the following prescription items if the items are determined to be medically necessary:
(1)Insulin.
(2)Prescriptive medications for the treatment of diabetes.
(3)Glucagon.
(c)The copayments and deductibles for the benefits specified in subdivisions (a) and (b) shall not exceed those established for similar benefits within the given plan.
(d)(1)Notwithstanding subdivision (c), a large group health care service plan contract that is issued, amended, or renewed on or after January 1, 2026, or a contract offered in the individual or small group market on or after January 1, 2027, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply. At least one insulin for a given drug type in all forms and concentrations shall be on the prescription drug formulary.
(2)If Notwithstanding subdivision (c), an individual or small group health care service plan contract that is issued, amended, or renewed on or after January 1, 2027, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply. If an individual or small group health care service plan contract maintains a drug formulary grouped into tiers, and if there are at least two insulins of each drug type in all forms and concentrations on a preferred tier, the cost-sharing cap pursuant to paragraph (1) shall apply only to insulin prescription drugs that are in Tier 1 and Tier 2. If there is only At least one insulin for a given drug type, then this requirement shall be met by placing that one insulin type in all forms and concentrations shall be on Tier 1 or Tier 2. For purposes of this paragraph, drug type means rapid acting, rapid acting inhaled, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed. If there is no Tier 1 or Tier 2 insulin prescription drug that is clinically appropriate for an enrollee, the health care service plan shall limit the cost sharing for a higher tier drug to no more than thirty-five dollars ($35) for a 30-day supply for an individual enrollee.
(3)Notwithstanding paragraph (1), paragraphs (1) and (2), if a health care service plan contract is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose a deductible, coinsurance, or any other cost sharing on an insulin prescription drug, unless not applying the deductible, coinsurance, or other cost sharing to an insulin prescription drug would conflict with federal requirements for high deductible health plans.
(4)When the state has the capacity to label or produce an insulin prescription drug, the deductible and copayment limitations in paragraph (1) shall also apply to an insulin prescription drug, or any therapeutic equivalent insulin prescription drug, that is labeled or produced by the state.
(5)For purposes of this subdivision, insulin subdivision:
(A)Drug type includes, but is not limited to, rapid acting, rapid acting inhaled, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed.
(B)Insulin prescription drug means a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.
(e)(1)Consistent with this section, on and after January 1, 2026, a health care service plan shall not impose step therapy protocols as a prerequisite to authorizing coverage of insulin, an insulin prescription drug described in subdivision (d), except as provided in paragraph (2). For purposes of this section, step therapy protocol means a process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed. For purposes of this section, step therapy is prohibited for both self-administered drugs and physician-administered drugs. drugs, except as provided in paragraph (2).
(2)Because the United States Food and Drug Administration has approved one or more types of insulin, this section does not require a health care service plan to cover all of the types of insulin without step therapy, if at least one insulin in each drug type is covered without step therapy. For purposes of this paragraph, drug type means includes, but is not limited to, rapid acting, rapid acting inhaled, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed.
(f)A health care service plan shall provide coverage for diabetes outpatient self-management training, education, and medical nutrition therapy necessary to enable an enrollee to properly use the equipment, supplies, and medications set forth in subdivisions (a) and (b), and additional diabetes outpatient self-management training, education, and medical nutrition therapy upon the direction or prescription of those services by the enrollees participating physician. If a plan delegates outpatient self-management training to contracting providers, the plan shall require contracting providers to ensure that diabetes outpatient self-management training, education, and medical nutrition therapy are provided by appropriately licensed or registered health care professionals.
(g)The diabetes outpatient self-management training, education, and medical nutrition therapy services identified in subdivision (f) shall be provided by appropriately licensed or registered health care professionals as prescribed by a participating health care professional legally authorized to prescribe the service. These benefits shall include, but not be limited to, instruction that will enable diabetic patients and their families to gain an understanding of the diabetic disease process, and the daily management of diabetic therapy, in order to thereby avoid frequent hospitalizations and complications.
(h)The copayments for the benefits specified in subdivision (f) shall not exceed those established for physician office visits by the plan.
(i)A health care service plan governed by this section shall disclose the benefits covered pursuant to this section in the plans evidence of coverage and disclosure forms.
(j)A health care service plan shall not reduce or eliminate coverage as a result of this section.
(k)This section does not deny or restrict in any way the departments authority to ensure plan compliance with this chapter if a plan provides coverage for prescription drugs.
SEC. 3.Section 10176.61 of the Insurance Code is amended to read:10176.61.(a)An insurer issuing, amending, delivering, or renewing a disability insurance policy on or after January 1, 2000, that covers hospital, medical, or surgical expenses shall include coverage for the following equipment and supplies for the management and treatment of insulin-using diabetes, non-insulin-using diabetes, and gestational diabetes as medically necessary, even if the items are available without a prescription:
(1)Blood glucose monitors and blood glucose testing strips.
(2)Blood glucose monitors designed to assist the visually impaired.
(3)Insulin pumps and all related necessary supplies.
(4)Ketone urine testing strips.
(5)Lancets and lancet puncture devices.
(6)Pen delivery systems for the administration of insulin.
(7)Podiatric devices to prevent or treat diabetes-related complications.
(8)Insulin syringes.
(9)Visual aids, excluding eyewear, to assist the visually impaired with proper dosing of insulin.
(b)An insurer issuing, amending, delivering, or renewing a disability insurance policy on or after January 1, 2000, that covers prescription benefits shall include coverage for the following prescription items if the items are determined to be medically necessary:
(1)Insulin.
(2)Prescriptive medications for the treatment of diabetes.
(3)Glucagon.
(c)The coinsurances and deductibles for the benefits specified in subdivisions (a) and (b) shall not exceed those established for similar benefits within the given policy.
(d)(1)Notwithstanding subdivision (c), a large group health insurance policy that is issued, amended, or renewed on or after January 1, 2026, or a policy offered in the individual or small group market on or after January 1, 2027, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply. At least one insulin for a given drug type in all forms and concentrations shall be on the prescription drug formulary.
(2)If Notwithstanding subdivision (c), an individual or small group health insurance policy that is issued, amended, or renewed on or after January 1, 2027, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply. If an individual or small group health insurance policy maintains a drug formulary grouped into tiers, and if there are at least two insulins of each drug type in all forms and concentrations on a preferred tier, the cost-sharing cap pursuant to paragraph (1) shall apply only to insulin prescription drugs that are in Tier 1 and Tier 2. If there is only At least one insulin for a given drug type, then this requirement shall be met by placing that one insulin type in all forms and concentrations shall be on Tier 1 or Tier 2. For purposes of this paragraph, drug type means rapid acting, rapid acting inhaled, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed. If there is no Tier 1 or Tier 2 insulin prescription drug that is clinically appropriate for an insured, the health insurer shall limit the cost sharing for a higher tier drug to no more than thirty-five dollars ($35) for a 30-day supply for an individual insured.
(3)Notwithstanding paragraph (1), paragraphs (1) and (2), if a health insurance policy is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the policy shall not impose a deductible, coinsurance, or any other cost sharing on an insulin prescription drug, unless not applying the deductible, coinsurance, or other cost sharing to an insulin prescription drug would conflict with federal requirements for high deductible health plans.
(4)When the state has the capacity to label or produce an insulin prescription drug, the deductible and copayment limitations in paragraph (1) shall also apply to an insulin prescription drug, or any therapeutic equivalent insulin prescription drug, that is labeled or produced by the state.
(5)For purposes of this subdivision, insulin subdivision:
(A)Drug type includes, but is not limited to, rapid acting, rapid acting inhaled, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed.
(B)Insulin prescription drug means a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.
(e)(1)Consistent with this section, on and after January 1, 2026, a health insurer shall not impose step therapy as a prerequisite to authorizing coverage of insulin, an insulin prescription drug described in subdivision (d), except as provided in paragraph (2). For purposes of this section, step therapy has the same meaning as defined in paragraph (2) of subdivision (i) of Section 10123.201. For purposes of this section, step therapy is prohibited for both self-administered drugs and physician-administered drugs. drugs, except as provided in paragraph (2).
(2)Because the United States Food and Drug Administration has approved one or more types of insulin, this section does not require a health care service plan to cover all of the types of insulin without step therapy, if at least one insulin in each drug type is covered without step therapy. For purposes of this paragraph, drug type means includes, but is not limited to, rapid acting, rapid acting inhaled, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed.
(f)An insurer shall provide coverage for diabetes outpatient self-management training, education, and medical nutrition therapy necessary to enable an insured to properly use the equipment, supplies, and medications set forth in subdivisions (a) and (b) and additional diabetes outpatient self-management training, education, and medical nutrition therapy upon the direction or prescription of those services by the insureds participating physician. If an insurer delegates outpatient self-management training to contracting providers, the insurer shall require contracting providers to ensure that diabetes outpatient self-management training, education, and medical nutrition therapy are provided by appropriately licensed or registered health care professionals.
(g)The diabetes outpatient self-management training, education, and medical nutrition therapy services identified in subdivision (f) shall be provided by appropriately licensed or registered health care professionals as prescribed by a health care professional legally authorized to prescribe the services.
(h)The coinsurances and deductibles for the benefits specified in subdivision (f) shall not exceed those established for physician office visits by the insurer.
(i)Every disability insurer governed by this section shall disclose the benefits covered pursuant to this section in the insurers evidence of coverage and disclosure forms.
(j)An insurer shall not reduce or eliminate coverage as a result of this section.
(k)This section does not apply to vision-only, dental-only, accident-only, specified disease, hospital indemnity, Medicare supplement, long-term care, or disability income insurance, except that for accident-only, specified disease, and hospital indemnity insurance coverage, benefits under this section only apply to the extent that the benefits are covered under the general terms and conditions that apply to all other benefits under the policy. This section does not impose a new benefit mandate on accident-only, specified disease, or hospital indemnity insurance.
SEC. 4.The provisions of this act are severable. If any provision of this act or its application is held invalid, that invalidity shall not affect other provisions or applications that can be given effect without the invalid provision or application.
SEC. 4.SEC. 5.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)The Legislature finds and declares all of the following:
(1)Approximately 263,000 Californians are diagnosed with type 1 diabetes each year. Approximately 4,037,000 Californian adults have diabetes.
(2)Every Californian with type 1 diabetes, and many with type 2 diabetes, rely on daily doses of insulin to survive.
(3)Insulin prices have nearly tripled, creating financial hardships for people who rely on it to survive.
(4)One in four people using insulin have reported insulin underuse due to the high cost of insulin.
(5)Imposing a deductible on insulin, and requiring individuals to meet that deductible, creates a financial burden that presents a barrier to accessing insulin.
(6)Diabetes is the seventh leading cause of death, and it is a leading cause of disabling and life-threatening complications, including heart disease, stroke, kidney failure, amputation of the lower extremities, and new cases of blindness among adults.
(7)Studies have shown that managing diabetes can prevent complications and medical emergencies associated with diabetes that result in emergency room visits, hospitalizations, and costly treatments.
(b)Therefore, it is the intent of the Legislature to enact legislation on important policies to reduce the costs for Californians with diabetes to obtain lifesaving and life-sustaining insulin.
SEC. 2.Section 1367.51 of the Health and Safety Code is amended to read:1367.51.(a)A health care service plan contract, except a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after January 1, 2000, and that covers hospital, medical, or surgical expenses shall include coverage for the following equipment and supplies for the management and treatment of insulin-using diabetes, non-insulin-using diabetes, and gestational diabetes as medically necessary, even if the items are available without a prescription:
(1)Blood glucose monitors and blood glucose testing strips.
(2)Blood glucose monitors designed to assist the visually impaired.
(3)Insulin pumps and all related necessary supplies.
(4)Ketone urine testing strips.
(5)Lancets and lancet puncture devices.
(6)Pen delivery systems for the administration of insulin.
(7)Podiatric devices to prevent or treat diabetes-related complications.
(8)Insulin syringes.
(9)Visual aids, excluding eyewear, to assist the visually impaired with proper dosing of insulin.
(b)A health care service plan contract, except a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after January 1, 2000, that covers prescription benefits shall include coverage for the following prescription items if the items are determined to be medically necessary:
(1)Insulin.
(2)Prescriptive medications for the treatment of diabetes.
(3)Glucagon.
(c)The copayments and deductibles for the benefits specified in subdivisions (a) and (b) shall not exceed those established for similar benefits within the given plan.
(d)(1)Notwithstanding subdivision (c), a health care service plan contract that is issued, amended, or renewed on or after January 1, 2026, or a contract offered in the individual or small group market on or after January 1, 2027, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply.
(2)If an individual or small group health care service plan contract maintains a drug formulary grouped into tiers, and if there are at least two insulins of each drug type in all forms and concentrations on a preferred tier, the cost-sharing cap pursuant to paragraph (1) shall apply only to insulin prescription drugs that are in Tier 1 and Tier 2. If there is only one insulin for a given drug type, then this requirement shall be met by placing that one insulin on Tier 1 or Tier 2. For purposes of this paragraph, drug type means rapid acting, rapid acting inhaled, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed.
(2)(3)Notwithstanding paragraph (1), if a health care service plan contract is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose a deductible, coinsurance, or any other cost sharing on an insulin prescription drug, unless not applying the deductible, coinsurance, or other cost sharing to an insulin prescription drug would conflict with federal requirements for high deductible health plans.
(3)(4)When the state has the capacity to label or produce an insulin prescription drug, the deductible and copayment limitations in paragraph (1) shall also apply to an insulin prescription drug, or any therapeutic equivalent insulin prescription drug, that is labeled or produced by the state.
(4)(5)For purposes of this subdivision, insulin prescription drug means a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.
(e)(1)Consistent with this section, on and after January 1, 2026, a health care service plan shall not impose step therapy protocols as a prerequisite to authorizing coverage of insulin, except as provided in paragraph (2). For purposes of this section, step therapy protocol means a process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed. For purposes of this section, step therapy is prohibited for self-administered drugs and physician-administered drugs.
(2)Because the United States Food and Drug Administration has approved one or more types of insulin, this section does not require a health care service plan to cover all of the types of insulin without step therapy, if at least one insulin in each drug type is covered without step therapy. For purposes of this paragraph, drug type means rapid acting, rapid acting inhaled, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed.
(f)A health care service plan shall provide coverage for diabetes outpatient self-management training, education, and medical nutrition therapy necessary to enable an enrollee to properly use the equipment, supplies, and medications set forth in subdivisions (a) and (b), and additional diabetes outpatient self-management training, education, and medical nutrition therapy upon the direction or prescription of those services by the enrollees participating physician. If a plan delegates outpatient self-management training to contracting providers, the plan shall require contracting providers to ensure that diabetes outpatient self-management training, education, and medical nutrition therapy are provided by appropriately licensed or registered health care professionals.
(g)The diabetes outpatient self-management training, education, and medical nutrition therapy services identified in subdivision (f) shall be provided by appropriately licensed or registered health care professionals as prescribed by a participating health care professional legally authorized to prescribe the service. These benefits shall include, but not be limited to, instruction that will enable diabetic patients and their families to gain an understanding of the diabetic disease process, and the daily management of diabetic therapy, in order to thereby avoid frequent hospitalizations and complications.
(h)The copayments for the benefits specified in subdivision (f) shall not exceed those established for physician office visits by the plan.
(i)A health care service plan governed by this section shall disclose the benefits covered pursuant to this section in the plans evidence of coverage and disclosure forms.
(j)A health care service plan shall not reduce or eliminate coverage as a result of this section.
(k)This section does not deny or restrict in any way the departments authority to ensure plan compliance with this chapter if a plan provides coverage for prescription drugs.
SEC. 3.Section 10176.61 of the Insurance Code is amended to read:10176.61.(a)An insurer issuing, amending, delivering, or renewing a disability insurance policy on or after January 1, 2000, that covers hospital, medical, or surgical expenses shall include coverage for the following equipment and supplies for the management and treatment of insulin-using diabetes, non-insulin-using diabetes, and gestational diabetes as medically necessary, even if the items are available without a prescription:
(1)Blood glucose monitors and blood glucose testing strips.
(2)Blood glucose monitors designed to assist the visually impaired.
(3)Insulin pumps and all related necessary supplies.
(4)Ketone urine testing strips.
(5)Lancets and lancet puncture devices.
(6)Pen delivery systems for the administration of insulin.
(7)Podiatric devices to prevent or treat diabetes-related complications.
(8)Insulin syringes.
(9)Visual aids, excluding eyewear, to assist the visually impaired with proper dosing of insulin.
(b)An insurer issuing, amending, delivering, or renewing a disability insurance policy on or after January 1, 2000, that covers prescription benefits shall include coverage for the following prescription items if the items are determined to be medically necessary:
(1)Insulin.
(2)Prescriptive medications for the treatment of diabetes.
(3)Glucagon.
(c)The coinsurances and deductibles for the benefits specified in subdivisions (a) and (b) shall not exceed those established for similar benefits within the given policy.
(d)(1)Notwithstanding subdivision (c), a health insurance policy that is issued, amended, or renewed on or after January 1, 2026, or a policy offered in the individual or small group market on or after January 1, 2027, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply.
(2)If an individual or small group health insurance policy maintains a drug formulary grouped into tiers, and if there are at least two insulins of each drug type in all forms and concentrations on a preferred tier, the cost-sharing cap pursuant to paragraph (1) shall apply only to insulin prescription drugs that are in Tier 1 and Tier 2. If there is only one insulin for a given drug type, then this requirement shall be met by placing that one insulin on Tier 1 or Tier 2. For purposes of this paragraph, drug type means rapid acting, rapid acting inhaled, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed.
(2)(3)Notwithstanding paragraph (1), if a health insurance policy is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the policy shall not impose a deductible, coinsurance, or any other cost sharing on an insulin prescription drug, unless not applying the deductible, coinsurance, or other cost sharing to an insulin prescription drug would conflict with federal requirements for high deductible health plans.
(3)(4)When the state has the capacity to label or produce an insulin prescription drug, the deductible and copayment limitations in paragraph (1) shall also apply to an insulin prescription drug, or any therapeutic equivalent insulin prescription drug, that is labeled or produced by the state.
(4)(5)For purposes of this subdivision, insulin prescription drug means a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.
(e)(1)Consistent with this section, on and after January 1, 2026, a health insurer shall not impose step therapy as a prerequisite to authorizing coverage of insulin, except as provided in paragraph (2). For purposes of this section, step therapy has the same meaning as defined in paragraph (2) of subdivision (i) of Section 10123.201. For purposes of this section, step therapy is prohibited for self-administered drugs and physician-administered drugs.
(2)Because the United States Food and Drug Administration has approved one or more types of insulin, this section does not require a health care service plan to cover all of the types of insulin without step therapy, if at least one insulin in each drug type is covered without step therapy. For purposes of this paragraph, drug type means rapid acting, rapid acting inhaled, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed.
(f)An insurer shall provide coverage for diabetes outpatient self-management training, education, and medical nutrition therapy necessary to enable an insured to properly use the equipment, supplies, and medications set forth in subdivisions (a) and (b) and additional diabetes outpatient self-management training, education, and medical nutrition therapy upon the direction or prescription of those services by the insureds participating physician. If an insurer delegates outpatient self-management training to contracting providers, the insurer shall require contracting providers to ensure that diabetes outpatient self-management training, education, and medical nutrition therapy are provided by appropriately licensed or registered health care professionals.
(g)The diabetes outpatient self-management training, education, and medical nutrition therapy services identified in subdivision (f) shall be provided by appropriately licensed or registered health care professionals as prescribed by a health care professional legally authorized to prescribe the services.
(h)The coinsurances and deductibles for the benefits specified in subdivision (f) shall not exceed those established for physician office visits by the insurer.
(i)Every disability insurer governed by this section shall disclose the benefits covered pursuant to this section in the insurers evidence of coverage and disclosure forms.
(j)An insurer shall not reduce or eliminate coverage as a result of this section.
(k)This section does not apply to vision-only, dental-only, accident-only, specified disease, hospital indemnity, Medicare supplement, long-term care, or disability income insurance, except that for accident-only, specified disease, and hospital indemnity insurance coverage, benefits under this section only apply to the extent that the benefits are covered under the general terms and conditions that apply to all other benefits under the policy. This section does not impose a new benefit mandate on accident-only, specified disease, or hospital indemnity insurance.
SEC. 4.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)The Legislature finds and declares all of the following:
(1)Approximately 263,000 Californians are diagnosed with type 1 diabetes each year. Approximately 4,037,000 Californian adults have diabetes.
(2)Every Californian with type 1 diabetes, and many with type 2 diabetes, rely on daily doses of insulin to survive.
(3)Insulin prices have nearly tripled, creating financial hardships for people who rely on it to survive.
(4)One in four people using insulin have reported insulin underuse due to the high cost of insulin.
(5)Imposing a deductible on insulin, and requiring individuals to meet that deductible, creates a financial burden that presents a barrier to accessing insulin.
(6)Diabetes is the seventh leading cause of death, and it is a leading cause of disabling and life-threatening complications, including heart disease, stroke, kidney failure, amputation of the lower extremities, and new cases of blindness among adults.
(7)Studies have shown that managing diabetes can prevent complications and medical emergencies associated with diabetes that result in emergency room visits, hospitalizations, and costly treatments.
(b)Therefore, it is the intent of the Legislature to enact legislation on important policies to reduce the costs for Californians with diabetes to obtain lifesaving and life-sustaining insulin.
SEC. 2.Section 1367.51 of the Health and Safety Code is amended to read:1367.51.(a)A health care service plan contract, except a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after January 1, 2000, and that covers hospital, medical, or surgical expenses shall include coverage for the following equipment and supplies for the management and treatment of insulin-using diabetes, non-insulin-using diabetes, and gestational diabetes as medically necessary, even if the items are available without a prescription:
(1)Blood glucose monitors and blood glucose testing strips.
(2)Blood glucose monitors designed to assist the visually impaired.
(3)Insulin pumps and all related necessary supplies.
(4)Ketone urine testing strips.
(5)Lancets and lancet puncture devices.
(6)Pen delivery systems for the administration of insulin.
(7)Podiatric devices to prevent or treat diabetes-related complications.
(8)Insulin syringes.
(9)Visual aids, excluding eyewear, to assist the visually impaired with proper dosing of insulin.
(b)A health care service plan contract, except a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after January 1, 2000, that covers prescription benefits shall include coverage for the following prescription items if the items are determined to be medically necessary:
(1)Insulin.
(2)Prescriptive medications for the treatment of diabetes.
(3)Glucagon.
(c)The copayments and deductibles for the benefits specified in subdivisions (a) and (b) shall not exceed those established for similar benefits within the given plan.
(d)(1)Notwithstanding subdivision (c), a health care service plan contract that is issued, amended, or renewed on or after January 1, 2026, or a contract offered in the individual or small group market on or after January 1, 2027, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply.
(2)Notwithstanding paragraph (1), if a health care service plan contract is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose a deductible, coinsurance, or any other cost sharing on an insulin prescription drug, unless not applying the deductible, coinsurance, or other cost sharing to an insulin prescription drug would conflict with federal requirements for high deductible health plans.
(3)When the state has the capacity to label or produce an insulin prescription drug, the deductible and copayment limitations in paragraph (1) shall also apply to an insulin prescription drug, or any therapeutic equivalent insulin prescription drug, that is labeled or produced by the state.
(4)For purposes of this subdivision, insulin prescription drug means a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.
(e)(1)Consistent with this section, on and after January 1, 2026, a health care service plan shall not impose step therapy protocols as a prerequisite to authorizing coverage of insulin. insulin, except as provided in paragraph (2). For purposes of this section, step therapy protocol means a protocol or program that establishes the specific sequence in which prescription drugs for a specified condition, including self-administered drugs and physician-administered drugs, are medically appropriate for a particular enrollee and are covered under a health care service plan contract. process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed. For purposes of this section, step therapy is prohibited for self-administered drugs and physician-administered drugs.
(2)Because the United States Food and Drug Administration has approved one or more types of insulin, this section does not require a health care service plan to cover all of the types of insulin without step therapy, if at least one insulin in each drug type is covered without step therapy. For purposes of this paragraph, drug type means rapid acting, rapid acting inhaled, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed.
(f)A health care service plan shall provide coverage for diabetes outpatient self-management training, education, and medical nutrition therapy necessary to enable an enrollee to properly use the equipment, supplies, and medications set forth in subdivisions (a) and (b), and additional diabetes outpatient self-management training, education, and medical nutrition therapy upon the direction or prescription of those services by the enrollees participating physician. If a plan delegates outpatient self-management training to contracting providers, the plan shall require contracting providers to ensure that diabetes outpatient self-management training, education, and medical nutrition therapy are provided by appropriately licensed or registered health care professionals.
(g)The diabetes outpatient self-management training, education, and medical nutrition therapy services identified in subdivision (f) shall be provided by appropriately licensed or registered health care professionals as prescribed by a participating health care professional legally authorized to prescribe the service. These benefits shall include, but not be limited to, instruction that will enable diabetic patients and their families to gain an understanding of the diabetic disease process, and the daily management of diabetic therapy, in order to thereby avoid frequent hospitalizations and complications.
(h)The copayments for the benefits specified in subdivision (f) shall not exceed those established for physician office visits by the plan.
(i)A health care service plan governed by this section shall disclose the benefits covered pursuant to this section in the plans evidence of coverage and disclosure forms.
(j)A health care service plan shall not reduce or eliminate coverage as a result of this section.
(k)This section does not deny or restrict in any way the departments authority to ensure plan compliance with this chapter if a plan provides coverage for prescription drugs.
SEC. 3.Section 10176.61 of the Insurance Code is amended to read:10176.61.(a)An insurer issuing, amending, delivering, or renewing a disability insurance policy on or after January 1, 2000, that covers hospital, medical, or surgical expenses shall include coverage for the following equipment and supplies for the management and treatment of insulin-using diabetes, non-insulin-using diabetes, and gestational diabetes as medically necessary, even if the items are available without a prescription:
(1)Blood glucose monitors and blood glucose testing strips.
(2)Blood glucose monitors designed to assist the visually impaired.
(3)Insulin pumps and all related necessary supplies.
(4)Ketone urine testing strips.
(5)Lancets and lancet puncture devices.
(6)Pen delivery systems for the administration of insulin.
(7)Podiatric devices to prevent or treat diabetes-related complications.
(8)Insulin syringes.
(9)Visual aids, excluding eyewear, to assist the visually impaired with proper dosing of insulin.
(b)An insurer issuing, amending, delivering, or renewing a disability insurance policy on or after January 1, 2000, that covers prescription benefits shall include coverage for the following prescription items if the items are determined to be medically necessary:
(1)Insulin.
(2)Prescriptive medications for the treatment of diabetes.
(3)Glucagon.
(c)The coinsurances and deductibles for the benefits specified in subdivisions (a) and (b) shall not exceed those established for similar benefits within the given policy.
(d)(1)Notwithstanding subdivision (c), a health insurance policy that is issued, amended, or renewed on or after January 1, 2026, or a policy offered in the individual or small group market on or after January 1, 2027, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply.
(2)Notwithstanding paragraph (1), if a health insurance policy is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the policy shall not impose a deductible, coinsurance, or any other cost sharing on an insulin prescription drug, unless not applying the deductible, coinsurance, or other cost sharing to an insulin prescription drug would conflict with federal requirements for high deductible health plans.
(3)When the state has the capacity to label or produce an insulin prescription drug, the deductible and copayment limitations in paragraph (1) shall also apply to an insulin prescription drug, or any therapeutic equivalent insulin prescription drug, that is labeled or produced by the state.
(4)For purposes of this subdivision, insulin prescription drug means a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.
(e)(1)Consistent with this section, on and after January 1, 2026, a health insurer shall not impose step therapy as a prerequisite to authorizing coverage of insulin. insulin, except as provided in paragraph (2). For purposes of this section, step therapy has the same meaning as defined in paragraph (2) of subdivision (i) of Section 10123.201. For purposes of this section, step therapy is prohibited for self-administered drugs and physician-administered drugs.
(2)Because the United States Food and Drug Administration has approved one or more types of insulin, this section does not require a health care service plan to cover all of the types of insulin without step therapy, if at least one insulin in each drug type is covered without step therapy. For purposes of this paragraph, drug type means rapid acting, rapid acting inhaled, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed.
(f)An insurer shall provide coverage for diabetes outpatient self-management training, education, and medical nutrition therapy necessary to enable an insured to properly use the equipment, supplies, and medications set forth in subdivisions (a) and (b) and additional diabetes outpatient self-management training, education, and medical nutrition therapy upon the direction or prescription of those services by the insureds participating physician. If an insurer delegates outpatient self-management training to contracting providers, the insurer shall require contracting providers to ensure that diabetes outpatient self-management training, education, and medical nutrition therapy are provided by appropriately licensed or registered health care professionals.
(g)The diabetes outpatient self-management training, education, and medical nutrition therapy services identified in subdivision (f) shall be provided by appropriately licensed or registered health care professionals as prescribed by a health care professional legally authorized to prescribe the services.
(h)The coinsurances and deductibles for the benefits specified in subdivision (f) shall not exceed those established for physician office visits by the insurer.
(i)Every disability insurer governed by this section shall disclose the benefits covered pursuant to this section in the insurers evidence of coverage and disclosure forms.
(j)An insurer shall not reduce or eliminate coverage as a result of this section.
(k)This section does not apply to vision-only, dental-only, accident-only, specified disease, hospital indemnity, Medicare supplement, long-term care, or disability income insurance, except that for accident-only, specified disease, and hospital indemnity insurance coverage, benefits under this section only apply to the extent that the benefits are covered under the general terms and conditions that apply to all other benefits under the policy. This section does not impose a new benefit mandate on accident-only, specified disease, or hospital indemnity insurance.
SEC. 4.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)The Legislature finds and declares all of the following:
(1)Approximately 263,000 Californians are diagnosed with type 1 diabetes each year. Approximately 4,037,000 Californian adults have diabetes.
(2)Every Californian with type 1 diabetes, and many with type 2 diabetes, rely on daily doses of insulin to survive.
(3)Insulin prices have nearly tripled, creating financial hardships for people who rely on it to survive.
(4)One in four people using insulin have reported insulin underuse due to the high cost of insulin.
(5)Imposing a deductible on insulin, and requiring individuals to meet that deductible, creates a financial burden that presents a barrier to accessing insulin.
(6)Diabetes is the seventh leading cause of death, and it is a leading cause of disabling and life-threatening complications, including heart disease, stroke, kidney failure, amputation of the lower extremities, and new cases of blindness among adults.
(7)Studies have shown that managing diabetes can prevent complications and medical emergencies associated with diabetes that result in emergency room visits, hospitalizations, and costly treatments.
(b)Therefore, it is the intent of the Legislature to enact legislation on important policies to reduce the costs for Californians with diabetes to obtain lifesaving and life-sustaining insulin.
SEC. 2.Section 1367.51 of the Health and Safety Code is amended to read:1367.51.(a)A health care service plan contract, except a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after January 1, 2000, and that covers hospital, medical, or surgical expenses shall include coverage for the following equipment and supplies for the management and treatment of insulin-using diabetes, non-insulin-using diabetes, and gestational diabetes as medically necessary, even if the items are available without a prescription:
(1)Blood glucose monitors and blood glucose testing strips.
(2)Blood glucose monitors designed to assist the visually impaired.
(3)Insulin pumps and all related necessary supplies.
(4)Ketone urine testing strips.
(5)Lancets and lancet puncture devices.
(6)Pen delivery systems for the administration of insulin.
(7)Podiatric devices to prevent or treat diabetes-related complications.
(8)Insulin syringes.
(9)Visual aids, excluding eyewear, to assist the visually impaired with proper dosing of insulin.
(b)A health care service plan contract, except a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after January 1, 2000, that covers prescription benefits shall include coverage for the following prescription items if the items are determined to be medically necessary:
(1)Insulin.
(2)Prescriptive medications for the treatment of diabetes.
(3)Glucagon.
(c)The copayments and deductibles for the benefits specified in subdivisions (a) and (b) shall not exceed those established for similar benefits within the given plan.
(d)(1)Notwithstanding subdivision (c), a health care service plan contract that is issued, amended, or renewed on or after January 1, 2026, shall not impose a copayment copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply, and shall not impose a deductible, coinsurance, or any other cost sharing on an insulin prescription drug. supply.
(2)Notwithstanding paragraph (1), if a health care service plan contract is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose a deductible, coinsurance, or any other cost sharing on an insulin prescription drug, unless not applying the deductible, coinsurance, or other cost sharing to an insulin prescription drug would conflict with federal requirements for high deductible health plans.
(3)When the state has the capacity to label or produce an insulin prescription drug, the deductible and copayment limitations in paragraph (1) shall also apply to an insulin prescription drug, or any therapeutic equivalent insulin prescription drug, that is labeled or produced by the state.
(4)For purposes of this subdivision, insulin prescription drug means a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.
(e)Consistent with this section, on and after January 1, 2026, a health care service plan shall not impose step therapy protocols as a prerequisite to authorizing coverage of insulin. For purposes of this section, step therapy protocol means a protocol or program that establishes the specific sequence in which prescription drugs for a specified condition, including self-administered drugs and physician-administered drugs, are medically appropriate for a particular enrollee and are covered under a health care service plan contract.
(f)A health care service plan shall provide coverage for diabetes outpatient self-management training, education, and medical nutrition therapy necessary to enable an enrollee to properly use the equipment, supplies, and medications set forth in subdivisions (a) and (b), and additional diabetes outpatient self-management training, education, and medical nutrition therapy upon the direction or prescription of those services by the enrollees participating physician. If a plan delegates outpatient self-management training to contracting providers, the plan shall require contracting providers to ensure that diabetes outpatient self-management training, education, and medical nutrition therapy are provided by appropriately licensed or registered health care professionals.
(g)The diabetes outpatient self-management training, education, and medical nutrition therapy services identified in subdivision (f) shall be provided by appropriately licensed or registered health care professionals as prescribed by a participating health care professional legally authorized to prescribe the service. These benefits shall include, but not be limited to, instruction that will enable diabetic patients and their families to gain an understanding of the diabetic disease process, and the daily management of diabetic therapy, in order to thereby avoid frequent hospitalizations and complications.
(h)The copayments for the benefits specified in subdivision (f) shall not exceed those established for physician office visits by the plan.
(i)A health care service plan governed by this section shall disclose the benefits covered pursuant to this section in the plans evidence of coverage and disclosure forms.
(j)A health care service plan shall not reduce or eliminate coverage as a result of this section.
(k)This section does not deny or restrict in any way the departments authority to ensure plan compliance with this chapter if a plan provides coverage for prescription drugs.
SEC. 3.Section 10176.61 of the Insurance Code is amended to read:10176.61.(a)An insurer issuing, amending, delivering, or renewing a disability insurance policy on or after January 1, 2000, that covers hospital, medical, or surgical expenses shall include coverage for the following equipment and supplies for the management and treatment of insulin-using diabetes, non-insulin-using diabetes, and gestational diabetes as medically necessary, even if the items are available without a prescription:
(1)Blood glucose monitors and blood glucose testing strips.
(2)Blood glucose monitors designed to assist the visually impaired.
(3)Insulin pumps and all related necessary supplies.
(4)Ketone urine testing strips.
(5)Lancets and lancet puncture devices.
(6)Pen delivery systems for the administration of insulin.
(7)Podiatric devices to prevent or treat diabetes-related complications.
(8)Insulin syringes.
(9)Visual aids, excluding eyewear, to assist the visually impaired with proper dosing of insulin.
(b)An insurer issuing, amending, delivering, or renewing a disability insurance policy on or after January 1, 2000, that covers prescription benefits shall include coverage for the following prescription items if the items are determined to be medically necessary:
(1)Insulin.
(2)Prescriptive medications for the treatment of diabetes.
(3)Glucagon.
(c)The coinsurances and deductibles for the benefits specified in subdivisions (a) and (b) shall not exceed those established for similar benefits within the given policy.
(d)(1)Notwithstanding subdivision (c), a disability health insurance policy that is issued, amended, or renewed on or after January 1, 2026, shall not impose a copayment copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply, and shall not impose a deductible, coinsurance, or any other cost sharing on an insulin prescription drug. supply.
(2)Notwithstanding paragraph (1), if a disability health insurance policy is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the policy shall not impose a deductible, coinsurance, or any other cost sharing on an insulin prescription drug, unless not applying the deductible, coinsurance, or other cost sharing to an insulin prescription drug would conflict with federal requirements for high deductible health plans.
(3)When the state has the capacity to label or produce an insulin prescription drug, the deductible and copayment limitations in paragraph (1) shall also apply to an insulin prescription drug, or any therapeutic equivalent insulin prescription drug, that is labeled or produced by the state.
(4)For purposes of this subdivision, insulin prescription drug means a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.
(e)Consistent with this section, on and after January 1, 2026, a disability health insurer shall not impose step therapy protocols as a prerequisite to authorizing coverage of insulin. For purposes of this section, step therapy protocol means a protocol or program that establishes the specific sequence in which prescription drugs for a specified condition, including self-administered drugs and physician-administered drugs, are medically appropriate for a particular insured and are covered under a disability insurance policy. therapy has the same meaning as defined in paragraph (2) of subdivision (i) of Section 10123.201. For purposes of this section, step therapy is prohibited for self-administered drugs and physician-administered drugs.
(f)An insurer shall provide coverage for diabetes outpatient self-management training, education, and medical nutrition therapy necessary to enable an insured to properly use the equipment, supplies, and medications set forth in subdivisions (a) and (b) and additional diabetes outpatient self-management training, education, and medical nutrition therapy upon the direction or prescription of those services by the insureds participating physician. If an insurer delegates outpatient self-management training to contracting providers, the insurer shall require contracting providers to ensure that diabetes outpatient self-management training, education, and medical nutrition therapy are provided by appropriately licensed or registered health care professionals.
(g)The diabetes outpatient self-management training, education, and medical nutrition therapy services identified in subdivision (f) shall be provided by appropriately licensed or registered health care professionals as prescribed by a health care professional legally authorized to prescribe the services.
(h)The coinsurances and deductibles for the benefits specified in subdivision (f) shall not exceed those established for physician office visits by the insurer.
(i)Every disability insurer governed by this section shall disclose the benefits covered pursuant to this section in the insurers evidence of coverage and disclosure forms.
(j)An insurer shall not reduce or eliminate coverage as a result of this section.
(k)This section does not apply to vision-only, dental-only, accident-only, specified disease, hospital indemnity, Medicare supplement, long-term care, or disability income insurance, except that for accident-only, specified disease, and hospital indemnity insurance coverage, benefits under this section only apply to the extent that the benefits are covered under the general terms and conditions that apply to all other benefits under the policy. This section does not impose a new benefit mandate on accident-only, specified disease, or hospital indemnity insurance.
SEC. 4.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)The Legislature finds and declares all of the following:
(1)Approximately 263,000 Californians are diagnosed with type 1 diabetes each year. Approximately 4,037,000 Californian adults have diabetes.
(2)Every Californian with type 1 diabetes, and many with type 2 diabetes, rely on daily doses of insulin to survive.
(3)Insulin prices have nearly tripled, creating financial hardships for people who rely on it to survive.
(4)One in four people using insulin have reported insulin underuse due to the high cost of insulin.
(5)Imposing a deductible on insulin, and requiring individuals to meet that deductible, creates a financial burden that presents a barrier to accessing insulin.
(6)Diabetes is the seventh leading cause of death, and it is a leading cause of disabling and life-threatening complications, including heart disease, stroke, kidney failure, amputation of the lower extremities, and new cases of blindness among adults.
(7)Studies have shown that managing diabetes can prevent complications and medical emergencies associated with diabetes that result in emergency room visits, hospitalizations, and costly treatments.
(b)Therefore, it is the intent of the Legislature to enact legislation on important policies to reduce the costs for Californians with diabetes to obtain lifesaving and life-sustaining insulin.
SEC. 2.Section 1367.51 of the Health and Safety Code is amended to read:1367.51.(a)Every A health care service plan contract, except a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after January 1, 2000, and that covers hospital, medical, or surgical expenses shall include coverage for the following equipment and supplies for the management and treatment of insulin-using diabetes, non-insulin-using diabetes, and gestational diabetes as medically necessary, even if the items are available without a prescription:
(1)Blood glucose monitors and blood glucose testing strips.
(2)Blood glucose monitors designed to assist the visually impaired.
(3)Insulin pumps and all related necessary supplies.
(4)Ketone urine testing strips.
(5)Lancets and lancet puncture devices.
(6)Pen delivery systems for the administration of insulin.
(7)Podiatric devices to prevent or treat diabetes-related complications.
(8)Insulin syringes.
(9)Visual aids, excluding eyewear, to assist the visually impaired with proper dosing of insulin.
(b)Every A health care service plan contract, except a specialized health care service plan contract, that is issued, amended, delivered, or renewed on or after January 1, 2000, that covers prescription benefits shall include coverage for the following prescription items if the items are determined to be medically necessary:
(1)Insulin.
(2)Prescriptive medications for the treatment of diabetes.
(3)Glucagon.
(c)The copayments and deductibles for the benefits specified in subdivisions (a) and (b) shall not exceed those established for similar benefits within the given plan.
(d)(1)Notwithstanding subdivision (c), a health care service plan contract that is issued, amended, or renewed on or after January 1, 2026, shall not impose a copayment on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply, and shall not impose a deductible, coinsurance, or any other cost sharing on an insulin prescription drug.
(2)Notwithstanding paragraph (1), if a health care service plan contract is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose a deductible, coinsurance, or any other cost sharing on an insulin prescription drug, unless not applying the deductible, coinsurance, or other cost sharing to an insulin prescription drug would conflict with federal requirements for high deductible health plans.
(3)When the state has the capacity to label or produce an insulin prescription drug, the deductible and copayment limitations in paragraph (1) shall also apply to an insulin prescription drug, or any therapeutic equivalent insulin prescription drug, that is labeled or produced by the state.
(4)For purposes of this subdivision, insulin prescription drug means a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.
(e)Consistent with this section, on and after January 1, 2026, a health care service plan shall not impose step therapy protocols as a prerequisite to authorizing coverage of insulin. For purposes of this section, step therapy protocol means a protocol or program that establishes the specific sequence in which prescription drugs for a specified condition, including self-administered drugs and physician-administered drugs, are medically appropriate for a particular enrollee and are covered under a health care service plan contract.
(d)Every(f)A health care service plan shall provide coverage for diabetes outpatient self-management training, education, and medical nutrition therapy necessary to enable an enrollee to properly use the equipment, supplies, and medications set forth in subdivisions (a) and (b), and additional diabetes outpatient self-management training, education, and medical nutrition therapy upon the direction or prescription of those services by the enrollees participating physician. If a plan delegates outpatient self-management training to contracting providers, the plan shall require contracting providers to ensure that diabetes outpatient self-management training, education, and medical nutrition therapy are provided by appropriately licensed or registered health care professionals.
(e)(g)The diabetes outpatient self-management training, education, and medical nutrition therapy services identified in subdivision (d) (f) shall be provided by appropriately licensed or registered health care professionals as prescribed by a participating health care professional legally authorized to prescribe the service. These benefits shall include, but not be limited to, instruction that will enable diabetic patients and their families to gain an understanding of the diabetic disease process, and the daily management of diabetic therapy, in order to thereby avoid frequent hospitalizations and complications.
(f)(h)The copayments for the benefits specified in subdivision (d) (f) shall not exceed those established for physician office visits by the plan.
(g)Every(i)A health care service plan governed by this section shall disclose the benefits covered pursuant to this section in the plans evidence of coverage and disclosure forms.
(h)(j)A health care service plan may shall not reduce or eliminate coverage as a result of the requirements of this section.
(i)Nothing in this section shall be construed to(k)This section does not deny or restrict in any way the departments authority to ensure plan compliance with this chapter when if a plan provides coverage for prescription drugs.
SEC. 3.Section 10176.61 of the Insurance Code is amended to read:10176.61.(a)Every An insurer issuing, amending, delivering, or renewing a disability insurance policy on or after January 1, 2000, that covers hospital, medical, or surgical expenses shall include coverage for the following equipment and supplies for the management and treatment of insulin-using diabetes, non-insulin-using diabetes, and gestational diabetes as medically necessary, even if the items are available without a prescription:
(1)Blood glucose monitors and blood glucose testing strips.
(2)Blood glucose monitors designed to assist the visually impaired.
(3)Insulin pumps and all related necessary supplies.
(4)Ketone urine testing strips.
(5)Lancets and lancet puncture devices.
(6)Pen delivery systems for the administration of insulin.
(7)Podiatric devices to prevent or treat diabetes-related complications.
(8)Insulin syringes.
(9)Visual aids, excluding eyewear, to assist the visually impaired with proper dosing of insulin.
(b)Every An insurer issuing, amending, delivering, or renewing a disability insurance policy on or after January 1, 2000, that covers prescription benefits shall include coverage for the following prescription items if the items are determined to be medically necessary:
(1)Insulin.
(2)Prescriptive medications for the treatment of diabetes.
(3)Glucagon.
(c)The coinsurances and deductibles for the benefits specified in subdivisions (a) and (b) shall not exceed those established for similar benefits within the given policy.
(d)(1)Notwithstanding subdivision (c), a disability insurance policy that is issued, amended, or renewed on or after January 1, 2026, shall not impose a copayment on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply, and shall not impose a deductible, coinsurance, or any other cost sharing on an insulin prescription drug.
(2)Notwithstanding paragraph (1), if a disability insurance policy is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the policy shall not impose a deductible, coinsurance, or any other cost sharing on an insulin prescription drug, unless not applying the deductible, coinsurance, or other cost sharing to an insulin prescription drug would conflict with federal requirements for high deductible health plans.
(3)When the state has the capacity to label or produce an insulin prescription drug, the deductible and copayment limitations in paragraph (1) shall also apply to an insulin prescription drug, or any therapeutic equivalent insulin prescription drug, that is labeled or produced by the state.
(4)For purposes of this subdivision, insulin prescription drug means a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.
(e)Consistent with this section, on and after January 1, 2026, a disability insurer shall not impose step therapy protocols as a prerequisite to authorizing coverage of insulin. For purposes of this section, step therapy protocol means a protocol or program that establishes the specific sequence in which prescription drugs for a specified condition, including self-administered drugs and physician-administered drugs, are medically appropriate for a particular insured and are covered under a disability insurance policy.
(d)Every(f)An insurer shall provide coverage for diabetes outpatient self-management training, education, and medical nutrition therapy necessary to enable an insured to properly use the equipment, supplies, and medications set forth in subdivisions (a) and (b) and additional diabetes outpatient self-management training, education, and medical nutrition therapy upon the direction or prescription of those services by the insureds participating physician. If an insurer delegates outpatient self-management training to contracting providers, the insurer shall require contracting providers to ensure that diabetes outpatient self-management training, education, and medical nutrition therapy are provided by appropriately licensed or registered health care professionals.
(e)(g)The diabetes outpatient self-management training, education, and medical nutrition therapy services identified in subdivision (d) (f) shall be provided by appropriately licensed or registered health care professionals as prescribed by a health care professional legally authorized to prescribe the services.
(f)(h)The coinsurances and deductibles for the benefits specified in subdivision (d) (f) shall not exceed those established for physician office visits by the insurer.
(g)(i)Every disability insurer governed by this section shall disclose the benefits covered pursuant to this section in the insurers evidence of coverage and disclosure forms.
(h)(j)An insurer may shall not reduce or eliminate coverage as a result of the requirements of this section.
(i)(k)This section does not apply to vision-only, dental-only, accident-only, specified disease, hospital indemnity, Medicare supplement, long-term care, or disability income insurance, except that for accident-only, specified disease, and hospital indemnity insurance coverage, benefits under this section only apply to the extent that the benefits are covered under the general terms and conditions that apply to all other benefits under the policy. Nothing in this section may be construed as imposing This section does not impose a new benefit mandate on accident-only, specified disease, or hospital indemnity insurance.
SEC. 4.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
|
Date
|
Status
|
|---|---|
| Oct 13, 2025 | Chaptered by Secretary of State. Chapter 737, Statutes of 2025. |
| Oct 13, 2025 | Approved by the Governor. |
| Sep 16, 2025 | Enrolled and presented to the Governor at 3 p.m. |
| Sep 9, 2025 | Assembly amendments concurred in. (Ayes 40. Noes 0. Page 2709.) Ordered to engrossing and enrolling. |
| Sep 3, 2025 | In Senate. Concurrence in Assembly amendments pending. |
| Sep 3, 2025 | Read third time. Passed. (Ayes 79. Noes 0. Page 2865.) Ordered to the Senate. |
| Aug 29, 2025 | Ordered to third reading. |
| Aug 29, 2025 | Read third time and amended. |
| Aug 21, 2025 | Read second time. Ordered to third reading. |
| Aug 20, 2025 | From committee: Do pass. (Ayes 15. Noes 0.) (August 20). |
| Jul 17, 2025 | Read second time and amended. Re-referred to Com. on APPR. |
| Jul 16, 2025 | From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 16. Noes 0.) (July 15). |
| Jun 27, 2025 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on HEALTH. |
| Jun 18, 2025 | June 24 hearing postponed by committee. |
| Jun 5, 2025 | Referred to Com. on HEALTH. |
| May 28, 2025 | In Assembly. Read first time. Held at Desk. |
| May 28, 2025 | Read third time. Passed. (Ayes 37. Noes 0. Page 1280.) Ordered to the Assembly. |
| May 27, 2025 | Read second time. Ordered to third reading. |
| May 23, 2025 | Read second time and amended. Ordered to second reading. |
| May 23, 2025 | From committee: Do pass as amended. (Ayes 6. Noes 0. Page 1189.) (May 23). |
| May 16, 2025 | Set for hearing May 23. |
| Apr 21, 2025 | April 21 hearing: Placed on APPR. suspense file. |
| Apr 8, 2025 | Set for hearing April 21. |
| Apr 7, 2025 | Read second time and amended. Re-referred to Com. on APPR. |
| Apr 3, 2025 | From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 11. Noes 0. Page 635.) (April 2). |
| Mar 25, 2025 | Set for hearing April 2. |
| Mar 17, 2025 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on HEALTH. |
| Jan 29, 2025 | Referred to Com. on HEALTH. |
| Jan 6, 2025 | Read first time. |
| Dec 4, 2024 | From printer. May be acted upon on or after January 3. |
| Dec 3, 2024 | Introduced. To Com. on RLS. for assignment. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Sep 9, 2025 | Unfinished Business SB40 Wiener et al. Concurrence | Senate Floor |
Passed |
|
| Sep 3, 2025 | The committee(s) on EIG recommend(s) that the measure be PASSED, WITH AMENDMENTS and be recommitted | Assembly Floor |
Passed |
|
| Aug 20, 2025 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Jul 15, 2025 | Do pass as amended and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
|
| May 28, 2025 | Senate 3rd Reading SB40 Wiener et al. | Senate Floor |
Passed |
|
| May 23, 2025 | Do pass as amended | Senate Standing Committee on Appropriations |
Passed |
|
| Apr 21, 2025 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Apr 2, 2025 | Do pass as amended, but first amend, and re-refer to the Committee on [Appropriations] | Senate Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| Aids Healthcare Foundation | ** Support | |
| American Academy of Pediatrics, California Beta Cell Action | ** Support | |
| American College Of Obstetricians Gynecologists District Ix | ** Support | |
| American Diabetes Association (Source) | ** Support | |
| Association Of California Life And Health Insurance Companies | ** Against | |
| ASSOCIATION OF CALIFORNIA LIFE AND HEALTH INSURANCE COMPANIES (ACLHIC PAC) | ** Against | |
| Beta Cell Action | ** Support | |
| California Academy Of Family Physicians | ** Support | |
| California Academy of Preventative Medicine | ** Support | |
| California Association For Health Services At Home | ** Support | |
| California Association Of Health Plans | ** Against | |
| California Chronic Care Coalition | ** Support | |
| California Life Sciences Association | ** Support | |
| California Medical Association | ** Support | |
| California Nurses Association | ** Support | |
| California Pharmacists Association | ** Support | |
| California Podiatric Medical Association | ** Support | |
| California Society Of Health-System Pharmacists | ** Support | |
| California State Board of Pharmacy | ** Support | |
| California State Council of Service Employees International Union | ** Support | |
| California State PTA | ** Support | |
| Cystic Fibrosis Foundation | ** Support | |
| Davis College Democrats | ** Support | |
| Diabetes Patient Advocacy Coalition | ** Support | |
| Health Access California | ** Support | |
| Insurance Commissioner Ricardo Lara | ** Support | |
| san francisco marin medical society | ** Support |
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | SB 40 |
UNFINISHED BUSINESS
Bill No: SB 40
Author: Wiener (D) and Wahab (D), et al.
Amended: 8/29/25 in Assembly
Vote: 21
SENATE HEALTH COMMITTEE: 11-0, 4/2/25
AYES: Menjivar, Valladares, Durazo, Gonzalez, Grove, Limón, Padilla, Richardson, Rubio, Weber Pierson, Wiener
SENATE APPROPRIATIONS COMMITTEE: 6-0, 5/23/25
AYES: Caballero, Seyarto, Cabaldon, Grayson, Richardson, Wahab
NO VOTE RECORDED: Dahle
SENATE FLOOR: 37-0, 5/28/25
AYES: Allen, Alvarado-Gil, Archuleta, Arreguín, Ashby, Becker, Blakespear, Cabaldon, Caballero, Choi, Cortese, Dahle, Durazo, Gonzalez, Grayson, Grove, Hurtado, Jones, Laird, McGuire, McNerney, Menjivar, Niello, Ochoa Bogh, Padilla, Pérez, Richardson, Rubio, Seyarto, Smallwood-Cuevas, Stern, Strickland, Umberg, Valladares, Wahab, Weber Pierson, Wiener
NO VOTE RECORDED: Cervantes, Limón, Reyes
ASSEMBLY FLOOR: 79-0, 9/3/25 - See last page for vote
SUBJECT: Health care coverage: insulin
SOURCE: American Diabetes Association
DIGEST:
This bill prohibits a health plan contract and health insurance policy from imposing a copayment, coinsurance, deductible, or any other cost-sharing on an insulin prescription drug that exceeds $35 for a 30-day supply. Requires at least one insulin for a given drug type in all forms and concentrations to be on the prescription drug formulary. Prohibits a health plan from imposing step therapy as a prerequisite to authorizing coverage of at least one insulin drug type, as specified.
Assembly Amendments
of 8/29/25 clarify on or after January 1, 2026, large group plans and policies are required to cover at least one insulin for a given drug type in all forms and concentrations to be on the prescription drug formulary; and on or after January 1, 2027, for individual and small group plans and policies at least one insulin for a given drug type in all forms and concentrations to be on Tier 1 or Tier 2 of a formulary, and if an insulin in Tier 1 or 2 is not clinically appropriate for an enrollee or insured, a higher tier insulin’s copayment, coinsurance, deductible or cost-sharing must be limited to $35. Exclude rapid acting inhaled insulin from the definition of drug type. Exempt Medi-Cal managed care plans from this bill.
ANALYSIS:
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act) and the California Department of Insurance (CDI) to regulate health insurers under the Insurance Code. [Health and Safety Code (HSC) §1340, et seq. and Insurance Code (INS) §106, et seq.]
- Requires coverage for medically necessary insulin, prescriptive medications for the treatment of diabetes, and glucagon. [HSC §1367.51 and INS §10176.61]
- Requires every plan and policy to provide coverage for diabetes outpatient self-management training, education, and medical nutrition therapy that meets specified requirements including that it is provided by an appropriately licensed or registered heath care professional. [HSC §1367.51 and INS §10176.61]
- Permits health plans and insurers to require step therapy and prior authorization. Requires a health plan or physician group that contracts with a pharmacy benefit manager to include a contract provision to comply with specified law regarding prior authorizations. [HSC §1342.71, §1367.206, Title 28 California Code of Regulations (CCR) §1300.67.205 and INS §10123.193 and §10123.201]
This bill:
- Prohibits a large group health plan contract and health insurance policy that is issued, amended, or renewed on or after January 1, 2026, or a contract or policy offered in the individual or small group market on or after January 1, 2027, from imposing a copayment, coinsurance, deductible, or any other cost-sharing on an insulin prescription drug that exceeds $35 for a 30-day supply. Requires for the large group market at least one insulin for a given drug type in all forms and concentrations to be on the prescription drug formulary.
- Requires the cost-sharing cap described in 1) above to apply only to insulin prescription drugs in Tier 1 and Tier 2 for individual or small group plan contracts and insurance policies that maintain a drug formulary grouped into tiers. Requires at least one insulin for a given drug type in all forms and concentrations to be on Tier 1 or Tier 2. Requires if there is no Tier 1 or Tier 2 insulin prescription drug that is clinically appropriate for an enrollee or insured, the plan or insurer to limit the cost-sharing for a higher tier drug as described in 1) above.
- Defines drug type to include, but not be limited to, rapid acting, regular or short acting, intermediate acting, long acting, ultra-long acting and premixed.
- Prohibits application on a high deductible health plan (HDHP), as defined under federal law, if not applying a deductible, coinsurance, or other cost-sharing to an insulin prescription would conflict with federal HDHP requirements.
- Applies the deductible and copayment limitations in 1) and 2) above to an insulin prescription drug, or any therapeutic insulin prescription drug, that is labeled or produced by the state.
- Defines insulin prescription drug to mean a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.
- Prohibits a health plan or health insurer from imposing step therapy protocols as a prerequisite to authorizing coverage of an insulin prescription drug. For health plans, defines step therapy protocol as a process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed. Prohibits step therapy for both self-administered drugs and physician-administered drugs, except as described in 2) above. For health insurers, defines step therapy as having the same meaning as defined in existing law. Additionally, for health insurers step therapy is prohibited for self-administered drugs and physician-administered drugs. Requires plans and insurers to cover at least one insulin in each drug type without step therapy.
- Exempts Medi-Cal managed care plans.
- Makes the provisions of this bill severable, if any are held invalid.
Comments
According to the author of this bill:
The bill prohibits cost-sharing for an insulin prescription drug from exceeding $35 for a 30 day-supply, and from requiring step therapy treatment. It makes no sense that people with diabetes in states like West Virginia can access affordable insulin while Californians are stuck with higher prices. When basic life necessities like medication become unaffordable in blue states, working people pay the price. It is past time California put basic protections in place to contain the astronomical cost of basic medications and bring economic relief to Californians forced to stretch beyond their means every month to pay for their insulin.
Related/Prior legislation
SB 90 (Wiener) of 2023–24 would have prohibited a health plan contract or disability insurance policy that is issued, amended, or renewed on or after January 1, 2024, or plan or policy offered in in the individual or small group market on or after January 1, 2025, from imposing a copayment, deductible, coinsurance, or any other out-of-pocket expense on an insulin prescription drug that exceeds $35 for a 30-day supply, as specified. SB 90 was vetoed by Governor Newsom. In his veto message, the Governor stated:
This bill would prohibit health plans from imposing a copayment of more than $35 for a 30-day supply of an insulin prescription drug. Bringing down the costs of prescription drugs, and particularly insulin, has long been a priority of mine. People should not be forced to go into debt to get lifesaving medicines. In March, I announced the state’s partnership with Civica to create our own line of CalRx biosimilar insulins that will cost no more than $30 per 10mL vial or $55 for five 3mL cartridges. This is a fraction of the current price for most insulins, and CalRx biosimilar insulins will be available to insured and uninsured patients nationwide. With CalRx, we are getting at the underlying cost, which is the true sustainable solution to high-cost pharmaceuticals. With copay caps however, the long-term costs are still passed down to consumers through higher premiums from health plans. As a state, we have led the nation in our efforts and investments to address the true underlying costs of insulin prescription affordability.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
According to the Assembly Appropriations Committee:
- CDI estimates costs of $6,000 in fiscal year 2025-26 for state administration (Insurance Fund).
- DMHC anticipates minor and absorbable costs.
- The California Public Employees Retirement System (CalPERS) anticipates no fiscal impact.
- The California Health Benefits Review Program (CHBRP) estimates this bill will increase total health insurance premiums paid by employers and enrollees by $10.38 million and decrease enrollee expenses by $8.23 million, for a total net increase in annual expenditures of $2.15 million (0.001%).
SUPPORT: (Verified 9/3/25)
American Diabetes Association (Source)
AIDS Healthcare Foundation
American College of Obstetricians & Gynecologists – District IX
American Academy of Pediatrics, California Beta Cell Action
California Academy of Family Physicians
California Academy of Preventative Medicine
California Association for Health Services at Home
California Chronic Care Coalition
California Life Sciences Association
California Medical Association
California Nurses Association
California Pharmacists Association
California Podiatric Medical Association
California Society of Health-System Pharmacists
California State Board of Pharmacy
California State Council of Service Employees International Union
California State PTA
Cystic Fibrosis Foundation
Davis College Democrats
Diabetes Patient Advocacy Coalition
Health Access California
Insurance Commissioner Ricardo Lara
San Francisco Marin Medical Society
OPPOSITION: (Verified 9/3/25)
Association of California Life and Health Insurance Companies
California Association of Health Plans
ARGUMENTS IN SUPPORT: This bill is sponsored by the American Diabetes Association (ADA), which believes this bill is a solution to help Californians with diabetes as they await CalRx biosimilar insulins. According to ADA, Californians would be protected from predatory practices that are the subject of a Federal Trade Commission complaint filed against the three largest pharmacy benefit managers for inflating the list price of insulin. ADA writes, according to the complaint, “In some cases, the patient may pay more at the pharmacy counter than the actual cost to their commercial insurer. In other words, the insurer functionally makes a profit from the prescription, instead of paying its share of the cost. This turns the normal insurance model on its head with the sick subsidizing the healthy, rather than the other way around. As one PBM manager bluntly put it: ‘I don’t see how it’s justifiable to charge someone 100% of the cost of the drug (during the deductible phase) while you receive a rebate on the backend … I can’t think of any other insurance industry that works like that.” ADA also writes that a recent study on the impact of the first copay cap legislation passed in the country (Colorado) found significant savings for enrollees, with out-of-pocket payments falling in half, and only a minor 1% increase in the amount paid by plans per prescription. ADA indicates researchers also found that the number of prescriptions and days supplied increased after the law passed, indicating that some patients may have been rationing insulin prior to the cap. ADA writes, to date, more than half the country, twenty-six states (plus Washington, D.C.) have passed legislation to limit out-of-pocket costs for insulin. The Diabetes Patient Advocacy Coalition (DPAC) writes that this bill would be a strong step in ensuring access to affordable care for Californians with diabetes. DPAC says one in four diabetes patients rations insulin due to its high cost, which can have life-threatening health conditions including heart disease, stroke, kidney failure, amputation of the lower extremities and blindness.
ARGUMENTS IN OPPOSITION: The California Association of Health Plans (CAHP) and the Association of California Life and Health Insurance Companies (ACLHIC) write in opposition to 17 health insurance mandate bills including this one. The opposition writes these bills will increase costs, reduce choice and competition and further incent some employers and individuals to avoid state regulation by seeking other coverage options. According to the opposition, benefit mandates impose a one-size-fits all approach to medical care and benefit design without consideration for consumer choice. The opposition strongly urges the Legislature to pause any new mandate bills at this time given the uncertainty regarding what benefits may or may not be covered in the essential health benefits (EHB) benchmark plan. The opposition also indicates that adding new mandates at a time when the Office of Health Care Affordability (OHCA) is working to curb healthcare costs could disrupt those efforts and make it difficult for health care entities to meet the OCHA spending target. The opposition urges the Legislature to consider the cumulative impacts of these mandates on premiums and access to coverage, and they believe that benefit mandates stifle the use of innovative, evidence-based medicine.
ASSEMBLY FLOOR: 79-0, 9/3/25
AYES: Addis, Aguiar-Curry, Ahrens, Alanis, Alvarez, Arambula, Ávila Farías, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Caloza, Carrillo, Castillo, Chen, Connolly, Davies, DeMaio, Dixon, Elhawary, Ellis, Flora, Fong, Gabriel, Gallagher, Garcia, Gipson, Jeff Gonzalez, Mark González, Hadwick, Haney, Harabedian, Hart, Hoover, Irwin, Jackson, Kalra, Krell, Lackey, Lee, Lowenthal, Macedo, McKinnor, Muratsuchi, Nguyen, Ortega, Pacheco, Papan, Patel, Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Ransom, Celeste Rodriguez, Michelle Rodriguez, Rogers, Blanca Rubio, Sanchez, Schiavo, Schultz, Sharp-Collins, Solache, Soria, Stefani, Ta, Tangipa, Valencia, Wallis, Ward, Wicks, Wilson, Zbur, Rivas
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
9/3/25 18:38:05
**** END ****
SENATE THIRD READING
STR Bill Id:SB 40
Author:(Wiener and Wahab)
As Amended Ver:August 29, 2025
Majority vote
SUMMARY
Prohibits health plans, health insurers and high-deductible health plan contracts and policies from imposing a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds $35 for a 30-day supply, on a phased-in basis and subject to limitations in the individual and small group market. Implements the $35 cap in high-deductible health plan and health insurance contracts and policies unless applying the cap conflicts with federal requirements for these plans. Prohibits health plans and health insurers from imposing step therapy as a prerequisite to authorizing coverage of insulin, except if at least one insulin in each drug type is covered without step therapy (step therapy means a process that specifies the sequence in which different prescription drugs for a given medical condition and that are medically appropriate for a particular patient are prescribed). Exempts Medi-Cal managed care (MCMC) plans and Program of All-Inclusive Care for the Elderly plans (PACE is a form of MCMC plan for persons who are eligible for Medi-Cal for persons above age 55 who meet the requirement for skilled nursing care under which the PACE plan provides both Medicare [for individuals who are also Medicare eligible] and Medi-Cal services) from the step therapy provisions in this bill, and the existing law coverage requirements for diabetic supplies and equipment for the management and treatment of diabetes, to the extent that the services in this bill are excluded from coverage under the contract between the Department of Health Care Services and the MCMC plan or PACE plan. Contains a severability clause.
Major Provisions
COMMENTS
Existing state law does not cap cost-sharing (co-payments, co-insurance) for insulin prescription drugs. H.R. 5376 of 2022, known as the Inflation Reduction Act, amended federal Medicare law to prohibit, effective January 1, 2023, Medicare beneficiaries with Medicare Part D coverage (for prescription drugs) or a Medicare Advantage plan that covers prescription drugs (MA-PD), from paying more than $35 for a 1-month supply of each covered insulin product. This cap applies regardless of whether the beneficiary has met their deductible. For people who use an insulin pump and get insulin through Medicare Part B, a similar $35 monthly copayment limit began on July 1, 2023. During plan year 2026 and each subsequent plan year, the out-of-pocket cost is the lowest of the following three amounts:
- $35;
- 25% of the "maximum fair price" (the “maximum fair price” is a new concept created by the IRA’s Medicare drug price negotiation program is determined by the Centers for Medicare & Medicaid Services (CMS) after negotiations with drug manufacturers; or,
- 25% of the negotiated price (this is 25% of the price that the insurance plan and manufacturer agree to, which may be less than the list price due to rebates or discounts).
According to the Author
This bill caps the out-of-pocket cost patients pay for insulin, as 25 states have already done, at $35 for a 30-day supply. Beyond that co-pay amount, plans are prohibited from cost-sharing for prescription insulin drugs, and from pursuing step therapy for insulin. The author argues it makes no sense that people with diabetes in states like West Virginia can access affordable insulin while Californians are stuck with higher prices. When basic life necessities like medication become unaffordable in blue states, working people pay the price as they are forced to choose between risking bankruptcy or risking their lives by rationing essential medication. The author concludes that California should lead the nation in making people's lives better and more affordable, and we shouldn’t ask people to wait any longer for affordable medications.
Arguments in Support
This bill is sponsored by the American Diabetes Association (ADA), which argues it is imperative to provide access to affordable insulin, as its survey found that roughly a quarter of respondents indicate the cost of insulin affected filling their prescription or usage of insulin. Further, a study in the Journal of American Medical Association regarding the impact of insulin affordability on those too young to access Medicare's $35 copay cap found that 20% of those under age 65 reported rationing insulin. The ramifications of inadequate access to insulin can lead to severe health complications, increased hospitalizations, and even preventable deaths. From 2009 to 2015, hospitalizations for diabetic ketoacidosis increased from 24.4 to 43.5 per 1000 adults with diabetes in those aged 18 to 44 years. The study went on to state that "these findings are consistent with previous work examining the prevalence of cost-related insulin rationing but extend existing research by characterizing differences within adults younger than 65 years and assessing ineligibility for insulin co-pay limits introduced by the Inflation Reduction Act." The ADA states that, for countless Californians, the cost of insulin remains an obstacle, particularly now with rising inflation on basic necessities. ADA concludes this bill provides a solution through the $35 copay cap to help Californians with diabetes as they await CalRx biosimilar insulins.
Arguments in Opposition
The California Association of Health Plans (CAHP) and the Association of California Life and Health Insurance Companies (ACLHIC) write in opposition to 17 health insurance mandate bills including this one. The opposition writes these bills will increase costs, reduce choice and competition and further incentivize some employers and individuals to avoid state regulation by seeking other coverage options. Benefit mandates impose a one-size-fits all approach to medical care and benefit design without consideration for consumer choice. The opposition strongly urges the Legislature to pause any new mandate bills given the uncertainty regarding what benefits may or may not be covered in the Essential Health Benefits (EHB) benchmark plan. The opposition also indicates that adding new mandates at a time when the Office of Health Care Affordability (OHCA) is working to curb health care costs could disrupt those efforts and make it difficult for health care entities to meet the OCHA spending target. The opposition urges the Legislature to consider the cumulative impacts of these mandates on premiums and access to coverage, and they believe that benefit mandates stifle the use of innovative, evidence-based medicine.
FISCAL COMMENTS
According to the Assembly Appropriations committee:
- The Department of Insurance estimates costs of $6,000 in fiscal year 2025-26 for state administration (Insurance Fund).
- The Department of Managed Health Care anticipates minor and absorbable costs.
- The California Public Employees Retirement System (CalPERS) anticipates no fiscal impact.
- The California Health Benefits Review Program (CHBRP) estimates this bill will increase total health insurance premiums paid by employers and enrollees by $10.38 million and decrease enrollee expenses by $8.23 million, for a total net increase in annual expenditures of $2.15 million (0.001%).
VOTES
SENATE FLOOR: 37-0-3
YES: Allen, Alvarado-Gil, Archuleta, Arreguín, Ashby, Becker, Blakespear, Cabaldon, Caballero, Choi, Cortese, Dahle, Durazo, Gonzalez, Grayson, Grove, Hurtado, Jones, Laird, McGuire, McNerney, Menjivar, Niello, Ochoa Bogh, Padilla, Pérez, Richardson, Rubio, Seyarto, Smallwood-Cuevas, Stern, Strickland, Umberg, Valladares, Wahab, Weber Pierson, Wiener
ABS, ABST OR NV: Cervantes, Limón, Reyes
ASM HEALTH: 16-0-0
YES: Bonta, Chen, Addis, Aguiar-Curry, Caloza, Carrillo, Flora, Mark González, Krell, Patel, Patterson, Celeste Rodriguez, Sanchez, Schiavo, Sharp-Collins, Stefani
ASM APPROPRIATIONS: 15-0-0
YES: Wicks, Arambula, Calderon, Caloza, Dixon, Elhawary, Fong, Mark González, Hart, Pacheco, Pellerin, Jeff Gonzalez, Solache, Ta, Tangipa
UPDATED
VERSION: August 29, 2025
CONSULTANT: Scott Bain / HEALTH / (916) 319-2097 FN: 0001347
SENATE THIRD READING
STR Bill Id:SB 40
Author:(Wiener and Wahab)
As Amended Ver:July 17, 2025
Majority vote
SUMMARY
Prohibits health plan and health insurers from imposing a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds $35 for a 30-day supply, on a phased-in basis and subject to limitations in the individual and small group market. Prohibits health plans and health insurers from imposing step therapy as a prerequisite to authorizing coverage of insulin, except if at least one insulin in each drug type is covered without step therapy (step therapy means a process that specifies the sequence in which different prescription drugs for a given medical condition and that are medically appropriate for a particular patient are prescribed).
Major Provisions
COMMENTS
Inflation Reduction Act (IRA). H.R. 5376 of 2022, known as the Inflation Reduction Act, amended federal Medicare to prohibit, effective January 1, 2023, Medicare beneficiaries with a Medicare Part D coverage (for prescription drugs) or a Medicare Advantage plan that covers prescription drugs (MA-PD), from paying more than $35 for a 1-month supply of each covered insulin product. This cap applies regardless of whether the beneficiary has met their deductible. For people who use an insulin pump and get insulin through Medicare Part B, a similar $35 monthly copayment limit began on July 1, 2023. During plan year 2026 and each subsequent plan year, the out-of-pocket cost is the lowest of the following three amounts:
- $35;
- 25% of the ″maximum fair price″ (the ″maximum fair price″ is a new concept created by the IRA′s Medicare drug price negotiation program is determined by the Centers for Medicare & Medicaid Services (CMS) after negotiations with drug manufacturers; or,
- 25% of the negotiated price (this is 25% of the price that the insurance plan and manufacturer agree to, which may be less than the list price due to rebates or discounts).
According to the Author
This bill caps the out-of-pocket cost patients pay for insulin, as 25 states have already done, at $35 for a 30-day supply. Beyond that co-pay amount, plans are prohibited from cost-sharing for prescription insulin drugs, and from pursuing step therapy for insulin. The author argues it makes no sense that people with diabetes in states like West Virginia can access affordable insulin while Californians are stuck with higher prices. When basic life necessities like medication become unaffordable in blue states, working people pay the price as they are forced to choose between risking bankruptcy or risking their lives by rationing essential medication. The author concludes that California should lead the nation in making people′s lives better and more affordable, and we shouldn′t ask people to wait any longer for affordable medications.
Arguments in Support
This bill is sponsored by the American Diabetes Association (ADA), which argues it is imperative to provide access to affordable insulin, as its survey found that roughly a quarter of respondents indicate the cost of insulin affected filling their prescription or usage of insulin. Further, a study in the Journal of American Medical Association regarding the impact of insulin affordability on those too young to access Medicare′s $35 copay cap found that 20% of those under age 65 reported rationing insulin. The ramifications of inadequate access to insulin can lead to severe health complications, increased hospitalizations, and even preventable deaths. From 2009 to 2015, hospitalizations for diabetic ketoacidosis increased from 24.4 to 43.5 per 1000 adults with diabetes in those aged 18 to 44 years. The study went on to state that ″these findings are consistent with previous work examining the prevalence of cost-related insulin rationing but extend existing research by characterizing differences within adults younger than 65 years and assessing ineligibility for insulin co-pay limits introduced by the Inflation Reduction Act.″ The ADA states that, for countless Californians, the cost of insulin remains an obstacle, particularly now with rising inflation on basic necessities. ADA concludes this bill provides a solution through the $35 copay cap to help Californians with diabetes as they await CalRx biosimilar insulins.
Arguments in Opposition
The California Association of Health Plans (CAHP) and the Association of California Life and Health Insurance Companies (ACLHIC) write in opposition to 17 health insurance mandate bills including this one. The opposition writes these bills will increase costs, reduce choice and competition and further incentivize some employers and individuals to avoid state regulation by seeking other coverage options. Benefit mandates impose a one-size-fits all approach to medical care and benefit design without consideration for consumer choice. The opposition strongly urges the Legislature to pause any new mandate bills given the uncertainty regarding what benefits may or may not be covered in the Essential Health Benefits (EHB) benchmark plan. The opposition also indicates that adding new mandates at a time when the Office of Health Care Affordability (OHCA) is working to curb health care costs could disrupt those efforts and make it difficult for health care entities to meet the OCHA spending target. The opposition urges the Legislature to consider the cumulative impacts of these mandates on premiums and access to coverage, and they believe that benefit mandates stifle the use of innovative, evidence-based medicine.
FISCAL COMMENTS
According to the Assembly Appropriations committee:
- The Department of Insurance estimates costs of $6,000 in fiscal year 2025-26 for state administration (Insurance Fund).
- The Department of Managed Health Care anticipates minor and absorbable costs.
- The California Public Employees Retirement System (CalPERS) anticipates no fiscal impact.
- The California Health Benefits Review Program (CHBRP) estimates this bill will increase total health insurance premiums paid by employers and enrollees by $10.38 million and decrease enrollee expenses by $8.23 million, for a total net increase in annual expenditures of $2.15 million (0.001%).
VOTES
SENATE FLOOR: 37-0-3
YES: Allen, Alvarado-Gil, Archuleta, Arreguín, Ashby, Becker, Blakespear, Cabaldon, Caballero, Choi, Cortese, Dahle, Durazo, Gonzalez, Grayson, Grove, Hurtado, Jones, Laird, McGuire, McNerney, Menjivar, Niello, Ochoa Bogh, Padilla, Pérez, Richardson, Rubio, Seyarto, Smallwood-Cuevas, Stern, Strickland, Umberg, Valladares, Wahab, Weber Pierson, Wiener
ABS, ABST OR NV: Cervantes, Limón, Reyes
ASM HEALTH: 16-0-0
YES: Bonta, Chen, Addis, Aguiar-Curry, Caloza, Carrillo, Flora, Mark González, Krell, Patel, Patterson, Celeste Rodriguez, Sanchez, Schiavo, Sharp-Collins, Stefani
ASM APPROPRIATIONS: 15-0-0
YES: Wicks, Arambula, Calderon, Caloza, Dixon, Elhawary, Fong, Mark González, Hart, Pacheco, Pellerin, Jeff Gonzalez, Solache, Ta, Tangipa
UPDATED
VERSION: June 27, 2025
CONSULTANT: Scott Bain / HEALTH / (916) 319-2097 FN: 0001210
Date of Hearing: August 20, 2025
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Buffy Wicks, Chair
SBPCA Bill Id:SB 40
Author:(Wiener) – As Amended Ver:July 17, 2025
Policy Committee: | Health | Vote: | 16 - 0 |
|
| ||
|
|
Urgency: No State Mandated Local Program: Yes Reimbursable: No
SUMMARY:
This bill generally prohibits a health plan contract or insurance policy (collectively, “health plan”) from imposing a copayment, coinsurance, deductible, or other cost sharing of more than $35 for a 30-day supply of an insulin prescription drug.
Specifically, this bill:
- Prohibits a large group health care service plan contract or policy issued, amended, or renewed on or after January 1, 2026, from imposing a copayment, coinsurance, deductible, or any other cost sharing exceeding $35 for a 30-day supply of an insulin prescription drug. Requires the prescription drug formulary include at least one insulin for a given drug type in all forms and concentrations.
- Prohibits an individual or small group health plan contract or policy issued, amended, or renewed on or after January 1, 2027, from imposing any cost sharing that exceeds $35 for a 30-day supply of an insulin prescription drug. Specifies the cost-sharing cap applies only to insulin prescription drugs in Tier 1 and Tier 2 if the individual or small group health plan maintains a drug formulary grouped into tiers, and requires at least one insulin for a given drug type in all forms and concentrations be on Tier 1 or Tier 2. Requires the health plan limit the cost sharing for a higher tier drug to no more than $35 for a 30-day supply for an individual enrollee if no Tier 1 or Tier 2 insulin prescription drug is clinically appropriate for that enrollee.
- Prohibits a high deductible health plan, as defined, from imposing a deductible, coinsurance, or any other cost sharing on an insulin prescription drug, unless not applying the cost sharing would conflict with federal requirements for high deductible health plans.
- Applies the deductible and copayment limitations in item 1, above, to an insulin prescription drug, or any therapeutic equivalent insulin prescription drug, that is labeled or produced by the state, when the state labels or produces an insulin prescription drug.
- Provides that “drug type” includes rapid acting, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed.
- Defines “insulin prescription drug” to mean a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.
- Defines, for purposes of this bill, “step therapy protocol” to mean a process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed.
- Prohibits, on and after January 1, 2026, a health plan from imposing step therapy as a prerequisite to authorizing coverage of an insulin prescription drug, with the following exceptions:
- Self-administered drugs and physician-administered drugs.
- If at least one insulin in each drug type is covered without step therapy.
- Self-administered drugs and physician-administered drugs.
- Makes findings and declarations concerning diabetes and the need to reduce insulin costs.
- Provides that the provisions of this bill are severable.
FISCAL EFFECT:
The Department of Insurance estimates costs of $6,000 in fiscal year 2025-26 for state administration (Insurance Fund).
The Department of Managed Health Care anticipates minor and absorbable costs.
The California Public Employees Retirement System (CalPERS) anticipates no fiscal impact.
The California Health Benefits Review Program (CHBRP) estimates this bill will increase total health insurance premiums paid by employers and enrollees by $10.38 million and decrease enrollee expenses by $8.23 million, for a total net increase in annual expenditures of $2.15 million (0.001%).
COMMENTS:
- Purpose. This bill is sponsored by the American Diabetes Association. According to the author:
Senate Bill 40 caps the out-of-pocket cost patients pay for insulin, as 25 states have already done, at thirty-five dollars ($35) for a 30-day supply. Beyond that co-pay amount, [this bill will prohibit plans from requiring] cost-sharing for prescription insulin drugs, and from pursuing step therapy for insulin. It makes no sense that people with diabetes in states like West Virginia can access affordable insulin while Californians are stuck with higher prices. When basic life necessities like medication become unaffordable…, working people pay the price as they are forced to choose between risking bankruptcy or risking their lives by rationing essential medication. California should lead the nation in making people’s lives better and more affordable, and we shouldn’t ask people to wait any longer for affordable medications.
- Background. CHBRP Analysis. According to CHBRP, there is clinical consensus that insulin is essential for effective treatment of diabetes and that delayed introduction of insulin or ineffective insulin therapy contributes to poor glycemic control and places patients at risk of complications.
CHBRP estimates that of 92,636 enrollees in commercial and CalPERS health plans and insurance who use insulin, 39,178 (42%) have cost sharing that exceeds the $35 cap proposed by this bill. This bill limits cost sharing for these enrollees to $35 per month – a 44% reduction, and the average share of cost would drop to $29 – which CHBRP estimates would increase insulin utilization by 4%. CHBRP states there is strong evidence that higher cost sharing reduces adherence, and lower cost sharing increases adherence. CHBRP further states there is some evidence that reducing cost sharing is associated with decreased diabetes-related complications, emergency department visits, and hospitalizations. CHBRP assumes a 10% reduction in diabetes-related emergency department visits associated with reduced cost sharing and increased insulin utilization.
CHBRP found strong evidence that step therapy is associated with lower likelihood of initiating or continuing medications and with poorer adherence to medication, and expert consensus that step therapy protocols for insulin would be associated with lowered use and adherence. CHBRP also states that removal of step therapy could result in a portion of enrollees using more expensive insulins within the same therapeutic class, which would result in an increase in the average unit cost of insulin.
Federal Inflation Reduction Act (IRA). H.R. 5376 of 2022, also known as the IRA, amended federal Medicare to prohibit, effective January 1, 2023, Medicare beneficiaries with Medicare Part D coverage (for prescription drugs) or a Medicare Advantage plan that covers prescription drugs, from paying more than $35 for a one-month supply of a covered insulin product. This cap applies regardless of whether the beneficiary has met their deductible. For people who use an insulin pump and get insulin through Medicare Part B, a similar $35 monthly copayment limit began on July 1, 2023. During plan year 2026 and each subsequent plan year, the out-of-pocket cost is the lowest of the following three amounts: (a) $35, (b) 25% of the "maximum fair price" (determined through federal government negotiations with drug manufacturers), or (c) 25% of the negotiated price that the insurance plan and manufacturer agree to, which may be less than the list price due to rebates or discounts.
- Prior Legislation. SB 90 (Wiener), of the 2023-24 Legislative Session, would have prohibited health plans from imposing a copayment of more than $35 for a 30-day supply of an insulin prescription drug. Governor Newsom vetoed SB 90, stating:
In March, I announced the state's partnership with Civica to create our own line of CalRx biosimilar insulins that will cost no more than $30 per 10 mL vial or $55 for five 3 mL cartridges. This is a fraction of the current price for most insulins, and CalRx biosimilar insulins will be available to insured and uninsured patients nationwide. With CalRx, we are getting at the underlying cost, which is the true sustainable solution to high-cost pharmaceuticals. With copay caps however, the long-term costs are still passed down to consumers through higher premiums from health plans. As a state, we have led the nation in our efforts and investments to address the true underlying costs of insulin prescription affordability.
Recently, several other bills have proposed limits on cost sharing for insulin, including: SB 473 (Bates), of the 2021-22 Legislative Session ($35 for a monthly supply; held in this committee); AB 97 (Nazarian), of the 2021-22 Legislative Session (prohibited imposing a deductible on insulin; held in the Senate Appropriations Committee), and AB 2203 (Nazarian), of the 2019-20 Legislative Session ($50 per 30-day supply of insulin, and $100 total per month; due to the shortened Legislative calendar brought on by the COVID-19 pandemic, AB 2203 was not heard in the Senate Health Committee).
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: July 15, 2025
ASSEMBLY COMMITTEE ON HEALTH
Mia Bonta, Chair
SBPCA Bill Id:SB 40
Author:(Wiener) – As Amended Ver:June 27, 2025
SENATE VOTE: 37-0
SUBJECT: Health care coverage: insulin.
SUMMARY: Prohibits health plan and health insurers from imposing a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds $35 for a 30-day supply, on a phased-in basis and subject to limitations in the individual and small group market. Prohibits health plans and health insurers from imposing step therapy as a prerequisite to authorizing coverage of insulin, except if at least one insulin in each drug type is covered without step therapy (step therapy means a process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed). Specifically, this bill:
- Prohibits a large group health plan contract or large group health insurance policy that is issued, amended, or renewed on or after January 1, 2026, from imposing a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds $35 for a 30-day supply.
- Defines for purposes of this bill “insulin prescription drug” to mean a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.
- Requires at least one insulin for a given drug type in all forms and concentrations to be on the prescription drug formulary of large group health plan and insurers.
- Defines a “drug type” to include, but is not limited to, rapid acting, rapid acting inhaled, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed.
- Prohibits an individual or small group health plan contract or health insurance policy that is issued, amended, or renewed on or after January 1, 2027, from imposing a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds $35 for a 30-day supply.
- Requires, if an individual or small group health plan contract or health insurance policy maintains a drug formulary grouped into tiers, the $35 cost-sharing cap to apply only to insulin prescription drugs that are in Tier 1 and Tier 2.
- Requires at least one insulin for a given drug type in all forms and concentrations to be on Tier 1 or Tier 2.
- Requires, if there is no Tier 1 or Tier 2 insulin prescription drug that is clinically appropriate for an enrollee, the health plan or health insurer to limit the cost sharing for a higher tier drug to no more than $35 for a 30-day supply for an individual enrollee.
- Prohibits, if a health plan contract or health insurance policy is a high deductible health plan, as defined in a specified provision of federal law, the contract or policy from imposing a deductible, coinsurance, or any other cost sharing on an insulin prescription drug, unless not applying the deductible, coinsurance, or other cost sharing to an insulin prescription drug would conflict with federal requirements for high deductible health plans.
- Requires, when the state has the capacity to label or produce an insulin prescription drug, the deductible and copayment limitations to also apply to an insulin prescription drug, or any therapeutic equivalent insulin prescription drug, that is labeled or produced by the state.
- Prohibits a health plan or health insurer, consistent with this bill and the diabetes-related coverage provisions in existing law in the section of law that this bill amends, on and after January 1, 2026, from imposing step therapy protocols (for health plans) or step therapy (for health insurers) for both self-administered drugs and physician-administered drugs as a prerequisite to authorizing coverage of an insulin prescription drug except as specified in 12) below.
- Prohibits this bill from requiring a health plan or health insurer to cover all of the types of insulin without step therapy, if at least one insulin in each drug type is covered without step therapy.
- Defines “step therapy protocol” for health plans to mean a process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed.
- Defines “step therapy” for health insurers (by cross reference to an existing law provision) to mean a type of protocol that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are to be prescribed.
- Requires the provisions of this bill to be severable, and if any provision of this bill or its application is held invalid, that invalidity is prohibited from affecting other provisions or applications that can be given effect without the invalid provision or application.
- Makes legislative findings and declarations that:
- Approximately 263,000 Californians are diagnosed with type 1 diabetes each year, approximately four million Californian adults have diabetes, diabetes is the seventh leading cause of death, and it is a leading cause of disabling and life-threatening complications, including heart disease, stroke, kidney failure, amputation of the lower extremities, and new cases of blindness among adults, every Californian with type 1 diabetes, and many with type 2 diabetes, rely on daily doses of insulin to survive; and,
- Insulin prices have nearly tripled, creating financial hardships for people who rely on it to survive, and one in four people using insulin have reported insulin underuse due to the high cost of insulin; and,
- Imposing a deductible on insulin, and requiring individuals to meet that deductible, creates a financial burden that presents a barrier to accessing insulin, and studies have shown that managing diabetes can prevent complications and medical emergencies associated with diabetes that result in emergency room visits, hospitalizations, and costly treatments.
- States legislative intent to enact legislation on important policies to reduce the costs for Californians with diabetes to obtain lifesaving and life-sustaining insulin.
EXISTING LAW:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act) and the California Department of Insurance (CDI) to regulate health insurers under the Insurance Code. [Health and Safety Code (HSC) § 1340, et seq. and Insurance Code (INS) § 106, et seq.]
- Requires health plans and health insurers that cover hospital, medical, or surgical expenses to include coverage for the following equipment and supplies for the management and treatment of insulin-using diabetes, non-insulin-using diabetes, and gestational diabetes as medically necessary, even if the items are available without a prescription:
- Blood glucose monitors and blood glucose testing strips;
- Blood glucose monitors designed to assist the visually impaired;
- Insulin pumps and all related necessary supplies;
- Ketone urine testing strips;
- Lancets and lancet puncture devices;
- Pen delivery systems for insulin administration;
- Podiatric devices to prevent or treat diabetes-related complications;
- Insulin syringes; and,
- Visual aids, excluding eyewear, to assist the visually impaired with proper dosing of insulin. [HSC § 1367.51 and INS § 10176.61]
- Requires a health plan contract and health insurance policy that covers prescription benefits to include coverage for the following prescription items if the items are determined to be medically necessary:
- Insulin;
- Prescriptive medications for the treatment of diabetes;
- Glucagon; and,
- Prohibits the copayments and deductibles for the benefits from exceeding those established for similar benefits within the given plan or policy. [Ibid.]
- Defines a “high deductible health plan” for purposes of tax-favored health savings accounts in federal law, as a health plans which has an annual deductible which is not less than $1,000 for self-only coverage, and twice the dollar amount for family coverage, and the sum of the annual deductible and the other annual out-of-pocket expenses required to be paid under the plan (other than for premiums) for covered benefits does not exceed $5,000 for self-only coverage, and twice that amount family coverage. [26 United States Code (USC) § 223]
- Prohibits a plan from failing to be treated as a high deductible health plan by reason of failing to have a deductible for preventive care (as defined in federal law), except as otherwise provided by the Secretary of the federal Department of Health and Human Services. [Ibid.]
FISCAL EFFECT: According to the Senate Appropriations Committee:
- Likely minor and absorbable costs for DMHC for state operations.
- Likely minor or no fiscal impact to the CDI for state operations.
- Unknown, potential General Fund costs for CalPERS plans due to the limits on step therapy.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, this bill caps the out-of-pocket cost patients pay for insulin, as 25 states have already done, at $35 for a 30-day supply. Beyond that co-pay amount, plans are prohibited from cost-sharing for prescription insulin drugs, and from pursuing step therapy for insulin. The author argues it makes no sense that people with diabetes in states like West Virginia can access affordable insulin while Californians are stuck with higher prices. When basic life necessities like medication become unaffordable in blue states, working people pay the price as they are forced to choose between risking bankruptcy or risking their lives by rationing essential medication. The author concludes that California should lead the nation in making people’s lives better and more affordable, and we shouldn’t ask people to wait any longer for affordable medications.
- BACKGROUND. AB 1996 (Thomson), Chapter 795, Statutes of 2002 requests the University of California to assess legislation mandating a benefit or service and prepare a report with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. The California Health Benefits Review Program (CHBRP) was created in response to AB 1996, and reviewed this bill. According to CHBRP, diabetes mellitus (diabetes) is a chronic disease that prevents the proper production of and/or response to insulin, a hormone that facilitates the transfer of glucose into cells to provide energy. Three common types of diabetes are type 1 diabetes, type 2 diabetes, and gestational diabetes. Insulin is frequently used to treat all three types of diabetes. As of 2023, about 11.5% of the adult population in California has been diagnosed with diabetes. The incidence of diabetes is highest among adults aged 65 years and older.
CHBRP states the American Diabetes Association (ADA) recommends different insulin regimens based on the patient’s level of insulin deficiency, pattern of glucose levels, and individual patient characteristics. Insulin is necessary for the treatment of type 1 diabetes and is often needed for the treatment of type 2 diabetes and diabetes in pregnancy. Sometimes insulin is needed for type 2 diabetes for patients who have symptoms of acute insulin deficiency. However, most patients begin treatment with non-insulin medications for type 2 diabetes. Relatively new medications such as SGLT2 inhibitors and GLP-1 agonists are playing an increasingly important role in the management of type 2 diabetes because of their proven efficacy at improving long-term cardiovascular and renal outcomes compared to other medications (including insulin). As a result, the number of enrollees in California using insulin has decreased over time.
Key findings of CHBRP’s analysis of the introduced version of this bill include:
- Coverage impacts and enrollees covered. There are 92,636 California enrollees who use insulin who are covered in commercial and California Public Employees’ Retirement System (CalPERS) state-regulated insurance. More than half (58%) have insulin cost-sharing below the cap required in this bill. However, 39,178 enrollees have cost-sharing that would exceed the cap with average monthly cost-sharing of $52 per month.
- Medical effectiveness. There is strong evidence from seven observational studies on cost-related insulin use/adherence that cost-sharing affects insulin use and adherence in patients with diabetes; higher cost-sharing reduces adherence and lower cost-sharing increases adherence. There is some evidence from four studies on the effect of cost-sharing for insulin on diabetes-related health outcomes and utilization. These studies suggest that reduced cost-sharing is associated with decreased diabetes-related complications, emergency department visits, and hospitalizations. The effect of cost-sharing on additional health outcomes, such as glycemic control, is unknown. There is strong evidence based on CHBRP’s previous analysis of AB 2144 (Arambula) of 2019 that step therapy is associated with a lower likelihood of initiating or continuing medications and with poorer adherence to medication. There is expert consensus, consistent with the finding for prescription medications, that step therapy protocols for insulin are associated with lowered use and adherence. Additionally, there is clinical consensus that insulin is considered essential for effective treatment of diabetes and that delayed introduction of, or ineffective insulin therapy contributes to poor glycemic control and places patients at risk of complications. There are several limitations that contributed to the medical effectiveness evaluation provided in this review, most notably the barriers to conducting rigorous randomized controlled trials of differential cost-sharing or utilization management strategies on insulin use, inherent differences between the types of diabetes, and the multifaceted nature of diabetes treatment, resulting in a literature base that is not as rigorous as ideal and thereby limiting the certainty of conclusions drawn from the evidence.
- Utilization. CHBRP estimates that the 39,178 enrollees would see a reduction in monthly cost-sharing to $29. CHBRP assumes that utilization of insulin will increase by 4% because of this bill. This compares to 6.6% estimated increase in utilization in CHBRP’s 2023 report of a similar bill, SB 90 (Wiener) of 2023. There are at least two reasons for CHBRP’s 4% reduced increase in utilization under this bill. One reason is because clinical guidelines now recommend other newer noninsulin medications that are equally or more effective for many people with type 2 diabetes which has led to fewer patients using insulin. Another reason is because the unit costs of insulin has changed with some major manufacturers reducing the list prices in response to the removal of the average manufacturer price (AMP) cap under the American Rescue Plan Act (ARPA). CHBRP notes that removal of step therapy in this years’ bill, could result in a portion of enrollees using more expensive insulins within the same therapeutic class, which would result in an increase in the average unit cost of insulin. Consistent with its’ SB 90 report, CHBRP assumes a 10% reduction in diabetes-related emergency department visits for this population.
- Medi-Cal. There may be no impact to Medi-Cal because of how Medi-Cal administers the pharmacy benefits for Medi-Cal enrollees.
- CalPERS. There is no impact to enrollees associated with CalPERS, DMHC-regulated plans, because there are not enrollees for whom cost-sharing for insulin is higher than the cap.
- Impact on expenditures. CHBRP estimates an increase in total health insurance premiums paid by employers and enrollees of $10,377,000 and a decrease in cost-sharing for impacted enrollees of $8,230,000. Enrollees with out-of-pocket expenditures in the top 1% would have an annual savings of greater than $1,463. While 39,178 enrollees will see reductions in cost-sharing for insulin, over 12 million Californians will be impacted by increases in premiums. Individual enrollees would see premium increases between $.07 and $.08 per member per month. Small employers and their enrollees would see premium increases of $.19 per member per month and large employers and their enrollees would experience an increase in premiums of $.04 per member per month because of this bill.
- High Deductible Health Plans (HDHPs). CHBRP assumes that all Health Savings Account (HSA)-qualified HDHPs will cover insulin pre-deductible according to federal law. Preventive services that include treatments for chronic conditions which can be excluded from the deductible include insulin, and therefore would not interfere with an HDHP’s qualification for HSA.
- Essential Health Benefits (EHBs). This bill would not require coverage for a new state benefit mandate. This bill modifies cost-sharing terms and conditions of an already covered medication. As such, this bill would not exceed the definition of EHB and would not require the state to pay for the EHB costs.
- INFLATION REDUCTION ACT (IRA). H.R. 5376 of 2022, known as the Inflation Reduction Act, amended federal Medicare to prohibit, effective January 1, 2023, Medicare beneficiaries with a Medicare Part D coverage (for prescription drugs) or a Medicare Advantage plan that covers prescription drugs (MA-PD), from paying more than $35 for a 1-month supply of each covered insulin product. This cap applies regardless of whether the beneficiary has met their deductible. For people who use an insulin pump and get insulin through Medicare Part B, a similar $35 monthly copayment limit began on July 1, 2023. During plan year 2026 and each subsequent plan year, the out-of-pocket cost is the lowest of the following three amounts:
- $35;
- 25% of the "maximum fair price" (the “maximum fair price” is a new concept created by the IRA’s Medicare drug price negotiation program is determined by the CMS after negotiations with drug manufacturers; or,
- 25% of the negotiated price (this is 25% of the price that the insurance plan and manufacturer agree to, which may be less than the list price due to rebates or discounts).
- SUPPORT. This bill is sponsored by the American Diabetes Association (ADA), which argues it is imperative to provide access to affordable insulin, as its survey found that roughly a quarter of respondents indicate the cost of insulin affected filling their prescription or usage of insulin. Further, a study in the Journal of American Medical Association regarding the impact of insulin affordability on those too young to access Medicare’s $35 copay cap found that 20% of those under age 65 reported rationing insulin. The ramifications of inadequate access to insulin can lead to severe health complications, increased hospitalizations, and even preventable deaths. From 2009 to 2015, hospitalizations for diabetic ketoacidosis increased from 24.4 to 43.5 per 1000 adults with diabetes in those aged 18 to 44 years. The study went on to state that “these findings are consistent with previous work examining the prevalence of cost-related insulin rationing but extend existing research by characterizing differences within adults younger than 65 years and assessing ineligibility for insulin co-pay limits introduced by the Inflation Reduction Act.” The ADA states that, for countless Californians, the cost of insulin remains an obstacle, particularly now with rising inflation on basic necessities. ADA concludes this bill provides a solution through the $35 copay cap to help Californians with diabetes as they await CalRx biosimilar insulins.
- OPPOSITION. The California Association of Health Plans (CAHP) and the Association of California Life and Health Insurance Companies (ACLHIC) write in opposition to 17 health insurance mandate bills including this one. The opposition writes these bills will increase costs, reduce choice and competition and further incentivize some employers and individuals to avoid state regulation by seeking other coverage options. Benefit mandates impose a one-size-fits all approach to medical care and benefit design without consideration for consumer choice. The opposition strongly urges the Legislature to pause any new mandate bills given the uncertainty regarding what benefits may or may not be covered in the EHB benchmark plan. The opposition also indicates that adding new mandates at a time when the Office of Health Care Affordability (OHCA) is working to curb health care costs could disrupt those efforts and make it difficult for health care entities to meet the OCHA spending target. The opposition urges the Legislature to consider the cumulative impacts of these mandates on premiums and access to coverage, and they believe that benefit mandates stifle the use of innovative, evidence-based medicine.
- PREVIOUS LEGISLATION.
- SB 90 (Wiener) of 2023 would have prohibited a health plan contract or disability insurance policy that is issued, amended, or renewed on or after January 1, 2024, or plan or policy offered in in the individual or small group market on or after January 1, 2025, from imposing a copayment, deductible, coinsurance, or any other out-of-pocket expense on an insulin prescription drug that exceeds $35 for a 30-day supply, as specified. SB 90 was vetoed by Governor Newsom. In his veto message, the Governor stated:
This bill would prohibit health plans from imposing a copayment of more than $35 for a 30-day supply of an insulin prescription drug. Bringing down the costs of prescription drugs, and particularly insulin, has long been a priority of mine. People should not be forced to go into debt to get lifesaving medicines. In March, I announced the state's partnership with Civica to create our own line of CalRx biosimilar insulins that will cost no more than $30 per 10mL vial or $55 for five 3mL cartridges. This is a fraction of the current price for most insulins, and CalRx biosimilar insulins will be available to insured and uninsured patients nationwide. With CalRx, we are getting at the underlying cost, which is the true sustainable solution to high-cost pharmaceuticals. With copay caps however, the long-term costs are still passed down to consumers through higher premiums from health plans. As a state, we have led the nation in our efforts and investments to address the true underlying costs of insulin prescription affordability.
- SB 473 (Bates) of 2022 would have required a health plan or insurance policy to cover all available dosage forms and concentrations of insulin for a copayment of no more than $35 for a monthly supply. SB 473 was held in the Assembly Appropriations Committee.
- SB 852 (Pan) Chapter 207, Statutes of 2020 requires the California Health and Human Services Agency to enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and, to increase patient access to affordable drugs. Included in SB 852 is that partnerships include the production of at least one form of insulin, provided that a viable pathway for manufacturing a more affordable form of insulin exists.
- AB 97 (Nazarian) of 2021 would have prohibited a health plan contract or disability insurance policy from imposing a deductible on an insulin prescription drug. AB 97 was held in the Senate Appropriations Committee.
- AB 2203 (Nazarian) of 2020 would have established a copayment cap for insulin and prohibited a health plan contract or a health insurance policy from imposing cost-sharing on a covered insulin prescription, except for a copayment not to exceed $50 per 30-day supply of insulin, and no more than $100 total per month, regardless of the amount or type of insulin. AB 2203 would have authorized the Attorney General to investigate pricing of prescription insulin drugs made available to California consumers, considering the role of each entity in the entire supply chain, to ensure adequate consumer protections in pricing of prescription insulin drugs and determine whether additional consumer protections are needed, as specified. Due to the shortened Legislative calendar brought on by the COVID-19 pandemic, AB 2203 was not set for a hearing in the Senate Health Committee.
- AB 2144 (Arambula) of 2019 would have clarified that a health plan may require step therapy if there is more than one drug that is appropriate for the treatment of a medical condition; required a health plan or health insurer to expeditiously grant a step therapy exception if specified criteria are met; authorized an enrollee or insured or their designee, guardian, primary care physician, or health care provider to file an appeal of a prior authorization or the denial of a step therapy exception request, and would require a health care service plan or health insurer to designate a clinical peer to review those appeals; and required a health plan, health insurer, or utilization review organization to annually report specified information about their step therapy exception requests and prior authorization requests. AB 2144 was not set for a hearing in the Assembly Health Committee.
- AMENDMENTS. Following discussions, this bill will be amended to delete “rapid acting inhaled” from the definition of “drug type” in this bill and to include only one definition of “drug type” in this bill.
REGISTERED SUPPORT / OPPOSITION:
Support
American Diabetes Association (sponsor)
AIDS Healthcare Foundation
American Academy of Pediatrics, California
American College of Obstetricians & Gynecologists - District IX
California Association for Health Services At Home
California Chronic Care Coalition
California Pharmacists Association
California Podiatric Medical Association
California Society of Health-System Pharmacists
California State Council of Service Employees International Union (SEIU California)
Cystic Fibrosis Foundation
Health Access California
San Francisco Marin Medical Society
One individual
Opposition
California Association of Health Plans
Association of California Life and Health Insurance Companies
Analysis Prepared by: Scott Bain / HEALTH / (916) 319-2097
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | SB 40 |
THIRD READING
Bill No: SB 40
Author: Wiener (D) and Wahab (D), et al.
Amended: 5/23/25
Vote: 21
SENATE HEALTH COMMITTEE: 11-0, 4/2/25
AYES: Menjivar, Valladares, Durazo, Gonzalez, Grove, Limón, Padilla, Richardson, Rubio, Weber Pierson, Wiener
SENATE APPROPRIATIONS COMMITTEE: 6-0, 5/23/25
AYES: Caballero, Seyarto, Cabaldon, Grayson, Richardson, Wahab
NO VOTE RECORDED: Dahle
SUBJECT: Health care coverage: insulin
SOURCE: American Diabetes Association
DIGEST:
This bill prohibits a health plan contract and health insurance policy from imposing a copayment, coinsurance, deductible, or any other cost-sharing on an insulin prescription drug that exceeds $35 for a 30-day supply. Prohibits a health plan from imposing step therapy as a prerequisite to authorizing coverage of at least one insulin drug type.
ANALYSIS:
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act) and the California Department of Insurance (CDI) to regulate health insurers under the Insurance Code. [Health and Safety Code (HSC) §1340, et seq. and Insurance Code (INS) §106, et seq.]
- Requires every health plan contract and health insurance policy that cover hospital, medical, or surgical expenses to include coverage for equipment and supplies for the management and treatment of insulin using diabetes, non-insulin-using diabetes, and gestational diabetes as medically necessary, even if the items are available without a prescription. Requires coverage for medically necessary insulin, prescriptive medications for the treatment of diabetes, and glucagon. [HSC §1367.51 and INS §10176.61]
- Prohibits the copayments and deductibles for the benefits specified in 2) above from exceeding those established for similar benefits within the given plan. [HSC §1367.51 and INS §10176.61]
- Requires every plan and policy to provide coverage for diabetes outpatient self-management training, education, and medical nutrition therapy that meets specified requirements including that it is provided by an appropriately licensed or registered heath care professional. [HSC §1367.51 and INS §10176.61]
- Permits health plans and insurers to require step therapy and prior authorization, and defines step therapy as a type of protocol that specifies the sequence in which different prescription drugs for a given medical condition that are medically appropriate for a particular patient are to be prescribed. Applies this and other requirements in the Insurance Code to a utilization review organization that performs utilization review or utilization management functions for a health insurer. Requires a health plan or physician group that contracts with a pharmacy benefit manager to include a contract provision to comply with specified law regarding prior authorizations. [HSC §1342.71, §1367.206, Title 28 California Code of Regulations (CCR) §1300.67.205 and INS §10123.193 and §10123.201]
This bill:
- Prohibits a health plan contract and health insurance policy that is issued, amended, or renewed on or after January 1, 2026, or a contract or policy offered in the individual or small group market on or after January 1, 2027, from imposing a copayment, coinsurance, deductible, or any other cost-sharing on an insulin prescription drug that exceeds $35 for a 30-day supply.
- Requires the cost-sharing cap described in 1) above to apply only to insulin prescription drugs in Tier 1 and Tier 2 for individual or small group plan contracts and insurance policies that maintain a drug formulary grouped into tiers, if there are at least two insulins in each drug type in all forms and concentrations on a preferred tier. Requires if there is only one insulin for a given drug type, then that one insulin must be placed on Tier 1 or Tier 2. Drug type means rapid acting, rapid acting inhaled, regular or short acting, intermediate acting, long acting, ultra-long acting and premixed.
- Prohibits application of 1) above on a high deductible health plan (HDHP), as defined under federal law, if not applying a deductible, coinsurance, or other cost-sharing to an insulin prescription would conflict with federal HDHP requirements.
- Applies the deductible and copayment limitations in 1) above to an insulin prescription drug, or any therapeutic insulin prescription drug, that is labeled or produced by the state.
- Defines insulin prescription drug to mean a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.
- Prohibits a health plan or health insurer from imposing step therapy protocols as a prerequisite to authorizing coverage of insulin. For health plans, defines step therapy protocol as a process that specifies the sequence in which different prescription drugs for a given medical condition and medically appropriate for a particular patient are prescribed. Prohibits step therapy for self-administered drugs and physician-administered drugs. For health insurers, defines step therapy as having the same meaning as defined in existing law. Additionally, for health insurers step therapy is prohibited for self-administered drugs and physician-administered drugs. Requires plans and insurers to cover at least one insulin in each drug type (rapid acting, rapid acting inhaled, regular or short acting, intermediate acting, long acting, ultra-long acting and premixed) without step therapy.
Comments
According to the author of this bill:
The bill prohibits cost-sharing for an insulin prescription drug from exceeding $35 for a 30 day-supply, and from requiring step therapy treatment. It makes no sense that people with diabetes in states like West Virginia can access affordable insulin while Californians are stuck with higher prices. When basic life necessities like medication become unaffordable in blue states, working people pay the price. It is past time California put basic protections in place to contain the astronomical cost of basic medications and bring economic relief to Californians forced to stretch beyond their means every month to pay for their insulin.
Background
Inflation Reduction Act. According to a brief published by the U.S. HHS, Assistant Secretary for Planning and Evaluation, the federal Inflation Reduction Act of 2022 requires people enrolled in a Medicare Part D prescription drug plan or a Medicare Advantage plan with prescription drug coverage to have no deductible for covered insulin products and have a copayment cap of $35 per month supply of each covered insulin product. Medicare Part B beneficiaries or those enrolled in a Medicare Advantage plan who use an insulin pump furnished via durable medical equipment will no longer have to pay a deductible for insulin and will have a copayment cap of $35 per month supply for their Part B covered insulin. Additionally, eligibility for the Part D Low-Income Subsidy will expand from 135% of the Federal Poverty Level (FPL) to 150% of FPL, which will allow these enrollees to further reduce their out-of-pocket costs for insulin and other medications.
California manufacturing. California has a $50 million contract with the nonprofit generic drug and pharmaceutical company, Civica Rx, to produce the three most commonly used long-acting and rapid-acting types of insulin in both vial and pen forms under a state label called CalRx. There are two major steps when making insulin: a) manufacturing the drug substance, which is the active ingredient used to make the drug product; and, b) finishing and filling it into vials or pens. Civica is working with GeneSys Biologics to co-develop the drug substance for the three CalRx biosimilar insulins. The filling and finishing of the three insulins will be done at Civica’s state-of-the-art 140,000 square-foot manufacturing plant, being built in Petersburg, Virginia. Federal approval from the FDA was expected in 2024 but that has not yet occurred. The products will be available publicly after FDA approval. Civica has announced that the manufacturer suggested prices will be: a) a 10mL vial will be made available for no more than $30 (normally $300); and, b) a box of 5 pre-filled 3mL pens will be made available for no more than $55 (normally more than $500). CalRx plans to make biosimilar insulins available for Glargine, Aspart, and Lispro (expected to be interchangeable with Lantus, Humalog, and Novolog respectively). For CalRx, no new prescription will be needed. Californians will be able to ask for the CalRx generic at their local pharmacy or via mail order pharmacies, so long as pharmacies agree to order and stock the product. Cal Rx insulin prices are estimated to be about 90% lower than list prices for branded products, saving patients between $2,000 and $4,000 annually.
Voluntary price cuts. In March 2023, Eli Lilly, Novo Nordisk, and Sanofi (which make up roughly 90% of the U.S. insulin market) announced caps or cuts to the cost of many of their insulin products. Eli Lilly announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps patient out-of-pocket costs at $35 or less per month. Novo Nordisk announced that it is lowering the U.S. list prices of several insulin products by up to 75%. Products include both pre-filled pens and vials of long-acting, bolus short-acting and pre-mix insulins. Novo Nordisk also reduced the list price of unbranded biologics to match the lowered price of each respective branded insulin. Sanofi announced that it will cut the list price of Lantus (insulin glargine injection), its most widely prescribed insulin in the U.S., by 78%. The company also established a $35 cap on out-of-pocket costs for Lantus for all patients with commercial insurance. Sanofi also launched an unbranded Lantus biologic at 60% lower than the Lantus list price, and capped out-of-pocket costs on insulin to $35 for all people without insurance. Sanofi also cut the list price of its short-acting Apidra (insulin glulisine injection) by 70%.
DMHC Regulations on Step Therapy. DMHC requires any plan that requires step therapy to have an expeditious process in place to authorize exceptions to step therapy when medically necessary and to conform effectively and efficiently to continuity of care requirements of the Knox-Keene Act and regulations. In circumstances where an enrollee is changing plans, the new plan may not require the enrollee to repeat step therapy when that enrollee is already being treated for a medical condition by a prescription drug provided that the drug is appropriately prescribed and is considered safe and effective for the enrollee’s condition. This regulation does not preclude the new plan from imposing a prior authorization requirement for the continued coverage of a prescription drug prescribed pursuant to step therapy imposed by the former plan, or preclude the prescribing provider from prescribing another drug covered by the new plan that is medically appropriate for the enrollee.
California Health Benefits Review Program (CHBRP) analysis. Key findings include:
- Utilization. CHBRP estimates that the 39,178 enrollees would see a reduction in monthly cost-sharing to $29. CHBRP assumes that utilization of insulin will increase by 4% because of this bill. This compares to 6.6% estimated increase in utilization in CHBRP’s 2023 report of a similar bill, SB 90 (Wiener of 2023–24). There are at least two reasons for CHBRP’s 4% reduced increase in utilization under this bill. One reason is because clinical guidelines now recommend other newer noninsulin medications that are equally or more effective for many people with type 2 diabetes which has led to fewer patients using insulin. Another reason is because the unit costs of insulin has changed with some major manufacturers reducing the list prices in response to the removal of the average manufacture price (AMP) cap under the federal American Rescue Plan Act (ARPA) of 2021. CHBRP notes that removal of step therapy in this years’ bill, could result in a portion of enrollees using more expensive insulins within the same therapeutic class, which would result in an increase in the average unit cost of insulin. Consistent with its’ SB 90 report, CHBRP assumes a 10% reduction in diabetes-related emergency department visits for this population.
- Medi-Cal. There may be no impact to Medi-Cal because of how Medi-Cal administers the pharmacy benefits for Medi-Cal enrollees.
- CalPERS. There is no impact to enrollees associated with CalPERS, DMHC-regulated plans, because there are not enrollees for whom cost-sharing for insulin is higher than the cap.
- Impact on expenditures. CHBRP estimates an increase in total health insurance premiums paid by employers and enrollees of $10,377,000 and a decrease in cost-sharing for impacted enrollees of $8,230,000. Enrollees with out-of-pocket expenditures in the top 1% would have an annual savings of greater than $1,463. While 39,178 enrollees will see reductions in cost-sharing for insulin, over 12 million Californians will be impacted by increases in premiums. Individual enrollees would see premium increases between $.07 and $.08 per member per month. Small employers and their enrollees would see premium increases of $.19 per member per month and large employers and their enrollees would experience an increase in premiums of $.04 per member per month because of this bill.
Related/Prior legislation
SB 90 (Wiener) of 2023–24 would have prohibited a health plan contract or disability insurance policy that is issued, amended, or renewed on or after January 1, 2024, or plan or policy offered in in the individual or small group market on or after January 1, 2025, from imposing a copayment, deductible, coinsurance, or any other out-of-pocket expense on an insulin prescription drug that exceeds $35 for a 30-day supply, as specified. SB 90 was vetoed by Governor Newsom. In his veto message, the Governor stated:
This bill would prohibit health plans from imposing a copayment of more than $35 for a 30-day supply of an insulin prescription drug. Bringing down the costs of prescription drugs, and particularly insulin, has long been a priority of mine. People should not be forced to go into debt to get lifesaving medicines. In March, I announced the state’s partnership with Civica to create our own line of CalRx biosimilar insulins that will cost no more than $30 per 10mL vial or $55 for five 3mL cartridges. This is a fraction of the current price for most insulins, and CalRx biosimilar insulins will be available to insured and uninsured patients nationwide. With CalRx, we are getting at the underlying cost, which is the true sustainable solution to high-cost pharmaceuticals. With copay caps however, the long-term costs are still passed down to consumers through higher premiums from health plans. As a state, we have led the nation in our efforts and investments to address the true underlying costs of insulin prescription affordability.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
According to the Senate Appropriations Committee
- Likely minor and absorbable costs for DMHC for state operations.
- Likely minor or no fiscal impact to CDI state operations.
- Unknown, potential General Fund costs for CalPERS plans due to the limits on step therapy.
SUPPORT: (Verified 5/7/25)
American Diabetes Association (Source)
Beta Cell Action
California Academy of Preventative Medicine
California Association for Health Services at Home
California Chronic Care Coalition
California Medical Association
California Pharmacists Association
California Podiatric Medical Association
California State Council of Service Employees International Union
California State PTA
Davis College Democrats
Diabetes Patient Advocacy Coalition
San Francisco Marin Medical Society
OPPOSITION: (Verified 5/7/25)
Association of California Life and Health Insurance Companies
California Association of Health Plans
ARGUMENTS IN SUPPORT: This bill is sponsored by the American Diabetes Association (ADA), which believes this bill is a solution to help Californians with diabetes as they await CalRx biosimilar insulins. According to ADA, Californians would be protected from predatory practices that are the subject of a Federal Trade Commission complaint filed against the three largest pharmacy benefit managers for inflating the list price of insulin. ADA writes, according to the complaint, “In some cases, the patient may pay more at the pharmacy counter than the actual cost to their commercial insurer. In other words, the insurer functionally makes a profit from the prescription, instead of paying its share of the cost. This turns the normal insurance model on its head with the sick subsidizing the healthy, rather than the other way around. As one PBM manager bluntly put it: ‘I don’t see how it’s justifiable to charge someone 100% of the cost of the drug (during the deductible phase) while you receive a rebate on the backend … I can’t think of any other insurance industry that works like that.” ADA also writes that a recent study on the impact of the first copay cap legislation passed in the country (Colorado) found significant savings for enrollees, with out-of-pocket payments falling in half, and only a minor 1% increase in the amount paid by plans per prescription. ADA indicates researchers also found that the number of prescriptions and days supplied increased after the law passed, indicating that some patients may have been rationing insulin prior to the cap. ADA writes, to date, more than half the country, twenty-six states (plus Washington, D.C.) have passed legislation to limit out-of-pocket costs for insulin. The Diabetes Patient Advocacy Coalition (DPAC) writes that this bill would be a strong step in ensuring access to affordable care for Californians with diabetes. DPAC says one in four diabetes patients rations insulin due to its high cost, which can have life-threatening health conditions including heart disease, stroke, kidney failure, amputation of the lower extremities and blindness.
ARGUMENTS IN OPPOSITION: The California Association of Health Plans (CAHP) and the Association of California Life and Health Insurance Companies (ACLHIC) write in opposition to 17 health insurance mandate bills including this one. The opposition writes these bills will increase costs, reduce choice and competition and further incent some employers and individuals to avoid state regulation by seeking other coverage options. According to the opposition, benefit mandates impose a one-size-fits all approach to medical care and benefit design without consideration for consumer choice. The opposition strongly urges the Legislature to pause any new mandate bills at this time given the uncertainty regarding what benefits may or may not be covered in the essential health benefits (EHB) benchmark plan. The opposition also indicates that adding new mandates at a time when the Office of Health Care Affordability (OHCA) is working to curb healthcare costs could disrupt those efforts and make it difficult for health care entities to meet the OCHA spending target. The opposition urges the Legislature to consider the cumulative impacts of these mandates on premiums and access to coverage, and they believe that benefit mandates stifle the use of innovative, evidence-based medicine.
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
5/27/25 11:42:28
**** END ****
SENATE COMMITTEE ON APPROPRIATIONS
Senator Anna Caballero, Chair
2025 - 2026 Regular Session
SB 40 (Wiener) - Health care coverage: insulin
Version: April 7, 2025 | Policy Vote: HEALTH 11 - 0 |
Urgency: No | Mandate: Yes |
Hearing Date: May 23, 2025 | Consultant: Agnes Lee |
Bill Summary:
SB 40 would prohibit a health plan contract and health insurance policy from imposing a copayment, coinsurance, deductible, or any other cost-sharing on an insulin prescription drug that exceeds $35 for a 30-day supply; and would limit a health plan or health insurer from imposing step therapy as a prerequisite to authorizing coverage of insulin, as specified.
*********** ANALYSIS ADDENDUM – SUSPENSE FILE ***********
The following information is revised to reflect amendments
adopted by the committee on May 23, 2025
Fiscal Impact:
- Likely minor and absorbable costs for the Department of Managed Health Care (DMHC) for state operations.
- Likely minor or no fiscal impact to the California Department of Insurance (CDI) for state operations.
- Unknown, potential General Fund costs for CalPERS plans due to the limits on step therapy.
Author Amendments:
Provide that if an individual or small group health plan contract/insurance policy maintains a drug formulary grouped into tiers, and if there are at least two insulins of each drug type in all forms and concentrations on a preferred tier, the proposed cost-sharing cap must apply only to insulin prescription drugs that are in Tier 1 and Tier 2; and if there is only one insulin for a given drug type, then the bill’s requirement must be met by placing that one insulin on Tier 1 or Tier 2.
-- END --
SENATE COMMITTEE ON APPROPRIATIONS
Senator Anna Caballero, Chair
2025 - 2026 Regular Session
SB 40 (Wiener) - Health care coverage: insulin
Version: April 7, 2025 | Policy Vote: HEALTH 11 - 0 |
Urgency: No | Mandate: Yes |
Hearing Date: April 21, 2025 | Consultant: Agnes Lee |
Bill Summary:
SB 40 would prohibit a health plan contract and health insurance policy from imposing a copayment, coinsurance, deductible, or any other cost-sharing on an insulin prescription drug that exceeds $35 for a 30-day supply; and would limit a health plan or health insurer from imposing step therapy as a prerequisite to authorizing coverage of insulin, as specified.
Fiscal Impact:
- The Department of Managed Health Care (DMHC) estimates minor and absorbable costs for state operations.
- The California Department of Insurance (CDI) estimates no fiscal impact to state operations.
- Unknown, potential General Fund costs for CalPERS plans due to the limits on step therapy.
Background:
Current law requires a health plan contract and health insurance policy that covers hospital, medical, or surgical expenses to include coverage for equipment and supplies for the management and treatment of insulin-using diabetes, non-insulin-using diabetes, and gestational diabetes as medically necessary, even if the items are available without a prescription. Current law requires that a health plan contract and health insurance policy that covers prescription benefits to include coverage for medically necessary insulin, prescriptive medications for the treatment of diabetes, and glucagon. Copayments and deductibles for these benefits cannot exceed those established for similar benefits within the given plan.
Current law permits health plans and health insurers to require step therapy for prescription drugs which may require that the enrollee first try and fail (one or more) alternatives before coverage becomes available for the initially prescribed medication. Thus health plans and health insurers may require enrollees to use one insulin before granting approval of another insulin of the same therapeutic class.
Proposed Law:
Specific provisions of the bill would:
- Prohibit a health plan contract and health insurance policy that is issued, amended, or renewed on or after January 1, 2026, or a contract or policy offered in the individual or small group market on or after January 1, 2027, from imposing a copayment, coinsurance, deductible, or any other cost-sharing on an insulin prescription drug that exceeds $35 for a 30-day supply.
- Prohibit a health plan and health insurer from imposing step therapy as a prerequisite to authorizing coverage of insulin, except this would not require a health plan or insurer to cover all of the types of insulin without step therapy, if at least one insulin in each drug type, as defined, is covered without step therapy.
Related Legislation:
SB 90 (Wiener, 2023) would have prohibited a health plan contract and health insurance policy from imposing a copayment, coinsurance, deductible, or other out-of-pocket expense on an insulin prescription drug that exceeds $35 for a 30-day supply. The bill was vetoed by the Governor.
Staff Comments:
According to the California Health Benefits Review Program (CHBRP), SB 40 (as introduced) would increase total net annual expenditures by $2,147,000 for enrollees with plans regulated by the DMHC and policies regulated by the CDI. This is due to an increase of $10,377,000 in total health insurance premiums paid by employers and enrollees, and a $8,230,000 decrease in enrollee expenses. CHBRP estimates at baseline there are 92,636 enrollees who use insulin in DMHC-regulated plans and CDI-regulated policies, where 53,458 enrollees (58%) using insulin have cost sharing that does not exceed the SB 40 cost-sharing cap. CHBRP estimates 39,178 enrollees (42%) using insulin have cost sharing that exceeds the SB 40 cap. For DMHC-regulated CalPERS plans, CHBRP estimates there is no impact because there are no enrollees for whom cost-sharing for insulin prescription is higher than the cap at baseline. The pharmacy benefit for Medi-Cal beneficiaries is administered by the Department of Health Care Services and therefore is not impacted by SB 40.
CHBRP indicates that removal of step therapy (as proposed in the introduced version of SB 40) could result in a portion of enrollees using more expensive insulins within the same therapeutic class, which would result in an increase in the average unit cost of insulin and could increase CHBRP’s estimated expenditures. Subsequent amendments to SB 40 would provide that the health plan or health insurer would not have to cover all of the types of insulin without step therapy, if at least one insulin in each drug type, as defined, is covered without step therapy.
-- END --
SENATE COMMITTEE ON HEALTH
Senator Caroline Menjivar, Chair
BILL NO: SB 40
AUTHOR: | Wiener, Wahab | ||
VERSION: | March 17, 2025 | ||
HEARING DATE: | April 2, 2025 | ||
CONSULTANT: | Teri Boughton | ||
SUBJECT: Health care coverage: insulin
SUMMARY:
Prohibits a health plan contract and health insurance policy from imposing a copayment, coinsurance, deductible, or any other cost-sharing on an insulin prescription drug that exceeds $35 for a 30-day supply. Prohibits a health plan from imposing step therapy as a prerequisite to authorizing coverage of insulin. Prohibits step therapy for self-administered drugs and physician-administered drugs.
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act) and the California Department of Insurance (CDI) to regulate health insurers under the Insurance Code. [HSC §1340, et seq. and INS §106, et seq.]
- Establishes essential health benefits (EHBs) under the Affordable Care Act (ACA), and requires non-grandfathered individual and small group health plan contracts and insurance policies to cover EHBs. [HSC §1367.005 and INS §10112.27]
- Limits, with respect to an individual or group health plan contract or health insurance policy that covers EHBs, the copayment, coinsurance, or any other form of cost-sharing for a covered outpatient prescription drug for a supply of up to 30 days from exceeding $250; for a product with an actuarial value (AV) at or equivalent to a Bronze level, limits cost-sharing to not more than $500 for a supply of up to 30 days; and for a high deductible health plan (HDHP) the $250 and $500 limits apply only after the deductible requirement is met. [HSC §1342.73 and INS §10123.1932]
- Prohibits a nongrandfathered individual or small group health plan contract or insurance policy from having an annual deductible for outpatient drugs, if any, from exceeding twice the amount specified in 3) above. Prohibits a copayment or percentage coinsurance from exceeding 50% of the cost to the plan or insurer, and, requires if there is a generic equivalent to a brand name drug, a plan or insurer to ensure that the enrollee or insured is subject to the lowest cost sharing that would be applied, whether or not both the generic equivalent and the brand name drug are on the formulary. This does not require both the generic equivalent and the brand name drug to be on the formulary. [HSC §1342.73 and INS §10123.1932]
- Requires if a health plan contract or insurance policy for a nongrandfathered individual or small group product maintains a drug formulary grouped into tiers that includes a fourth tier, the contract or policy to use the following definitions for each tier of the drug formulary:
- Tier one consists of most generic drugs and low-cost preferred brand name drugs;
- Tier two consists of nonpreferred generic drugs, preferred brand name drugs, and any other drugs recommended by the plan’s or insurer’s pharmacy and therapeutics committee based on safety, efficacy, and cost;
- Tier three consists of nonpreferred brand name drugs or drugs that are recommended by the pharmacy and therapeutics committee based on safety, efficacy, and cost, or that generally have a preferred and often less costly therapeutic alternative at a lower tier; and,
- Tier four consists of drugs that are biologics, drugs that the Food and Drug Administration (FDA) of the United States Department of Health and Human Services (HHS) or the manufacturer requires to be distributed through a specialty pharmacy, drugs that require the enrollee to have special training or clinical monitoring for self-administration, or drugs that cost the health plan more than $600 net of rebates for a supply of up to 30 days. [HSC §1342.73 and INS §10123.1932]
- Permits contracts and policies described in 5) above to maintain a drug formulary with fewer than four tiers, but not more than four tiers. Allows a health plan or insurer to place any drug in a lower tier. [HSC §1342.73 and INS §10123.1932]
- Requires every health plan contract and health insurance policy that cover hospital, medical, or surgical expenses to include coverage for equipment and supplies for the management and treatment of insulin using diabetes, non-insulin-using diabetes, and gestational diabetes as medically necessary, even if the items are available without a prescription. Requires coverage for medically necessary insulin, prescriptive medications for the treatment of diabetes, and glucagon. [HSC §1367.51 and INS §10176.61]
- Prohibits the copayments and deductibles for the benefits specified in 7) above from exceeding those established for similar benefits within the given plan. [HSC §1367.51 and INS §10176.61]
- Requires every plan and policy to provide coverage for diabetes outpatient self-management training, education, and medical nutrition therapy that meets specified requirements including that it is provided by an appropriately licensed or registered heath care professional. [HSC §1367.51 and INS §10176.61]
- Limits the maximum amount a health plan or health insurer can require an enrollee or insured to pay at the point of sale for a covered prescription drug to the lesser of the following:
- The applicable cost-sharing amount for the prescription drug; or,
- The retail price. [HSC §1367.47 and INS §10123.65]
- Prohibits a health plan or health insurer from requiring a pharmacist or pharmacy to charge or collect from an enrollee or insured a cost-sharing amount that exceeds the total retail price for the prescription drug. Requires the payment rendered to constitute the applicable cost-sharing and apply to the deductible, if any, and also to the maximum out-of-pocket limit in the same manner as if the enrollee or insured had purchased the prescription drug by paying the cost-sharing amount. [HSC §1367.47 and INS §10123.65]
- Permits health plans and insurers to require step therapy and prior authorization, and defines step therapy as a type of protocol that specifies the sequence in which different prescription drugs for a given medical condition that are medically appropriate for a particular patient are to be prescribed. Applies this and other requirements in the Insurance Code to a utilization review organization that performs utilization review or utilization management functions for a health insurer. Requires a health plan or physician group that contracts with a pharmacy benefit manager to include a contract provision to comply with specified law regarding prior authorizations. [HSC §1342.71, §1367.206, Title 28 CCR §1300.67.205 and INS §10123.193 and §10123.201]
- Prohibits a health plan or insurer from subjecting antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis (PREP) or postexposure prophylaxis (PEP), to prior authorization or step therapy, except if the FDA has approved one or more therapeutic equivalents of a drug, device, or product for the prevention of AIDS/HIV, in which case the plan or insurer is required to only cover one therapeutically equivalent version without prior authorization or step therapy. [HSC §1342.74 and INS §10123.1933]
This bill:
- Prohibits a health plan contract and health insurance policy that is issued, amended, or renewed on or after January 1, 2026 from imposing a copayment, coinsurance, deductible, or any other cost-sharing on an insulin prescription drug that exceeds $35 for a 30-day supply.
- Prohibits application of 1) above on a HDHP, as defined under federal law, if not applying a deductible, coinsurance, or other cost-sharing to an insulin prescription would conflict with federal HDHP requirements.
- Applies the deductible and copayment limitations in 1) above to an insulin prescription drug, or any therapeutic insulin prescription drug, that is labeled or produced by the state.
- Defines insulin prescription drug to mean a prescription drug that contains insulin and is used to control blood glucose levels to treat diabetes.
- Prohibits a health plan or health insurer from imposing step therapy protocols as a prerequisite to authorizing coverage of insulin. For health plans, defines step therapy protocol as a protocol or program that establishes the specific sequence in which prescription drugs for a specified condition, including self-administered drugs and physician-administered drugs are medically appropriate for a particular enrollee or insured and are covered under the contract or policy. For health insurers, defines step therapy as having the same meaning as defined in existing law. Additionally, for health insurers step therapy is prohibited for self-administered drugs and physician-administered drugs.
FISCAL EFFECT:
This bill has not been analyzed by a fiscal committee.
COMMENTS:
- Author’s statement. According to the author, the bill prohibits cost-sharing for an insulin prescription drug from exceeding $35 for a 30 day-supply, and from requiring step therapy treatment. It makes no sense that people with diabetes in states like West Virginia can access affordable insulin while Californians are stuck with higher prices. When basic life necessities like medication become unaffordable in blue states, working people pay the price. It is past time California put basic protections in place to contain the astronomical cost of basic medications and bring economic relief to Californians forced to stretch beyond their means every month to pay for their insulin.
- Inflation Reduction Act. According to a brief published by the U.S. HHS, Assistant Secretary for Planning and Evaluation, the federal Inflation Reduction Act of 2022 requires people enrolled in a Medicare Part D prescription drug plan or a Medicare Advantage plan with prescription drug coverage to have no deductible for covered insulin products and have a copayment cap of $35 per month supply of each covered insulin product. Medicare Part B beneficiaries or those enrolled in a Medicare Advantage plan who use an insulin pump furnished via durable medical equipment will no longer have to pay a deductible for insulin and will have a copayment cap of $35 per month supply for their Part B covered insulin. Additionally, eligibility for the Part D Low-Income Subsidy will expand from 135% of the Federal Poverty Level (FPL) to 150% of FPL, which will allow these enrollees to further reduce their out-of-pocket costs for insulin and other medications.
- California manufacturing. California has a $50 million contract with the nonprofit generic drug and pharmaceutical company, Civica Rx, to produce the three most commonly used long-acting and rapid-acting types of insulin in both vial and pen forms under a state label called CalRx. There are two major steps when making insulin: a) manufacturing the drug substance, which is the active ingredient used to make the drug product; and, b) finishing and filling it into vials or pens. Civica is working with GeneSys Biologics to co-develop the drug substance for the three CalRx biosimilar insulins. The filling and finishing of the three insulins will be done at Civica’s state-of- the-art 140,000 square-foot manufacturing plant, being built in Petersburg, Virginia. Federal approval from the FDA was expected in 2024 but that has not yet occurred. The products will be available publicly after FDA approval. Civica has announced that the manufacturer suggested prices will be: a) a 10mL vial will be made available for no more than $30 (normally $300); and, b) a box of 5 pre-filled 3mL pens will be made available for no more than $55 (normally more than $500). CalRx plans to make biosimilar insulins available for Glargine, Aspart, and Lispro (expected to be interchangeable with Lantus, Humalog, and Novolog respectively). For CalRx, no new prescription will be needed. Californians will be able to ask for the CalRx generic at their local pharmacy or via mail order pharmacies, so long as pharmacies agree to order and stock the product. Cal Rx insulin prices are estimated to be about 90% lower than list prices for branded products, saving patients between $2,000 and $4,000 annually.
- Removal of average manufacture price (AMP) cap. According to the Kaiser Family Foundation (KFF), drug manufacturers provide rebates to both the federal and state governments in exchange for Medicaid coverage of their drug. The rebates are based on a percentage of the AMP and an inflationary component (Consumer Price Index penalties) associated with price increases. The federal American Rescue Plan Act (ARPA) of 2021 removed the AMP limit (i.e., “AMP cap”) on Medicaid drug rebates beginning January 1, 2024. Without the cap, the rebate amount on a drug whose price increases quickly over time could exceed the AMP, which would increase the rebate amount the manufacturer would have to pay the government. The limit was put in place in 2010 at 100% of the AMP. KFF indicates in response to the elimination of the cap, some drug companies are lowering drug prices or discontinuing drugs in favor of lower priced alternatives to avoid paying additional Medicaid rebates.
- Voluntary price cuts. In March 2023, Eli Lilly, Novo Nordisk, and Sanofi (which make up roughly 90% of the U.S. insulin market) announced caps or cuts to the cost of many of their insulin products. Eli Lilly announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps patient out-of-pocket costs at $35 or less per month. Novo Nordisk announced that it is lowering the U.S. list prices of several insulin products by up to 75%. Products include both pre-filled pens and vials of long-acting, bolus short-acting and pre-mix insulins. Novo Nordisk also reduced the list price of unbranded biologics to match the lowered price of each respective branded insulin. Sanofi announced that it will cut the list price of Lantus (insulin glargine injection), its most widely prescribed insulin in the U.S., by 78%. The company also established a $35 cap on out-of-pocket costs for Lantus for all patients with commercial insurance. Sanofi also launched an unbranded Lantus biologic at 60% lower than the Lantus list price, and capped out-of-pocket costs on insulin to $35 for all people without insurance. Sanofi also cut the list price of its short-acting Apidra (insulin glulisine injection) by 70%.
- DMHC Regulations on Step Therapy. DMHC requires any plan that requires step therapy to have an expeditious process in place to authorize exceptions to step therapy when medically necessary and to conform effectively and efficiently to continuity of care requirements of the Knox-Keene Act and regulations. In circumstances where an enrollee is changing plans, the new plan may not require the enrollee to repeat step therapy when that enrollee is already being treated for a medical condition by a prescription drug provided that the drug is appropriately prescribed and is considered safe and effective for the enrollee’s condition. This regulation does not preclude the new plan from imposing a prior authorization requirement for the continued coverage of a prescription drug prescribed pursuant to step therapy imposed by the former plan, or preclude the prescribing provider from prescribing another drug covered by the new plan that is medically appropriate for the enrollee.
- California Health Benefits Review Program (CHBRP) analysis. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation mandating a benefit or service and prepare a report with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996, and reviewed this bill. Key findings include:
- Coverage impacts and enrollees covered. There are 92,636 California enrollees who use insulin who are covered in commercial and California Public Employees’ Retirement System (CalPERS) state-regulated insurance. More than half (58%) have insulin cost-sharing below the cap required in this bill. However, 39,178 enrollees have cost-sharing that would exceed the cap with average monthly cost-sharing of $52 per month.
- Medical effectiveness. There is strong evidence from seven observational studies on cost-related insulin use/adherence that cost-sharing affects insulin use and adherence in patients with diabetes; higher cost-sharing reduces adherence and lower cost-sharing increases adherence. There is some evidence from four studies on the effect of cost-sharing for insulin on diabetes-related health outcomes and utilization. These studies suggest that reduced cost-sharing is associated with decreased diabetes-related complications, emergency department visits, and hospitalizations. The effect of cost-sharing on additional health outcomes, such as glycemic control, is unknown. There is strong evidence based on CHBRP’s previous analysis of AB 2144 (Arambula of 2019) that step therapy is associated with a lower likelihood of initiating or continuing medications and with poorer adherence to medication. There is expert consensus, consistent with the finding for prescription medications, that step therapy protocols for insulin are associated with lowered use and adherence. Additionally, there is clinical consensus that insulin is considered essential for effective treatment of diabetes and that delayed introduction of, or ineffective insulin therapy contributes to poor glycemic control and places patients at risk of complications. There are several limitations that contributed to the medical effectiveness evaluation provided in this review, most notably the barriers to conducting rigorous randomized controlled trials of differential cost-sharing or utilization management strategies on insulin use, inherent differences between the types of diabetes, and the multifaceted nature of diabetes treatment, resulting in a literature base that is not as rigorous as ideal and thereby limiting the certainty of conclusions drawn from the evidence.
- Utilization. CHBRP estimates that the 39,178 enrollees would see a reduction in monthly cost-sharing to $29. CHBRP assumes that utilization of insulin will increase by 4% because of this bill. This compares to 6.6% estimated increase in utilization in CHBRP’s 2023 report of a similar bill, SB 90 (Wiener of 2023-24). There are at least two reasons for CHBRP’s 4% reduced increase in utilization under this bill. One reason is because clinical guidelines now recommend other newer noninsulin medications that are equally or more effective for many people with type 2 diabetes which has led to fewer patients using insulin. Another reason is because the unit costs of insulin has changed with some major manufacturers reducing the list prices in response to the removal of the AMP cap under ARPA. CHBRP notes that removal of step therapy in this years’ bill, could result in a portion of enrollees using more expensive insulins within the same therapeutic class, which would result in an increase in the average unit cost of insulin. Consistent with its’ SB 90 report, CHBRP assumes a 10% reduction in diabetes-related emergency department visits for this population.
- Medi-Cal. There may be no impact to Medi-Cal because of how Medi-Cal administers the pharmacy benefits for Medi-Cal enrollees.
- CalPERS. There is no impact to enrollees associated with CalPERS, DMHC-regulated plans, because there are not enrollees for whom cost-sharing for insulin is higher than the cap.
- Impact on expenditures. CHBRP estimates an increase in total health insurance premiums paid by employers and enrollees of $10,377,000 and a decrease in cost-sharing for impacted enrollees of $8,230,000. Enrollees with out-of-pocket expenditures in the top 1% would have an annual savings of greater than $1,463.While 39,178 enrollees will see reductions in cost-sharing for insulin, over 12 million Californians will be impacted by increases in premiums. Individual enrollees would see premium increases between $.07 and $.08 per member per month. Small employers and their enrollees would see premium increases of $.19 per member per month and large employers and their enrollees would experience an increase in premiums of $.04 per member per month because of this bill.
- HDHPs. CHBRP assumes that all Health Savings Account (HSA)-qualified HDHPs will cover insulin predeductible according to federal law. Preventive services that include treatments for chronic conditions which can be excluded from the deductible include insulin, and therefore would not interfere with an HDHP’s qualification for HSA.
- EHBs. This bill would not require coverage for a new state benefit mandate. This bill modifies cost-sharing terms and conditions of an already covered medication. As such, this bill would not exceed the definition of EHB and would not require the state to pay for the EHB costs.
- Covered California Standard Plan Designs. Covered California is California’s state based marketplace (or exchange), which was created as a result of the federal ACA. Covered California makes health insurance plans available to purchase for individuals (and families) and small employers. Qualified individuals can also get financial assistance when purchasing individual/family policies through Covered California. State and federal law require plans sold in the individual and small group market to meet 90/80/70/60% AV requirements. This means that a platinum plan with 90% AV requires the plan to pay on average 90% of the cost of covered benefits and the enrollee pays 10% in the form of cost-sharing. These tend to be higher cost premium plans with the lowest cost-sharing requirements. On the other end, a bronze plan has a 60% AV which means the plan pays on average 60% of costs of covered benefits and the enrollee pays 40% in the form of cost-sharing. Bronze plans are typically the lowest cost premium plans but have the highest enrollee cost-sharing. There is some room allowance, referred to as de minimis range, which allows Covered California benefit designs to fall a little outside the AV ranges but beyond that the products that fall outside of the AV requirements cannot be sold.
Covered California indicates that legislation, such as this bill, that limits cost-sharing for specific drugs or medical services could impact Covered California’s ability to set standard benefit designs, which also impact individual and small group products offered outside of Covered California. Reducing the cost-sharing for one benefit could result in higher cost-sharing for other benefits.
Covered California conducted an analysis of a substantially similar bill, SB 473 (Bates of 2022), and analyzed a $35 cap on insulin drugs listed under the Tier 2 category of “preferred drugs.” Based on 2022 plan designs, capping Tier 2 insulin drugs alone would have rendered Covered California’s bronze plans out of compliance with federal and state laws pertaining to AV, requiring cost-sharing adjustments to be made in other benefit categories. Like this bill, SB 90 applied a $35 cap to all insulin drugs, which would put additional pressure on Covered California’s ability to offer products consistent with federal AV requirements. As such, Covered California recommended for SB 90 narrowing the $35 cap to insulin drugs listed in Tier 1 and Tier 2 for the individual and small group markets (to exclude “non-preferred,” more costly drugs commonly listed in Tiers 3 and 4 of drug formularies). This tailored approach coupled with a delayed implementation for the individual and small group market limits the AV impact and allows Covered California to prospectively build the $35 limitation for Tier 1 and Tier 2 insulin into the following year’s standard benefit design. - Attorney General action. In January 2023, California Attorney General Rob Bonta announced a lawsuit against the nation's largest insulin makers (Eli Lilly, Novo Nordisk, and Sanofi) and three Pharmacy Benefit Managers (CVS Caremark, Express Scripts, and Optum Rx) for driving up the cost of insulin through unlawful, unfair, and deceptive business practices in violation of California's Unfair Competition Law. The lawsuit alleges these manufacturers and PBMs have leveraged their market power to overcharge patients. The complaint alleges the defendants separately conspired to artificially inflate prices while agreeing to provide secret rebates in an attempt to obtain preferred positions on drug formularies.
- Prior legislation. SB 90 (Wiener of 2023) would have prohibited a health plan contract or disability insurance policy that is issued, amended, or renewed on or after January 1, 2024, or plan or policy offered in in the individual or small group market on or after January 1, 2025, from imposing a copayment, deductible, coinsurance, or any other out-of-pocket expense on an insulin prescription drug that exceeds $35 for a 30-day supply, as specified. SB 90 was vetoed by Governor Newsom. In his veto message, the Governor stated:
This bill would prohibit health plans from imposing a copayment of more than $35 for a 30-day supply of an insulin prescription drug. Bringing down the costs of prescription drugs, and particularly insulin, has long been a priority of mine. People should not be forced to go into debt to get lifesaving medicines. In March, I announced the state's partnership with Civica to create our own line of CalRx biosimilar insulins that will cost no more than $30 per 10mL vial or $55 for five 3mL cartridges. This is a fraction of the current price for most insulins, and CalRx biosimilar insulins will be available to insured and uninsured patients nationwide. With CalRx, we are getting at the underlying cost, which is the true sustainable solution to high-cost pharmaceuticals. With copay caps however, the long-term costs are still passed down to consumers through higher premiums from health plans. As a state, we have led the nation in our efforts and investments to address the true underlying costs of insulin prescription affordability.
SB 473 (Bates of 2022) would have required a health plan or insurance policy to cover all available dosage forms and concentrations of insulin for a copayment of no more than $35 for a monthly supply. SB 473 was held in the Assembly Appropriations Committee.
SB 852 (Pan, Chapter 207, Statutes of 2020) requires the California Health and Human Services Agency to enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and, to increase patient access to affordable drugs. Included in SB 852 is that partnerships include the production of at least one form of insulin, provided that a viable pathway for manufacturing a more affordable form of insulin exists.
AB 97 (Nazarian of 2021) would have prohibited a health plan contract or disability insurance policy from imposing a deductible on an insulin prescription drug. AB 97 was held in the Senate Appropriations Committee.
AB 2203 (Nazarian of 2020) would have established a copayment cap for insulin and prohibited a health plan contract or a health insurance policy from imposing cost-sharing on a covered insulin prescription, except for a copayment not to exceed $50 per 30-day supply of insulin, and no more than $100 total per month, regardless of the amount or type of insulin. AB 2203 would have authorized the Attorney General to investigate pricing of prescription insulin drugs made available to California consumers, considering the role of each entity in the entire supply chain, to ensure adequate consumer protections in pricing of prescription insulin drugs and determine whether additional consumer protections are needed, as specified. Due to the shortened Legislative calendar brought on by the COVID-19 pandemic, AB 2203 was not set for a hearing in the Senate Health Committee.
AB 2144 (Arambula of 2019) would have clarified that a health plan may require step therapy if there is more than one drug that is appropriate for the treatment of a medical condition; required a health plan or health insurer to expeditiously grant a step therapy exception if specified criteria are met; authorized an enrollee or insured or their designee, guardian, primary care physician, or health care provider to file an appeal of a prior authorization or the denial of a step therapy exception request, and would require a health care service plan or health insurer to designate a clinical peer to review those appeals; and required a health plan, health insurer, or utilization review organization to annually report specified information about their step therapy exception requests and prior authorization requests. AB 2144 was not set for a hearing in the Assembly Health Committee.
- Support. This bill is sponsored by the American Diabetes Association (ADA), which believes this bill is a solution to help Californians with diabetes as they await CalRx biosimilar insulins. According to ADA, Californians would be protected from predatory practices that are the subject of a Federal Trade Commission complaint filed against the three largest PBMs for inflating the list price of insulin. ADA writes, according to the complaint, “In some cases, the patient may pay more at the pharmacy counter than the actual cost to their commercial insurer. In other words, the insurer functionally makes a profit from the prescription, instead of paying its share of the cost. This turns the normal insurance model on its head with the sick subsidizing the healthy, rather than the other way around. As one PBM manager bluntly put it: ‘I don’t see how it’s justifiable to charge someone 100% of the cost of the drug (during the deductible phase) while you receive a rebate on the backend … I can’t think of any other insurance industry that works like that.” ADA also writes that a recent study on the impact of the first copay cap legislation passed in the country (Colorado) found significant savings for enrollees, with out-of-pocket payments falling in half, and only a minor 1% increase in the amount paid by plans per prescription. ADA indicates researchers also found that the number of prescriptions and days supplied increased after the law passed, indicating that some patients may have been rationing insulin prior to the cap. To date, more than half the country, twenty-six states (plus Washington, D.C.) have passed legislation to limit out-of-pocket costs for insulin. The Diabetes Patient Advocacy Coalition (DPAC) writes that this bill would be a strong step in ensuring access to affordable care for Californians with diabetes. DPAC says one in four diabetes patients rations insulin due to its high cost, which can have life-threatening health conditions including heart disease, stroke, kidney failure, amputation of the lower extremities and blindness.
- Opposition. The California Association of Health Plans (CAHP) and the Association of California Life and Health Insurance Companies (ACLHIC) write in opposition to 17 health insurance mandate bills including this one. The opposition writes these bills will increase costs, reduce choice and completion and further incent some employers and individuals to avoid state regulation by seeking other coverage options. Benefit mandates impose a one-size-fits all approach to medical care and benefit design without consideration for consumer choice. The opposition strongly urges the Legislature to pause any new mandate bills at this time given the uncertainty regarding what benefits may or may not be covered in the EHB benchmark plan. The opposition also indicates that adding new mandates at a time when the Office of Health Care Affordability (OHCA) is working to curb healthcare costs could disrupt those efforts and make it difficult for health care entities to meet the OCHA spending target. The opposition urges the Legislature to consider the cumulative impacts of these mandates on premiums and access to coverage, and they believe that benefit mandates stifle the use of innovative, evidence-based medicine.
- Policy comments.
- California has two insurance regulators: DMHC and CDI. To ensure consistency, to the extent possible, it has been the practice of the Legislature to make sure the requirements for health plans and insurers are closely aligned, and as such, amendments are necessary to keep the codes consistent.
- To address the potential for increases in insulin unit costs due to removal of step therapy, this bill could be amended to include limits similar to what exists in statute for antiretroviral drugs. For example, HSC 1342.74., below, prohibits plans from subjecting antiretroviral drugs to prior authorization or step therapy, except as indicated in paragraph (a) (2).
(a) (1) Notwithstanding Section 1342.71, a health care service plan shall not subject antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis or postexposure prophylaxis, to prior authorization or step therapy, except as provided in paragraph (2).
(2) If the United States Food and Drug Administration has approved one or more therapeutic equivalents of a drug, device, or product for the prevention of AIDS/HIV, this section does not require a health care service plan to cover all of the therapeutically equivalent versions without prior authorization or step therapy, if at least one therapeutically equivalent version is covered without prior authorization or step therapy.
- Amendments similar to the ones this committee adopted for SB 90 should be considered to minimize impacts to Covered California benefit designs.
- Amendments similar to the ones this committee adopted for SB 90 should be considered to minimize impacts to Covered California benefit designs.
- Amendments. The amendments below respond to some of the policy comments above.
HSC Code (d) (1) Notwithstanding subdivision (c), a health care service plan contract that is issued, amended, or renewed on or after January 1, 2026, or a contract offered in the individual or small group market on or after January 1, 2027, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply.
(e) (1)Consistent with this section, on and after January 1, 2026, a health care service plan shall not impose step therapy protocols as a prerequisite to authorizing coverage of insulin except as provided in paragraph (2). For purposes of this section, “step therapy protocol” has the same meaning as defined in section 1367.206 subdivision (g).means a protocol or program that establishes the specific sequence in which prescription drugs for a specified condition, including self-administered drugs and physician-administered drugs, are medically appropriate for a particular enrollee and are covered under a health care service plan contract. For purposes of this section, step therapy is prohibited for self-administered drugs and physician-administered drugs. (2) Because the United States Food and Drug Administration has approved one or more types of insulin, this section does not require a health care service plan to cover all of the types of insulin without step therapy, if at least one insulin in each drug type is covered without step therapy. For purposes of this paragraph “drug type” means rapid acting, rapid acting inhaled, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed.
INS Code
(d) (1) Notwithstanding subdivision (c), a health insurance policy that is issued, amended, or renewed on or after January 1, 2026, or a policy offered in the individual or small group market on or after January 1, 2027, shall not impose a copayment, coinsurance, deductible, or any other cost sharing on an insulin prescription drug that exceeds thirty-five dollars ($35) for a 30-day supply.
(e)(1) Consistent with this section, on and after January 1, 2026, a health insurer shall not impose step therapy as a prerequisite to authorizing coverage of insulin. For purposes of this section, “step therapy” has the same meaning as defined in paragraph (2) of subdivision (i) of Section 10123.201except as provided in paragraph (2).For purposes of this section, step therapy is prohibited for self-administered drugs and physician-administered drugs. (2) Because the United States Food and Drug Administration has approved one or more types of insulin, this section does not require a health care service plan to cover all of the types without step therapy, if at least one insulin in each drug type is covered without step therapy. For purposes of this paragraph, “drug type” means rapid acting, rapid acting inhaled, regular or short acting, intermediate acting, long acting, ultra-long acting, and premixed.
SUPPORT AND OPPOSITION:
Support: American Diabetes Association (sponsor)
Beta Cell Action
California Association for Health Services at Home
California Pharmacists Association
California Podiatric Medical Association
California State Council of Service Employees International Union
Diabetes Patient Advocacy Coalition
Oppose: Association of California Life and Health Insurance Companies
California Association of Health Plans
-- END --
Bill Author
Bill Co-Author(s):